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 Preface 
        
       The specificity of biological effects in different cells types is determined 
by the composition of their proteome, the physical and functional interaction 
between different signaling pathways and theirs spatial and temporal 
organization in signaling complexes. Although the implication of some 
specific pathways with major phenotypes, such as proliferation, apoptosis or 
differentiation is well known, the final effect varies depending on cell type, 
which might even be the opposite. These phenotypes play an essential role, 
and are frequently deregulated in tumor cells, which make some of them 
potential targets for development of new drugs. In this context, protein 
kinases represent the main regulatory family, which can be activated and 
deactivated by reversible phosphorylation, or by integration in spatially 
organized signaling complexes with scaffold proteins. The human kinome is 
composed of 518 kinases and for many of them their characterization from 
the point of view of regulation and substrate specificity, as well as their 
integration in novel signaling pathways, or their effect on other better know 
pathways such as MAPK, are not yet understood.  
 In this book we have focused the attention on some of the less well 
known kinases such as Cot1/Tpl2, LKB1, WNK, GSK3, VRK, and PLK3. 
Also there is a chapter on development of specific inhibitors for mitotic 
kinases. There are two additional chapters. One focused on the KSR scaffold 
protein, an organizer of signaling complexes and intracellular signal 
compartmentalization, as well as another on DUSP phosphatases, the key 
deactivator of regulated kinases, which comparatively receive little attention, 
but are an essential component in regulatory mechanisms.  
 
Pedro A. Lazo 
 
 
 
 
 
 
 
 
 
 
 
 Contents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
Modulation of Ras signaling by the KSR family of molecular scaffolds     1      
Luís G. Pérez-Rivas, Stephanie Prieto and José Lozano      
  
Chapter 2 
The biological function of the proto-oncogene Cot/tpl-2  
(MAP kinase kinase kinase 8)     25    
Margarita Fernández, Irene Soria, Marta López-Peláez        
Antonio Martín-Duce and Susana Alemany    
 
Chapter 3 
WNK kinase signalling in cancer biology  43   
Sónia Moniz and Peter Jordan     
 
Chapter 4 
The tumour suppressor role of LKB1 in human cancer  71    
Paola A. Marignani and Montse Sanchez-Cespedes      
  
Chapter 5 
The role of glycogen synthase kinase-3 in the decision between  
cell survival and cell death 95  
Roberta Venè and Francesca Tosetti   
 
Chapter 6 
Polo-like kinase 3 in normal and tumor biology    117    
Dazhong Xu and Wei Dai     
 
Chapter 7 
Vaccinia-related kinase (VRK) signaling in cell and tumor biology      135 
Marta Sanz-García, Alberto Valbuena, Inmaculada López-Sánchez 
Sandra Blanco, Isabel F. Fernández, Marta Vázquez-Cedeira 
and Pedro A. Lazo   
 
Chapter 8 
Targeting mitotic kinases for anti-cancer treatment  157 
Hae-ock Lee, Yoo-Kyung Lee, and Hyunsook Lee   
 
Chapter 9 
Atypical DUSPs: 19 phosphatases in search of a role 185 
Yolanda Bayón and Andrés Alonso   
 
Transworld Research Network 
37/661 (2), Fort P.O. 
Trivandrum-695 023  
Kerala, India 
 
 
 
 
Emerging Signaling Pathways in Tumor Biology, 2010: 1-23                                                   
ISBN: 978-81-7895-477-6 Editor: Pedro A. Lazo 
 
1. Modulation of Ras signaling by the KSR 
family of molecular scaffolds   
 
Luís G. Pérez-Rivas, Stephanie Prieto and José Lozano   
Dpto. Biología Molecular y Bioquímica, Universidad de Málaga, 29071 Málaga, Spain 
 
 
 
Abstract. KSR proteins were initially identified in C. elegans and 
D. melanogaster as positive regulators of Ras signaling. Murine 
and human homologs were subsequently isolated, allowing for 
their characterization at the molecular level. The mammalian 
homologs are functionally classified as pseudokinases due to the 
lack of a catalytic lysine involved in the phosphotransfer reaction 
and found in most active kinases. Over the past 10 years, work 
done in several groups has allowed a detailed molecular 
characterization of KSR proteins, mainly at the functional level. In 
the near future, a more complete picture of the mode of action of 
KSR proteins will require additional studies at the structural level. 
However, the wealth of data currently known about KSR clearly 
indicates that it is a critical player in Ras signal transduction, 
functioning as a molecular scaffold that complexes the individual 
components of the Raf/MEK/ERK cascade into multiprotein 
signaling platforms (signalosomes). Here, we will review some of 
the well-established concepts regarding the regulation of Ras 
signaling by KSR proteins, in both normal and malignant cells. We 
will also include some recent and provocative data that sheds new 
light on the mechanism of KSR function. 
 
Correspondence/Reprint request: Dr. José Lozano, Dpto. Biología Molecular y Bioquímica, Universidad de 
Málaga. Campus de Teatinos s/n. 29071 Málaga, Spain. Phone: (+34) 95 213 6661, E-mail: jlozano@uma.es 
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1. Introduction 
 
      The kinase suppressor of Ras (KSR) family of proteins comprise an 
evolutionary conserved group of molecular scaffolds that function as 
modulators of Ras signaling by bringing together the different components of 
the Raf/MEK/ERK cascade [1, 2]. KSR1, the founding member of the KSR 
family of proteins, was identified in 1995 by means of genetic screens in           
D. melanogaster and C. elegans [3-5]. At that time, a murine ksr1 gene was 
also cloned by Therrien et al. [5]. The corresponding mKSR1 protein has 
been, since then, the most studied member of the KSR family and currently 
serves as a model to explain the biological function of these proteins. To date, 
the family includes one gene in Drosophila (ksr), two genes in mammalian 
cells (KSR1 and KSR2) and two genes in C. elegans (ksr-1 and ksr-2) [4-8].  
 All KSR proteins identified so far have a C-terminal sequence which 
includes the 11 highly conserved subdomains found in most eukaryotic 
kinases and, therefore, they were initially named as if they were true kinases. 
However, the failure to find a KSR-specific direct substrate and, more 
importantly, the lack of an invariant catalytic residue (K) in subdomain II of 
mammalian KSR isoforms has led to the classification of these proteins in the 
pseudokinase subgroup of the human kinome, together with other proteins 
also containing degenerated kinase domains [9]. Currently, KSR is 
considered to function mainly as a molecular scaffold that facilitates the 
assembling of the individual components of the Raf/MEK/ERK signaling 
cascade [10-13]. Mammalian KSR proteins are expressed in most adult 
tissues, although their levels are usually very low and, frecuently hard to 
detect by immunoblotting [10, 14, 15]. The highest expression level has been 
reported for a brain-specific isoform (B-KSR1) [16]. Titration experiments, 
showed that, in fact, the in vivo KSR levels need to be carefully regulated and 
kept below a certain limit in order for KSR to properly function as a 
molecular scaffold [17]. This also applies to other known scaffolds, such as 
JNK-interacting protein 1 (JIP1) [18] and the molecular explanation for these 
requirement is summarized in Figure 1. Essentially, the concentration of a 
scaffold protein cannot be increased above its optimal level (defined by the 
stoichiometry of the reaction) to avoid chelation of its ligands into non-
competent complexes [1]. For this reason, some of the early works aimed to 
define the role of KSR1 in Ras signaling resulted in contradictory outcomes, 
with some investigators reporting a negative role in ERK activation and Ras 
transformation and others reporting just the opposite [17, 19-24]. KSR1 
function was mainly investigated by overexpressing mKSR1 in cultured cells 
and, therefore, the amount of ectopic mKSR1 was usually way above the 
endogenous (suboptimal) level, resulting in inhibition of Ras signaling. 
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Under circumstances of low transfection efficiency, the ectopically expressed 
mKSR1 helped to reach the optimal scaffold concentration, enhancing signal 
transduction. To avoid this problem, which is inherent to the plasmid 
transfection methods, Morrison and coworkers developed an assay to 
measure the Ras-dependent ERK scaffolding activity of KSR in Xenopus 
laevis oocytes. The system allows for a careful titration of the amount of 
KSR expressed in each oocyte an scores their meiotic maturation (germinal 
vesicle breakdown, or GVBD) as the biological readout [1, 17].  
 More recently, the availability of immortalized KSR1-deficient cells has 
greatly facilitated the study of KSR function since variable amounts of 
mKSR1 proteins (wild-type or mutant) can be reintroduced in these cells by 
retroviral infection and subsequent sorting of cell populations with different 
KSR1 expression levels [25-27]. The following sections are a summary of the 
current molecular knowledge regarding KSR structure and function.  
 
 
 
Figure 1. The effective concentration of KSR1 is critical for an optimal scaffolding 
activity. This is achieved when the scaffold (KSR1, in red) and its ligands (C-Raf, 
MEK and ERK, in yellow, green and orange, respectively) are in a concentration near 
the stoichiometry of the reaction (B). Below such levels, a local increase in the 
effective concentration of KSR1 results in an increased signaling (A). However, an 
excess of the scaffold (i.e., a concentration higher than the optimal) results in the 
formation of non-productive complexes that block signaling (C). 
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2. Domain organization and function 
 
 KSR proteins are similar to members of the Raf family of S/T kinases [4-
7], and as such are included in the tyrosine-like kinase (TLK) group of 
kinases [9]. All KSR proteins identified so far have all or some of five distinct 
domains named Conserved Area (CA) 1 to CA5 (Figure 2) [5]. The CA1 
domain consists of about 40 amino acids and is unique to the KSR family of 
proteins. Although the functional role of this conserved region has not been 
fully characterized, two reported evidences suggest an important role in 
mediating Raf activation by means of a direct interaction. Thus, an intact 
CA1 domain is required for the interaction of Drosophila KSR (D-KSR) with 
D-Raf [28] while a D-KSR with two specific single amino acid substitutions 
in CA1 (L50G and R51S) behaves as a weak loss-of-function in Ras 
signaling [5]. Similarly, mutation of the equivalent sites in the CA1 region of 
mouse KSR1 (L56G and R57S), impaired binding to B-Raf [13] which was 
also found to be mediated by the N-terminal half of mKSR1 [29].  Intriguingly, 
  
 
 
Figure 2. Domain organization of KSR proteins. With the exception of ceKSR-2A 
(which lacks CA4), all members of the KSR family contain the CA2-CA5 domains. 
Two sequences for hKSR1 and hKSR2 have been published lacking the CA1 domain 
(blue boxes) but analysis of the human genome indicates that those sequences are 
incomplete. The domain organization of the related S/T kinase C-Raf is included for 
comparison. The length (number of residues) of each protein is indicated in 
parenthesis. GenBank accession numbers are also indicated. 
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all C. elegans KSR isoforms lack the CA1 domain, suggesting that a different 
region and/or mechanism participates in Raf activation [4, 6]. The CA2 
region is a short (13 Aas) proline-rich domain whose function has yet to be 
determined. 
 Fifty residues comprise the CA3 region, a cysteine-rich domain (CRD), 
defined by the consensus sequence HX10-12CX2CX11-19-CX2CX4HX2-4CX5-9C 
and similar to those found in Raf and the ζ isoform of protein kinase C 
(ζPKC) [5, 30, 31]. The CRDs of KSR, Raf and ζPKC are of the so-called 
atypical C1 class and, as opossed to the typical C1 domains –which bind 
diacylglycerol (DAG)- they are mainly involved in protein-protein 
interactions and membrane localization [32]. The primary sequences of both 
types of C1 domains are similar, however structural differences seem to 
account for their different functions. Thus, the CA3 atypical C1 domain of 
KSR1 is composed of two anti-parallel β-sheets an a C-terminal α helix 
(Figure 3), similar to typical C1 domains, but lacks four conserved residues 
in the loop between the β3 and β4 strands (β3-β4 loop) [31]. This deletion, 
which also occurs in C-Raf, makes the loop more rigid and impairs DAG 
binding [33].  
 The issue of lipid binding to the CA3 domain has long been a matter of 
debate. Work done in the Kolesnick´s group identified KSR1 as their 
previously reported ceramide-activated protein kinase (CAPK), a 97 kDa 
membrane-bound, proline-directed and ceramide-enhanced activity [34, 35]. 
This work raised the possibility that KSR might be a direct target of ceramide 
[30, 35]. Very recently, the same group have examined the ceramide-binding 
capabilities of an isolated GST-CA3 domain in an ELISA-based assay and 
found a marked preference for binding to different ceramides species over 
other lipids such as diacylglycerol, the ganglioside GM1, sphingomyelin and 
phosphatidylcholine [36]. Disrupting the tertiary structure of the CA3 domain 
by mutation of two conserved cysteines (C359S/C362S) reduced, although 
did not prevent, binding to C16-ceramide [36]. Interestingly, these authors 
also showed a rapid and transient EGF-dependent colocalization of an 
overexpressed KSR1 protein with different lipid rafts markers, including 
ceramide, caveolin-1 and ganglioside GM1 [36]. Although EGF did not 
induced a ceramide increase, the distribution of KSR1 into the ceramide-rich 
platforms was reduced by preincubation of the cells with Fumonisin B1 
(FB1) a competitive inhibitor of ceramide synthase [36]. Collectively, these 
results indicate that the ceramide content of the lipid rafts plays a role in the 
CA3-mediated recruitment of KSR1 to signaling platforms at the plasma 
membrane.  
Luís G. Pérez-Rivas  et al. 6
 
 
Figure 3. The CA3 region of KSR is an atypical cysteine-rich C1 domain. (A) 
Structures of the C1 domain of KSR1 (left) and C-Raf (right) in cartoon format. The 
β-sheets are colored in yellow while α-helices are in blue. In KSR1, residues C346, 
C349, C370 (all in green) and H367 (cyan) coordinate one Zn2+ atom while C359, 
C362, C77 (all in red) and H334 (magenta) coordinate the second Zn2+ atom. (B) The 
same structures shown in (A) rendered in surface view to highlight the charge 
distribution (acid = red, basic = blue, hydrophobic = green). Note that, compared with 
C-Raf, KSR1 has a unique patch of basic residues while lacking a Ras binding site. 
This basic region is located between chains β4 and β5 and mediates binding to CK2. 
The hydrophobic pocket is potentially involved in interactions with membrane lipids. 
 
 Direct ceramide binding to ζPKC or C-Raf has been reported by several 
groups [37-39] however, to date only one group has reported direct in vitro 
[14C16]-ceramide binding to an isolated, bacterially-expressed CA3 domain 
[40] and most other investigators have failed to observe neither binding nor a 
direct activation of KSR1 by ceramide [20, 41, 42]. It has been suggested that 
an additional positively charged residue in the β1-β2 loop might contribute to 
an overall structure competent for ceramide binding since the atypical C1 
domains of the ceramide-binding proteins C-Raf and ζPKC contains such a 
residue and KSR1 does not [31]. In summary, a direct evidence of lipid binding 
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to the CA3 region of KSR still remains to be unambiguously demonstrated. On 
the contrary its role as a multifunctional domain involved in protein-protein 
interactions and subcelullar localization has been firmly stablished. 
 The CA3 region is neccessary for the interaction of KSR1 with 14-3-3 
proteins [17, 43-45], the βγ subunits of heterotrimeric G-protein [46], and the 
Cdc25C-associated kinase 1 (C-TAK1) [44, 47] and, most importantly, an 
intact CA3 domain is required for KSR1 to modulate Ras signaling at the 
plasma membrane [20, 31]. Thus, a KSR1 mutant with a disrupted CA3 
domain (CRM mutant) is unable to accelerate Ras-induced maturation in 
Xenopus oocytes and to localize KSR1 to the membrane in response to Ras 
activation by oncogenic mutations or growth factor treatment [17, 20, 31]. CA3 
could be mediating the membrane targeting of KSR1 through association to an 
unidentified membrane lipid or by means of interaction with a membrane-
bound protein. In this regard, there is no evidence of KSR binding to Ras but an 
interaction of the membrane-associated βγ subunits of G proteins with the CA3 
domain has been reported [2, 46]. The CA3 domain of KSR1 can serve specific 
functions that cannot be replaced by other atypical C1 domains. Thus, a 
chimeric KSR1 protein in which its own C1 domain has been replaced with that 
of C-Raf (KRK mutant) did not change its subcelullar localization in NIH 3T3 
cells after PDGF treatment [31]. However, we an others have demonstrated that 
the KRK mutant binds 14-3-3 as efficiently as the wild-type protein [31, 45], 
suggesting that a general C1 domain structure can mediate interaction with the 
cytosolic anchors that keep KSR1 in the cytosol while Ras-dependent 
translocation to the plasma membrane is strictly dependent on specific features 
of its CA3 domain. In marked contrast, the C1 domain of C-Raf contributes to 
its membrane association but it is the Ras-binding domain (RBD) that is 
required for the translocation [48, 49]. 
  CA4 is a serine/threonine-rich domain of variable length in D-KSR, 
mKSR1 and ceKSR1 (61, 53 and 47 residues, respectively) while it is absent 
in ceKSR2 [5, 6]. This region contains a motif known as docking site for 
ERK, FxFP (DEF) which mediates the interaction of ERK with KSR to get 
phosphorylated on proline-directed S/T sites [13, 50]. As expected for such a 
critical function, DEF motifs are conserved in KSR proteins from different 
species, including ceKSR (FLFP), D-KSR (FNFP) and mKSR1/2 (FSFP) 
[50]. In mKSR1 the stretch of S/T residues is located in the N-terminal region 
of CA4 and includes one ERK phosphorylation site (S443) while the DEF 
motif is positioned in the C-terminal side of CA4 [5, 17]. The co-existence of 
S/T-rich stretches and a DEF motif in CA4 makes it resemble the C boxes of 
ETS proteins in the Elk subfamily [50]. Mutant KSR proteins lacking a 
functional DEF motif are poorly phosphorylated by ERK both in vitro and in 
vivo and this defect is due to a reduced affinity of the KSR1 mutants for 
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activated ERK [13, 50]. Thus, ERK phosphorylation assays using isolated 
CA4 domains as substrates showed that inactivating mutations in the 
conserved FxFP docking site of KSR proteins dramatically increased the Km 
(7-50-fold) of the reactions [50], indicating that a functional DEF motif is 
necessary for a productive KSR/ERK interaction. 
 While the CA1-4 regions fill the N-terminal half of KSR, the CA5 region 
expands over the C-terminal half and contains some features of a kinase 
domain [2-5]. The CA5 domain is closely related to the kinase domain of Raf 
proteins [5] and contains the eleven conserved subdomains found in all 
kinases [9, 51]. However, the issue of the kinase activity of KSR1 has been a 
matter of dispute. While some investigators reported that KSR1 can function 
as a Raf kinase [35, 52-54] others have been unable to reproduce neither the 
KSR1-dependent Raf phosphorylation nor any kinase activity at all [19-21, 
23, 24, 55]. In support of a non-catalytic function of mammalian KSR is the 
lack of a highly conserved lysine in kinase subdomain II of CA5 [5]. This 
invariant residue is found in the vast majority of kinases identified so far and 
participates in the positioning of the ATP molecule and in the 
phosphotransfer reaction [51]. Curiously, this conserved residue is present in 
D-KSR (K705) and ceKSR1 (K503) while in murine and human KSR1 is 
substituted by an arginine (R589 in mKSR1 and R571 in hKSR2) [5, 7]. A 
second ksr gene was identified in C. elegans (ksr-2) coding for two proteíns 
isoforms generated by alternative splicing (ceKSR-2A and ceKSR-2B) [6]. 
Similar to the mammalian isoforms, these two proteins have an arginine 
instead of the catalytic lysine [6], suggesting that in C. elegans KSR may 
serve both catalytic and non-catalytic functions. Even if KSR were proved to 
have kinase activity, it is not clear whether KSR is a tyrosine or a S/T kinase 
as the sequence YI(L)APE in subdomain VIII, which is conserved among S/T  
kinases, is present in all KSR genes cloned so far, while C. elegans and D. 
melanogaster KSR also contains the sequence HKDLR indicative of tyrosine 
kinases [5]. More recently, the full sequencing of the human kinome (the 
complete set of 518 human kinases) has revealed that KSR belongs to a small 
subgroup of kinases that differ significantly with respect to the key residues 
that are necessary for catalysis [9]. Members of this subgroup, which 
represents 10% of the kinome, are called pseudokinases and besides KSR1-2, 
also include vaccinia-related kinase 3 (VRK3), Janus kinases 1-3 (JAK1-3), 
integrin-linked kinase (ILK) and ErbB3, among others [9, 56, 57]. The 
pseudokinases are predicted to be enzimatically inactive due to sequence 
changes in essential motifs, however they are conserved throughout metazoans, 
suggesting that their unusual kinase domain still serve important functions 
[58]. The recently solved first 3D structures of pseudokinases VRK3 [57] and 
ROP2 [59] have provided evidence for a regulatory role of the their inactive 
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kinase domain. Thus, despite having the invariant lysine in the appropiate 
position, VRK3 has a highly degraded catalytic site with bulky residues that 
hinder ATP binding and prevent any kinase activity [57]. ROP2 has a more 
favorable open conformation and could accommodate nucleotide binding, 
however several unusual side chains lining the cavity prevent ATP binding 
[59]. Similar to KSR1, the S/T kinase WNK1 lacks the catalytic lysine and was 
initially considered to be a pseudokinase. Despite that, WNK1 can display 
kinase activity phosphorylating myelin basic protein and itself, due to a 
different lysine in kinase subdomain I that provides the catalytic function [60, 
61]. Therefore, in addition to its enzymatic funtion, kinases have clearly 
evolved to provide docking sites for specific protein-protein interactions. 
 
3. KSR-binding proteins 
 
 As true scaffolds, KSR proteins do not function alone and are tipically 
bound to other signaling proteins. Early work from different groups showed 
that KSR1 associates with all three components of the signaling module 
Raf/MEK/ERK. Thus, MEK1/2 binds constitutively to the CA5 region of 
KSR1 while the interaction with Raf and ERK1/2 is dependent on Ras 
activation and KSR1 translocation to the plasma membrane [17, 21, 24, 43]. 
The functional relevance of such interactions was later investigated by Therrien 
and co-workers, demonstrating that KSR functions as a scaffold linking MEK 
to its activator Raf [28, 62]. The first evidence that KSR proteins participate in 
signaling complexes came from work done by Stewart et al. [55] showing that 
KSR1 co-immunoprecipitates with a group of 10 different proteins, including 
MEK1/2, 14-3-3 and the heat-shock proteins HSP90, HSP70, HSP68 and 
p50CDC37, among others (Figure 4). The role of the heat-shock family of 
proteins in KSR regulation is still uncertain but they may stabilize KSR 
molecules or the whole complex, since treatment of cells with geldanamycin, a 
known inhibitor of HSP90, reduces the KSR half-life [55]. 
 
 
 
Figure 4. KSR-interacting proteins. The figure shows the name of some of the most 
relevant and well-studied KSR partners. They are positioned close to their mapped 
interaction sites. 
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 By using gel-filtration chromatography, Stewart et al. demonstrated that 
KSR1 exists in mammalian cells as part of multiprotein signaling complexes 
with apparent molecular masses ranging from 250 to 1000 kDa [10, 55]. 
Interestingly, MEK1/2 was incorporated into such complexes in a manner 
strictly dependent on its interaction with KSR1, since overexpression of a 
KSR1-C809Y mutant, defective in MEK1/2 binding displaced MEK1/2 from 
the high-molecular fractions to the 40-50 kDa fractions, indicative of a 
monomeric status [55]. The KSR/MEK interaction is constitutive and does not 
seem to change after growth factor stimulation or Ras activation. KSR1 has 
also been reported to bind the βγ subunits of heterotrimeric G proteins in 
response to lysophosphatidic acid stimulation [46]. Interestingly, the cysteine-
rich domain of KSR1 is both required and sufficient for the KSR1/βγ 
interaction, since an isolated CA3 domain is able to bind both subunits [46]. 
These results provide an alternative mechanism for the CA3-mediated 
translocation of KSR proteins to the plasma membrane in the absence of lipid 
binding: CA3 would localize KSR by interacting with other membrane-bound 
proteins, such as the G proteins. The KSR/14-3-3 interaction is critical for the 
regulation of KSR function since it helps to sequester KSR proteins in the 
cytosolic compartment in the absence of Ras activation [17, 44]. 14-3-3 
proteins bind to their targets at specific phosphoserine (pS) residues contained 
in two types of consensus motifs: RSXpSXP (mode 1) and RXXXpSXP  
(mode 2) [63, 64]. In particular, mKSR1 associates with 14-3-3 through mode 1 
sequences RSKpS297HE and RTEpS392VP, which flank the CA3 domain [43, 
44]. Our group have recently demonstrated the existence of functional 
specificity among 14-3-3 isoforms (β, γ, ε, η, σ, τ and ζ in mammals) by 
showing that KSR1 interacts preferentially with 14-3-3γ, regulating its ability 
to translocate to the plasma membrane and facilitating Ras-induced ERK2 
activation [45]. Further, we have provided data demonstrating that the 
flexible C-terminal tail of 14-3-3γ is required for a full and specific 
interaction with KSR1 and that 14-3-3γ heterodimerizes preferentially with 
selected isoforms when bound to KSR1 [45].  
 KSR1 also interacts with regulatory enzymes such as the S/T kinases C-
TAK1 [44] and CK2 [65] and the S/T phosphatase PP2A [66, 67]. The 
coordinated action of these three enzymes facilitate the activation of mKSR1 
as a scaffold for the RAF/MEK/ERK cascade (see below). The KSR1 
residues that are relevant for the specific interaction with these regulatory 
proteins have been identified by the Morrison group following a mutagenesis 
approach.  Thus, the stable interaction of KSR1 with C-TAK1 is mediated by 
residues 377-424, which include the phosphoacceptor site S392 and the 
characteristic motifs PxxR/K and ΦPK (Φ being a hydrophobic residue), 
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located C-terminal to the S392 [44, 47]. In particular I397, a residue located 
at the +5 position relative to the S392 phosphorylation site is absolutely 
required for the KSR1/C-TAK1 interaction [47]. The interaction of KSR1 
with the S/T phosphatase PP2A involves residues 249-320, which include the 
CA2 domain [66]. PP2A is a heterotrimeric holoenzyme composed of a 
structural A subunit, a regulatory B subunit and a catalytic C subunit. While 
subunits A and C associate constitutively with KSR1, binding to the B 
subunit is induced by growth factor stimulation, resulting in 
dephosphorylation of S392 and KSR1 translocation to the plasma membrane 
[66]. Interestingly, in addition to PP2A, KSR2 binds specifically to the 
Ca2+/calmodulin-regulated phosphatase calcineurin [8]. The interaction is 
constitutive and mediated by a region located between CA2 and CA3 that is 
unique to KSR2 and contains the calcineurin binding motif LSVP (residues 
390-393) [8]. 
 Casein kinase 2 (CK2) is a heterotetrameric kinase composed by two 
regulatory (β) and two catalytic (α/α´) subunits [65]. The interaction of CK2 
with KSR1 is constitutive and the region involved in the binding has been 
mapped to KSR1 residues 320-424 which includes the CA3 domain [65]. 
Swapping the CA3 domain with the C1 region of C-Raf abolishes binding to 
CK2, indicating that residues specific to the cysteine-rich domain of KSR 
participate in the interaction. In particular, a basic surface region in the β1 
sheet of the C1 domain is unique to KSR1 and mutation of K360 and R363 to 
A (KR/AA mutant) impairs binding to CK2 [65]. The scaffolding activity of 
KSR1 requires its interaction with CK2 since the KR/AA mutant is also 
impaired in its ability to facilitate activation of the associated MEK and ERK 
proteins [65]. This deficiency is due to the fact that the KSR1-associated CK2 
activity functions as a Raf N-region kinase, phosphorylating residues S338 in 
C-Raf and S446 and S430 in B-Raf [65]. Thus, for Raf proteins to be 
activated, KSR1 has to be competent in CK2 binding. Activated KSR1 
translocates to the plasma membrane where it associates with a Raf 
homodimer which then becomes phosphorylated by the pool of CK2 
molecules associated to KSR1 [65].  
 KSR1 also interacts with the ubiquitin E3 ligase IMP (Impedes 
Mitogenic Signal Propagation), a novel Ras effector that functions by 
limiting the formation of RAF/MEK complexes and inhibiting ERK 
activation [68]. KSR1 and IMP bind to each other via their N-terminal halves 
and this interaction provokes the hyperphosphorylation of KSR1 and its 
partitioning to a detergent (NP-40)-insoluble subcellular fraction [68]. It is 
unclear how IMP induces such changes in KSR1 but it has been 
demonstrated that IMP inhibits KSR1 homo-oligomerization without 
affecting its ability to interact with MEK [69]. 
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 Mouse KSR1 interacts with the F-actin binding protein leukocyte-
specific protein 1 (LSP1) and, as a result, the KSR/MEK/ERK complex gets 
targeted to peripheral actin filaments. The Rap guanine nucleotide exchange 
factor C3G has also been reported to bind KSR1 in complex with PP2A, 
MEK and ERK at the subcortical actin cytoskeleton, where it could 
contribute to ERK signaling by increasing the phosphatase activity of PP2A 
[70]. 
 A comprehensive set of KSR-associated proteins (the KSR 
interactome) has recently been reported by Morrison and coworkers [8]. 
Using mass spectrometry, they found >70 different proteins associated with 
recombinant mouse KSR1 and KSR2 isoforms immunopurified from 
overexpressing 293T cells. Importantly, they could discriminate between 
common and isoform-specific KSR partners. Thus, Raf, MEK, ERK, 14-3-
3, PP2A, C-TAK1 and CK2 bound to both KSR1 and KSR2 while 
Regulatory-associated protein of mTOR (Raptor) and the S/T phosphatase 
calcineurin (PP2B) bound specifically to KSR1 and KSR2, respectively [8]. 
Following the same functional proteomics strategy, Liu et al. have 
identified a set of 100 proteins specifically bound to overexpressed human 
KSR2, many of which are different from those identified by the Morrison 
group [12]. They also identified a group of 43 proteins, including A-Raf, 
p38 MAPK, PI3K and the IκB kinase complex-associated protein (IKAP), 
that were recruited to a KSR2 signaling complex in response to TNF-α 
treatment [12]. This, together with the fact that the authors did not detect 
binding to either B-Raf nor C-Raf would suggest specific roles for KSR2 
in A-Raf and p38 MAPK signaling. However, Morrison and coworkers 
did detect B-Raf in association to both KSR1 and KSR2 in their study [8]. 
In addition to using KSR2 proteins from different species (human and 
mouse) the construct used by Liu et al. lacked the first two coding exons 
of human KSR2 [8], which might account for the discrepancies observed 
between the two groups. It is not likely that all KSR-associated proteins 
are interacting directly with KSR in vivo. As part of multiprotein 
complexes, some of those proteins could associate with KSR through 
their specific interaction with other direct KSR-binding proteins. 
Alternatively, they could interact directly with different pools of KSR 
molecules defined by its phosphorylation status or subcellular 
localization. At least MEK1, ERK2, 14-3-3 and the γ subunit of the G-
protein appear to interact directly based on studies using the yeast two-
hybrid system or peptide competition [24, 43, 45, 46]. In any case, both 
studies indicate that, similar to KSR1, the KSR2 isoform also functions as 
a molecular scaffold in MAPK pathways.  
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 4. KSR kinases and phosphatases 
 
 In resting cells, KSR1 is phosphorylated on several S and T residues and 
growth factor stimulation induces dephosphorylation of specific sites as well 
as phosphorylation of new sites. Figure 5 shows the twelve KSR1 
phosphorylation sites reported so far and their known kinases. It is worth 
noting, however, that residues S190, S256, S320, S429 and S434 were 
identified initially by Lewis and coworkers in KSR mutants lacking at least 5 
major sites [71]. Therefore, they could be artifactual or represent in vivo 
phosphorylation events that function concomitantly with dephosphorylation 
of other sites. In favor of the later option, S320 has recently been shown to 
get phosphorylated by ERK after EGF treatment [13] and S434 has been 
reported to be phosphorylated by the Nm23-H1 metastasis suppressor only 
when phosphorylation was prevented on S392 [72] or S429 [71]. A mutant 
KSR1 protein, lacking de pseudokinase domain produced the same tryptic 
phosphopeptides than the wild-type version, indicating that none of the 
reported phosphosites were generated by autophosphorylation [71]. In resting 
cells, KSR2 is also constitutively phosphorylated on seven residues: S198, 
T287, S310, S469, S485, T492 and S623 [8]. 
  
 
 
Figure 5. KSR1 kinases and their phosphorylation sites. Residues S392 and S518 are 
phosphorylated constitutively by C-TAK1 and CK2, respectively. S297 is also 
constitutively phosphorylated by an unknown kinase. Ras activation induces 
phosphorylation of T260, T274, S320 and S443 by ERK and a concomitant 
dephosphorylation of S392 by PP2A. The Nm23-H1 metastasis suppressor 
phosphorylates S434 and also S392, although less efficiently than C-TAK1. The 
reported phosphorylation of KSR1 on residues S190, T256, T411 and S429 still 
awaits a detailed functional characterization.  
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 The identification and functional characterization of the major KSR1 and 
KSR2 phosphorylation sites have been reported by the Morrison group in a 
series of landmark papers [8, 17, 44, 65, 66]. Thus, phosphorylation on S297 
by an unknown kinase and on S392 by C-TAK1 creates two mode 1 motifs 
that allow binding to 14-3-3 and cytoplasmic retention of KSR1 [44, 45]. The 
major phosphorylation site S392 can also get phosphorylated by Nm23-H1 
but it is unclear how this event impacts KSR1 function [72]. Breast cancer 
cells expressing high levels of Nm23-H1 show an enhanced degradation of 
KSR1, likely due to its increased binding to the Hsp90 chaperone [73]. 
However, this effect seems to be independent of the kinase activity of Nm23-
H1 and relay exclusively on its expression level [73]. 
 In murine KSR2, residues S310 and S469 mediate binding to 14-3-3 
proteins and are constitutively phosphorylated [65]. Although the possibility 
exists that C-TAK1 phosphorylates one of these sites (KSR2 also binds C-
TAK1), it remains to be determined. 
 Casein kinase 2 (CK2) accounts for the constitutive phosphorylation of 
KSR1 on S518 [65, 71]. As mentioned above, binding to CK2 is essential for 
the scaffolding activity however, phosphorylation at S518 is not required for 
that function since a KSR1-S518A mutant is as efficient as the wild-type in 
two different assays measuring ERK activation [65]. The functional 
significance of S518 phosphorylation remains to be determined. 
 The scaffolding activity of KSR contributes to the Ras-dependent 
activation of ERK which, in turn, phosphorylates KSR1 on residues T260, 
T274, S320 and S443 [13, 17]. Thus, phosphorylation of these sites is 
minimal in resting cells and increases after mitogenic stimulation. Until 
recently, however, there was no known biological consequence of such event. 
Work done by McKay et al. indicates that, once activated, ERK 
phosphorylates both KSR1 and B-Raf to promote their dissociation and 
release of KSR1 from the plasma membrane [74]. These authors observed 
that a KSR1 mutant with a defective docking site for ERK had an increased 
and prolonged interaction with B-Raf after mitogenic stimulation, an effect 
that was mimicked by preincubation of the cells with a MEK inhibitor [74]. 
Since that mutant had reduced levels of phosphorylated proline-directed S/T 
(pS/TP) sites, the most plausible explanation to their data is that feedback 
phosphorylation of KSR1 by ERK impairs binding to B-Raf. This was further 
supported by experiments showing that KSR1 and B-Raf proteins with 
mutated ERK phosphorylation sites interacted strongly even in the absence of 
growth factor stimulation [74]. 
 Several KSR phosphatases have been identified that counteract the effect 
of KSR kinases. In particular, PP2A plays a critical role in the activation of 
KSR1 as a molecular scaffold for ERK. Thus, the phosphorylation status of 
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S392 is regulated by the coordinated action of the kinase C-TAK1 and the 
phosphatase PP2A, which dephosphorylates this major 14-3-3 binding site in 
response to growth factor stimulation and Ras activation [66, 67]. KSR2 also 
associates with PP2A and, similar to KSR1, gets dephosphorylated on a 14-3-
3 binding site (S469) after EGF stimulation [8]. This event is blocked by 
okadaic acid (OA) but not by cyclosporin A (CsA), suggesting that PP2A is 
the phosphatase responsible for pS469 dephosphorylation [8]. On the 
contrary, the phosphatase calcineurin binds selectively to KSR2 and 
dephosphorylates residues S198, T287 and S310 in response to Ca2+ 
signaling [8]. As a control, KSR1 phosphorylation was not altered after 
elevation of Ca2+ intracellular levels by PMA/ionomycin treatment, further 
indicating a specific role of KSR2 in Ca2+ signaling.  
 
5. Role of KSR in normal Ras signaling 
 
 The phosphorylation status of KSR proteins greatly affects their 
subcellular localization and, more particularly, their transport to the plasma 
membrane and the nucleus [8, 13, 44, 66, 68, 72, 75, 76]. In fact, KSR1 
translocation to the plasma membrane is a crucial step during Ras-dependent 
ERK activation. The current model to explain the scaffolding activity of 
KSR1 is depicted in Figure 6. A KSR1 multiprotein complex exists in resting 
cells which includes, among others, MEK, 14-3-3 and subunits A and C of 
the heterotrimeric PP2A phosphatase (Figure 6A).  
 Ras activation by growth factors allows reconstitution of a PP2A activity 
by recruitment of the regulatory subunit B to the complex [66]. As a result, 
the 14-3-3 binding site pS392 gets dephosphorylated by PP2A, KSR1 
partially dissociates from 14-3-3 and the CA3 domain gets exposed (Figure 
6B). Exposure of the cysteine-rich domain allows translocation of KSR1 to 
the plasma membrane, presumably by interaction with lipids [36]. 
Simultaneously, Raf kinases also get dephosphorylated by PP2A on 14-3-3 
binding sites (S259 in C-Raf) and recruited to the membrane by active, GTP-
loaded Ras (Figure 6B) [66]. The KSR1-associated CK2 activity then 
function as a Raf N-region kinase phosphorylating B-Raf on residue S446 
and C-Raf on S338 (Figure 6C) [65]. A negative charge at position +3 from 
the phosphorylation site is required for the Raf N-region kinase activity of 
CK2 [65]. Therefore, to get phosphorylated by CK2, C-Raf needs to be 
previously phosphorylated on Y341 by c-Src, whereas the presence of a 
negatively-charged aspartic acid residue at position 449 (D449) overcomes 
that requirement in B-Raf [65]. Raf proteins are able to form homo- and 
hetero-oligomers, with B-Raf/C-Raf dimers having a greater specific activity 
than   the   corresponding   homodimers   or   monomers [77].   The molecular 
Luís G. Pérez-Rivas  et al. 16
 
 
Figure 6. Mechanism of KSR1-mediated activation of ERK. (A) In resting cells, 
KSR1 is kept in an “inactive” state by 14-3-3 interaction and IMP-mediated 
partitioning to a detergent-insoluble fraction. Raf proteins are also inactivated by 
forming a complex with 14-3-3. (B) Ras activation disrupts the KSR1/IMP complex 
by recruiting IMP and promoting its autoubiquitination. In addition, the regulatory B 
subunit of PP2A associates with the catalytic core (subunits A and C), previously 
bound to KSR1 and Raf, dephosphorylating a 14-3-3 binding site (pS392 in KSR1). 
KSR1 then exposes its membrane-targeting C1 domain and a docking site for ERK. 
Dephosphorylation of Raf by PP2A, among other events, contributes to the formation 
of B-Raf/C-Raf heterodimers. Side-to-side dimerization and 14-3-3 bridging are likely 
involved in the formation of B-Raf/C-Raf complexes. (C) The KSR1-associated CK2 
enzyme contributes to Raf activation by functioning as a Raf N-region kinase. (D) 
Activated Raf phosphorylate KSR1-bound MEK, which in turn phosphorylate and 
activate ERK. Recent data indicate that activated ERK phosphorylate KSR1 and B-
Raf proteins on several feedback S/TP sites which results in KSR1 dissociation from 
B-Raf and attenuation of ERK signaling. 
 
determinants involved in the formation of Raf oligomers are beginning to be 
uncovered. Binding of 14-3-3 proteins to a C-terminal site in both B-Raf (pS729) 
and C-Raf (pS621) bridges the two monomers in B-Raf/C-Raf heterodimers 
[77, 78]. Surprisingly, C-Raf can be fully activated by heterodimerization with 
a kinase-inactive B-Raf mutant, indicating that B-Raf acts allosterically on C-Raf 
[78]. A very recent study has provided an explanation for this puzzling evidence. 
Thus, Therrien and coworkers have described the activation of Raf by a new 
and specific mode of dimerization of its kinase domain, which they call side-to-
side dimerization [79]. Interestingly, the dimerization surface is conserved in 
the Raf-related pseudokinase domain (CA5) of KSR, which could allow side-
to-side heterodimerization of both proteins and explain the intrinsic Raf 
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activating potential of mamalian KSR in the absence of catalytic activity [79]. 
Whether or not the associated CK2 activity contributes to the KSR scaffolding 
activity in different cellular contexts needs to be clarified since depletion of 
CK2 levels by RNA interference in Drosophila S2 cells had no impact on the 
side-to-side activation of Raf by D-KSR [79].  
 KSR1 can also form homodimers through interactions in the CA5 region 
[69] which could be mediated by side-to-side dimerization. The ubiquitin E3 
ligase IMP blocks KSR1 homodimerization and B-Raf/C-Raf heterodimerization, 
resulting in inhibition of MEK activation and signaling through the ERK 
cascade [29, 68, 69]. This effect seems to be a consequence of the KSR1/IMP 
complex partitioning to a detergent-insoluble cellular compartment, where 
KSR1 is kept “inactive” by hyperphosphorylation on S392 and 14-3-3 
binding [68]. Active, GTP-bound Ras prompts dissociation of the KSR1/IMP 
complex by a direct interaction with IMP and stimulation of its auto-
polyubiquitination activity (Figure 6B) [68]. Therefore, active Ras 
contributes to the scaffolding activity of KSR by a dual mechanism involving 
the potentiation of positive signals (dephosphorylation of KSR and Raf 
proteins) and blockade of the negative ones (IMP interaction) [29, 68, 69]. 
 A functional CA1 domain and MEK binding are required for KSR1 to 
associate with B-Raf and form a ternary complex competent for downstream 
signal transduction [13]. Once activated, Raf kinases phosphorylate and 
activate KSR-associated MEK which, in turn phosphorylate and activate 
ERK (Figure 6D). As mentioned above, activated ERK phosphorylates KSR1 
and B-Raf on several feedback S/TP residues to foster dissociation of the 
KSR1/B-Raf complex, release of KSR1 from the plasma membrane and 
attenuation of signaling through the pathway [13].  
 In addition to modulating the scaffolding activity of KSR1 at the plasma 
membrane, phosphorylation has also been reported to regulate the 
nucleocytoplasmatic transport of KSR1 [75]. In contrast to wild-type KSR1, 
which shuttles continuously between the nucleus and the cytoplam, a 
T274V/S392A double mutant is constitutively located in the nucleus [75]. 
Thus, the evidence suggests that 14-3-3 release, in the absence of ERK 
phosphorylation mediates the nuclear translocation of KSR1. The molecular 
mechanism involved in this process awaits its characterization, although 
proteomic analysis of immunopurified KSR has revealed several members of 
the importin family as part of the multiprotein complex [8]. 
 
6. Role of KSR in oncogenic Ras signaling 
 
 Since KSR was initially identified in C. elegans and D. Melanogaster by 
the isolation of mutants able to revert the phenotype of transgenic animals 
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expressing an hyperactive (“oncogenic”) form of Ras, it has always been 
considered an attractive target to investigate therapeutic strategies against 
Ras-dependent tumors [3-5, 80]. Initial efforts were aimed at the molecular 
characterization of KSR proteins and elucidation of the mechanism used to 
transmit Ras-dependent signals [17, 19, 21-24, 43, 55, 81]. However, it was 
not until the development of ksr1 knockout mice that an in vivo evidence for 
its role in Ras-mediated tumorigenesis was obtained. Two KSR1-deficient 
mice were generated by work done independently in the groups of Shaw [10] 
and Kolesnick [15]. In both cases, ksr1-/- mice were viable and developed 
normally, indicating that either KSR1 is dispensable for development or, 
more likely, KSR2 compensates for KSR1 deficiency. However, cultured 
primary embrionic fibroblasts (MEFs) and T cells obtained from KSR1-
deficient mice showed some important limitations, such as the exclusion of 
MEK and ERK from high molecular weight signaling complexes and, as a 
consequence, impaired MEK/ERK activation and reduced proliferation [10, 
15]. Further, ksr1-/- MEFs transduced with retroviral versions of the c-myc 
and Ras oncogenes were not transformed and did not form colonies in soft 
agar [15]. To address the in vivo relevance of KSR1 in Ras tumorigenesis, 
Lozano et al. bred ksr1-/- mice to hemizygous Tg.AC mice containing an 
oncogenic form of the ν-HA-ras transgene in the skin [82]. This animal 
model has been widely used to study two-stage skin carcinogenesis. The ν-
HA-ras oncogene is transcriptionally silent in latent neoplastic cells until 
induced by topical treatment with the tumor promoter 2-O-
tetradecanoylphorbol 13-acetate (TPA), wich induces papilloma formation 
[82]. Notably, while most Tg.AC mice (70%) in a ksr1+/+ background 
(Tg.AC/ksr1+/+) developed papillomas after repeated TPA treatment, only 
10% of the Tg.AC/ksr1-/- mice displayed papillomas [15], strongly indicating 
a critical role for KSR1 in Ras-mediated tumor formation. 
 In the work by Nguyen et al. their ksr1-/- mice were crossed with mice 
transgenic for the polyomavirus middle-T antigen (MT+), which develop 
breast tumors soon after birth [83]. MT functions like a constitutively active 
receptor at the membrane by recruiting several signaling molecules, including 
c-Src, PI3K and the adaptor protein ShcA. Tyrosine phosphorylation of ShcA 
creates binding sites for Grb2/Sos1 which initiates Ras/ERK signaling [84]. 
Therefore, breast tumors produced in MT+ mice can be considered Ras-
dependent [10]. Although they also developed tumors, the onset of tumor 
formation in MT+ ksr1-/- mice was almost twice slower than in MT+ ksr1+/- 
indicating that KSR1 deficency also impairs Ras-dependent tumorigenesis in 
this knockout model [10]. The different response observed in the two KSR1-
deficient mice after Ras activation (blockage in Tg.AC/ksr1-/- mice vs delayed 
tumor progression in MT+ ksr1-/- mice) might be related to the fact that MT 
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mammary tumors signals through wild-type Ras and PI3K [83, 85] while 
tumors arising in the Tg.AC/ksr1-/- are dependent on oncogenic Ras and ERK 
signaling [86]. In spite of this small difference, it is worth noting that both 
knockdown models are refractory to Ras-mediated tumorigenesis. 
 Xing et al. have provided proof-of-concept data for the consideration of 
KSR1 as a bona fide therapeutic target in the treatment of Ras-dependent 
tumors [87, 88]. Thus, A431 epidermoid carcinoma cells stably transfected 
with an antisense KSR1 construct to reduce KSR1 levels by 60%, did not 
form tumors when implanted subcutaneously in nude mice (the control, 
vector-transfected A431 cells were highly tumorogenic) [87]. In addition, 
delivery of a KSR1-specific synthetic phosphorothioate antisense 
oligonucleotide (AS-ODN-1) to human PANC-1 pancreatic cancer cells, 
reduced KSR1 levels by 90% and inhibited proliferation, invasion and 
transformation. More importantly, continuous infusion of AS-ODN-1 via 
implanted osmotic pumps in mice xenografted with PANC-1 tumors 
attenuated or completely abolished (depending on the dose) tumor growth 
without affecting signaling upstream of Ras [87]. When human A549 non-
small-cell lung tumors were xenografted instead of PANC-1, infusion of AS-
ODN-1 not only inhibited tumor growth but also reduced the number of 
metastatic foci in the lungs by 60-80% [87]. The tumorigenic activity of 
A431 cells is driven by EGFR overexpression and Ras hyperactivation while 
both PANC-1 and A549 express an oncogenic K-Ras protein (mutations 
G12D and G12S, respectively) [89, 90]. Therefore, the above experiments 
highlight the importance of KSR proteins in Ras-dependent tumor formation 
and further support its evaluation as a therapeutic target in neoplasias with a 
high incidence of oncogenic Ras mutations, such as pancreatic, 
gastrointestinal (GI) tract and lung carcinomas. Interestingly, KSR1 has also 
been suggested to be a potential prognostic marker in oncology since 
evaluation of a panel of cancer cell lines expressing different levels of KSR1 
indicates that KSR1 expression inversely correlates with anticancer drug 
sensitivity [91]. Thus, cancer cells with higher levels of KSR1 were more 
resistant to cytotoxic drugs while those with lower KSR1 levels showed 
enhanced sensitivity and increased ERK activation [91]. 
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Abstract. Cot, as well as its murine homologue tpl-2, was 
discovered in a COOH–terminal truncated form that unmasks the 
transformation capacity of the protein. The COOH-terminal 
domain of wt Cot contains an amino acid sequence that is a 
recognition signal for degradation via proteasome, besides, this 
domain of wt Cot is also an autoinhibitory domain of the specific 
activity of the wild type form. These data explain the 
transformation capacity of trunc-Cot/tpl-2, that when 
overexpressed is capable of activating several MAP kinases 
pathways as well as AP-1, NFAT, and NF-κB2 transcriptional 
activities. Earlier sobreexpression experiments lead to the proposal 
that Cot/tpl-2 could be involved in proliferative signalling, but the 
use of new technologies such as genetically modifies mice and 
interference RNA end up with the already accepted hypothesis that 
Cot/tpl-2 is involved in immune innate and adaptive processes. 
Cot/tpl-2 is activated in response to the activation of the TLR/IL-1 
receptor superfamily as well as in response to the activation of 
some receptors of the TNF family. Independently of the cell system  
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it is accepted that in resting cells Cot/tpl-2 forms a stable and inactive complex with 
p105 NF-κB among other proteins to protect it from degradation, adequate TLR/IL-
1R stimulation induces the activation of the IKK complex that targets p105 NF-κB 
to be rapidly degraded by the proteasome pathway to p50 NF-κB, a subunit of the 
NF-κB transcription factor. Consequently Cot/tpl-2 is released from the complex 
and susceptible to transduce the activatory signal, leading to the activation of the 
MEK1-Erk1/Erk2 pathway. However, actually it is not completely understood all 
the requests that Cot/tpl-2 needs to be fully active and to this end it is also accepted 
that Cot/tpl2 requires to be phosphorylated. In addition the possibility that the 
requirements vary from cell system to cell system cannot be excluded. 
Physiologically, Cot/tpl-2 is involved in provoking innate immunity to establish 
adaptive immunity. In fact it is the unique MAP3K that activates Erk1/Erk2 when 
the TLRs/IL-1 receptors are activated and mediates the production of pro-
inflammatory cytokines, such as TNFα, IL-1, or IL-6. More recently it has been 
shown that Cot/tpl-2 has the capacity to regulate the balance between Th1 and Th2 
cytokines. All these data indicate that, although mutations in Cot gene result in the 
expression of a protein linked with cell malignancies, physiologically wt Cot/tpl-2 
is involved in innate and adaptive immunity.  
 
Characterization of Cot/tpl-2 protein 
 
 Cot/tpl-2 is a MAP kinase kinase kinase (MAP3K8) capable of activating 
the MEK1-Erk1/Erk2 pathway. The human Cot gene was identified in a 3´ 
rearrangement form that leads to the expression of a truncated/modified 
protein. The normal homologue has an open reading frame encoding 467 
amino acids. The first 397 are identical to the truncated form (trunc-Cot), 
while the 69 amino acids from the COOH-terminal of wt Cot are replaced by 
18 amino acids without sequence homology in the truncated form (1). The 
murine homologue of the human Cot gene is the tpl-2 gene.  The tpl-2 gene 
was also identified in a similar truncated/modified form (2). The COOH-
terminal domains of both wt Cot and wt tpl-2 are almost identical. The only 
difference between the last 77 COOH-terminal amino acids of the human wt 
Cot and the murine wt tpl-2 are the two conservative substitutions of the 
residues M437 for V and K439 for R. However, there is no similarity in the 
amino acids inserted in either trunc-Cot or trunc-tpl-2. These 
truncations/modifications unmask the transforming capacity of this MAP 
kinase kinase kinase, a property of the trunc-Cot/tpl-2 protein (Fig. 1).  
 Nevertheless, it has been shown that overexpression of the proto-
oncogenic form is also capable of conferring a transformed phenotype to 
established cell lines (3-5). 
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 The COOH-terminal domain of wt Cot contains the 
EMLKRQRSLYIDLGALAGYFNL amino acid sequence that is a 
recognition signal for degradation via proteasome. This degron confers 
instability to other unrelated proteins and accounts for the 2.6-fold lower t1/2 
of wt Cot compared (35 min), to trunc-Cot (90 min). On the other hand, the 
deletion of the 44 amino acids of the COOH-terminal of wt Cot increases its 
specific activity in 3.8 fold, measured as MEK1-Erk1/Erk2 activation, 
indicating that the COOH-terminal domain of wt Cot is also an autoinhibitory 
domain of the specific activity of the wild type form (5) (Fig. 1). In fact, the 
COOH-terminal of tpl-2 is capable of inhibiting the kinase activity of trunc-
tpl-2 “in vitro” (2). Moreover, phosphorylation of the residue S400, which is 
contained in the carboxi-terminal of the wt form but not in the 
truncated/modified form, by extracellular stimuli, increases the specific 
activity of the protein (6). In conclusion, all these data indicate that deletion 
of the carboxi-terminal region of the murine and human wt forms increases 
their kinase activity through two independent mechanisms that leads to an 
increase in the t1/2 and an increase in the specific activity of the kinase, both 
potentiate each other in such a manner that equal amounts of trunc- and wt 
Cot mRNA results in a 10-fold increase in the activity of trunc-Cot.  
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Figure 1. Schematic representation of Cot protein kinase.PartA compares the 
structures of the wt Cot (above) and  trunc-Cot (below) proteins. The last 69 amino-
acids of the carboxi-terminal region from the wt protein have been substituted by 18 
unrelated amino-acids. The alternative translation start methionine (M29) is also 
indicated. Part B shows the different domains of the wt Cot protein. The amino-acid 
sequence of the destabilizing region located at the N terminus is shown. The C-
terminus sequence include both a destabilizing region and a kinase activity 
inhibitory domain. The main phosphorylation sites (residues S62, T290, and S400) 
are indicated. 
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 Two alternative translation initiation sites M(1) and M(29) has been 
described for wt Cot/tpl-2 (7). M(29) wt Cot does not contain the first 29 amino 
acids of M(1) wt Cot and exhibits a three -fold higher t1/2 than M(1) wt Cot (7). 
This data suggests that the N-terminal of wt Cot contains another signal that 
triggers the protein to degradation. In fact antibodies against the C-terminal of 
Cot wt recognized two bands in Western blot analysis, being the one with 
higher mass more rapidly degraded (8-10), although the sequence of amino 
acids in the N-terminal of the protein involved in this process remains to be 
established.  
 
Mutations in Cot/or tpl-2 gene are associated with tumorigenesis 
 
 Increased Cot/tpl-2 activity has been observed in different transformed 
cell types. In fact, different modifications in Cot/tpl-2 have been proposed to 
be responsible for cellular transformation (Table1). Cot was identified in a 
truncated/modified form that occurred as a consequence of a rearrangement 
in the 3´ terminal region of human Cot gene during transfection of the 
genomic DNA of a human carcinoma cell line into hamster SHOK cells; this 
rearrangement induced the transformation of the murine cells (1).  
 The insertion of the Moloney Leukaemia Provirus into tpl-2 gene also 
induced a rearrangement in the 3´terminal region of tpl-2 gene. This tpl-2 
gene reorganization plays an essential role in the progression of T 
lymphomas (11, 12). Similarly, the insertion of the Mouse Mammary Tumour 
Virus (MMTV) in the last intron of tpl-2 gene is associated with transformation 
 
Table 1 
 
Type of mutation Cell line/ tissue Reference 
3´ rearrangement of  
Cot/tpl-2 gene 
Hamster SHOK cells. In vitro 
transfection of human genomic 
DNA  
Miyoshi (1991) 
3´ rearrangement of  
Cot/tpl-2 gene 
Murine T cell. Insertion of the 
Moloney Leukemia provirus 
Patriotis  (1993) 
3´ rearrangement of  tpl-2 
gene 
Mammary gland. Insertion of 
Murine Mammary  provirus 
Erny (1996) 
3´ rearrangement of  Cot  
gene 
Primary human adenocarcinoma Clark (2004) 
Genomic locus 
amplification  
Human breast cancer cells Sourvinos (1999) 
Postraductional 
modifications 
Infection of the human T cell 
leukemia virus type-I 
Babu (2006) 
 
Unknown  Human large granular 
lymphocyte proliferative 
disorder 
Christoforidou (2004) 
Unknown Epstein-Barr virus infection  Eliopoulos (2002) 
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of mammary gland cells (13). More recently, in some human adenocarcinoma 
primary tumors a modification in the 3´ region of Cot gene has been 
confirmed (14). The deletion of the 3´ region of the Cot and tpl-2 genes 
provoke not only the expression of a truncated/modified protein, as explained 
above, but also the deletion of the 3´ untranslated region of both genes that 
harbor three copies of the RNA destabilizing sequence AUUUA. This, results 
in the higher expression levels of their corresponding mRNAs (12, 13).  On 
the other hand, the human Cot genomic locus, without modifications in the 
coding sequence of Cot gene, is amplified in some human breast cancers 
(15). Based on these data it has been proposed that Cot could be a prognostic 
factor in breast cancer development (16). Moreover, a correlation between 
high Cot mRNA levels and human large granular lymphocyte proliferative 
disorder has been also proposed (17). Besides the infection of the human T 
cell leukemia virus type-I (HTLV-I) induces high steady state expression 
levels of the M(29) wt Cot, that as previously mentioned, exhibit a high 
stability, resulting in high levels of Cot activity (18). Cot is also commonly 
highly expressed in Epstein Barr virus -associated malignancies, such as 
nasopharyngeal carcinoma and gastric cancer (19). All these data, indicate 
that increased Cot/tpl-2 activity plays a role in cell transformation, besides 
more recently it has been also proposed that Cot could also participate in cell 
invasion processes (20, 21).  
 However in contrast to the established role of Cot/tpl-2 as an oncogene, it 
has been also reported that wt Cot/tpl-2 can function as a tumour suppressor 
gene, since CD8+ T cell lymphomas are developed in old Cot/tpl-2 KO mice 
(22). In these cells the Cot/tpl-2 downregulation decreases the expression of 
the T cell co-receptor CTL4, which negatively regulate de signals transducer 
through the T cell receptor (TCR).   
 
Regulation of Cot/tpl-2 activity by extracellular signals 
 
 Cot and tpl-2 genes were identified in an oncogenic form; thereby for 
many years, it was expected, that the proto-onco Cot/tpl-2 protein could be 
involved in the intracellular proliferative signals pathways. However, the fact 
that the tpl-2 knock-out mice was resistant to LPS/D-Galactosamine-induced 
pathology, due to the low production of TNFα among other cytokines, 
indicated that, physiologically, endogenous Cot/tpl-2 would be involve in 
innate and adaptive immunity rather in proliferative signals (23). 
 Now it is accepted that Cot/tpl-2 is activated in response to the activation 
of the TLR/IL-1 receptor superfamily as well as in response to the activation 
of some receptors of the TNF family (24-26) and that Cot/tpl-2 plays a unique 
role in inflammatory processes. The TLRs, included in the TLR/IL-1R 
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superfamily, contain an extracellular leucine-rich repeat region and are 
sensors of the infection by pathogens since they recognized the different 
pathogen-associated molecular patterns (PAMPS): bacterial lipopeptides 
(TLRs1, 2, and 6) lipopolysaccharide (TLR4), flagellin (TLR5) and nucleic 
acids (TLRs3,7,8, and 9). The IL-1 receptor subfamily, with an Igg like 
extracellular region, includes receptors for IL-1 (IL-1R), IL-18 (IL-18R, and 
IL-33 (T1/ST2 R). However, despite their different extracellular structure, 
both TLRs and IL-1Rs contain in their intracellular region the TIR domain 
and activate similar intracellular pathways including the recruitment to the 
receptor of some adaptors like MyD88, the activation of the kinases IRAK, 
and the ubiquitination of the TRAF proteins, resulting in the activation of the 
IKK complex (reviewed in 27-29). 
  Independently of the cell system, it is accepted that in resting cells, 
Cot/tpl-2 forms a stable and inactive complex with p105 NF-κB among other 
proteins to protect it from degradation. The interaction between p105 NF-κB 
and wt Cot/tpl-2 was first described as a result of a yeast two-hybrid screen 
(30) and was further corroborated, by the fact that p105 NF-κB knock-out 
macrophages, show normal tpl-2 mRNA levels but tpl-2 protein, could be 
only detected when cells are treated with proteasome inhibitors (8,9). Studies 
performed with overexpressed p105 NF-κB and wt Cot/tpl-2, have indicated 
that Cot/tpl-2 protein interacts with p105 NF-κB trough two different 
domains (31). One interaction takes place through the COOH-domain of wt 
Cot/tpl-2, where a proteasome degradation signal is located. This interaction 
explains why the interaction between p105 NF-κB and Cot/tpl-2 protects 
Cot/tpl-2 from degradation. Another interaction between the kinase domain 
of Cot/tpl-2 and p105 NF-κB has been also proposed (31). This interaction 
does not allow the substrates of Cot/tpl-2, like MEK1, to interact with the 
kinase and to be subsequently phosphorylated (32). Besides, cotransfection 
experiments have also demonstrated that ABIN2 (A20-binding inhibitor of 
NF-κB2) also interacts with wt Cot/tpl-2 in addition to p105 NF-κB (33) 
(Fig. 2).  
 This interaction has been also further confirmed in knock-out ABIN2 
macrophages where, as occurred in p105 NF-κB knockout macrophages, 
endogenous wt Cot/tpl-2 protein is neither detected due to its rapid 
degradation. But, in contrast to p105 NF-κB, the interaction of ABIN2 with 
Cot/tpl-2 does not block its kinase activity (34, 35). All these data indicate 
that both p105 NF-κB and ABIN2 are necessary to form a complex with wt 
Cot/tpl-2 to protect the kinase from the proteasome degradation. Besides 
ABIN2 and p105 NF-κB it has been also reported that a member of the 
kinase suppressor family of RAS  (KSR2) interacts with Cot/tpl-2 when both  
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Figure 2. Mechanisms of Cot/tpl-2 activation. The figure shows a schematic 
representation of the mechanisms involved in the activation of Cot/tpl-2 by 
extracellular stimuli (TLRs/IL-1Rs). A) Cot protein status in basal conditions. In 
unstimulated cells Cot/tpl-2 protein is forming a complex with at least two proteins 
(p105 - NF−κB and ABIN-2), this association maintains Cot/tpl-2 inactive and stable. 
B) Upon ligand binding, activated IKKβ phosphorylates p105 tagging it for 
proteosoma degradation. Other signals, not clearly understood yet, allow Cot 
phosphorylation in different residues C) Cot is then released from its interaction with 
p105 and phosphorylated Cot/tpl-2 activates Erk1/2 pathway which is subsequently 
rapidly degraded by the proteasome. 
 
proteins are overexpressed. The co-expression of KSR2 with wt Cot/tpl-2 
significantly and specifically reduces Erk1/Erk2 and NF-κB activation by 
Cot/tpl-2 (36); however the physiological role of this interaction remains to 
be established. Further studies have to be performed to determine if other 
proteins are part of the p105 NF-κB-ABIN2-Cot/tpl-2 complex (37).  
 Adequate TLR/IL-1R stimulation induces the activation of the IKK 
complex; active IKKβ kinase phosphorylates p105 NF-κB in different 
residues (38-40). These phosphorylations target p105 NF-κB to be rapidly 
degraded by the proteasome pathway to p50 NF-κB, a subunit of the NF-κB 
transcription factor (38-41). Consequently Cot/tpl-2 is released from the 
complex and susceptible to transduce the activatory signal (8, 9, 31, 42). 
Once Cot/tpl-2 is dissociated from the complex is rapidly degraded just upon 
activation, by phosphorylation, of MEK1 (8,9). However, actually it is not 
completely understood all the requisites that Cot/tpl-2 needs to be fully active 
and the possibility that the requirements vary from cell system to cell system 
can not be excluded. In one hand, overexpression of TRAF6, an adaptor that 
mediates the activation of the IKK complex, is sufficient to induce Cot/tpl-2 
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activation in MEF cells (43), but not in HeLa cells (10). Overexpression of 
TRAF6 in HeLa cells induces IκBα degradation, indicating that TRAF6 
overexpression induces the activation of the IKK complex. However, the 
overexpression of this adaptor is not sufficient to induce Cot/tpl-2 activation, 
although TRAF6 is required to activate Cot in response to IL-1 stimulation 
(10). Similarly, in macrophages other TRAF protein, TRAF2, participates in 
the intracellular signalling to activate Cot/tpl-2 in response to TNFα but as in 
the case of HeLa it is not sufficient to induce the activation of the kinase (44). 
All together these data provide evidence that at least two intracellular signals 
are required to induce Cot activation (Fig. 2). One of which, is the 
dissociation of Cot from the inactive complex, being this intracellular 
pathway TRAF dependent, but others signal(s) is (are) required to fully 
activate the kinase. In this context it has been reported that upon cellular 
stimulation Cot/tpl-2 becomes phosphorylated in different residues, but the 
exact role of each of these phosphorylations remains to be elucidated (Fig. 1). 
It has been reported by several groups that in response to extracellular stimuli 
like LPS, TNFα or IL-1, Cot/tpl-2 is phosphorylated in the activation loop of 
the kinase, on residue T290 (45-47). This T290 phosphorylation, seems also 
to play a role in the dissociation of Cot/tpl-2 protein from the NF−κB p105 
complex and it is essential for the activation of Erk1/Erk2 by Cot/tpl-2 (45, 
48). Once Cot/tpl-2 is phosphorylated on residue T290, it phosphorylates 
itself in S62, this autophosphorylation enhances the capacity of Cot/tpl-2 to 
activate the Erk1/Erk2 pathway (45). On the other hand, a phosphorylation on 
the S400 of Cot/tpl-2 by LPS stimulation, is also required for a full Cot/tpl-2 
activation (6). AKT is capable of phosphorylating this residue “in vitro” (49), 
but does not plays any role in the phosphorylation of this residue “in vivo” 
and the identity of this kinase is still unknown (6). All these data indicate that 
in general to activate physiologically Cot/tpl-2 two requirements are 
necessary, dissociation of the inactive complex and an adequate 
phosphorylation state of the protein. 
  The specific kinases that phosphorylate both residues T290 and S400 on 
Cot/tpl-2 protein remain to be identified. However, it has been reported, that 
in response to IL-1 and TNFα stimulation Cot/tpl-2 activation requires the 
activity of a tyrosine kinase of the SRC family (10, 44), thereby it can not be 
excluded the possibility that a SRC tyrosine kinase activity, mediates the 
phosphorylation on residues T290 or S400 or both.  By using immobilized 
metal affinity chromatography (IMAC) and a linear trap mass spectrometer 
analysis, other phosphorylation sites on Cot/tpl-2 proteins have been also 
identified, but the role of these phosphorylations on Cot/tpl-2 protein are still 
unknown (50).   
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 More recently, it has been proposed that Cot/tpl-2 also mediates the 
activation of Erk1/Erk2 in response to the activation of the proteinase 
activating factor 1 (PAR-1) (21) and the adiponectin receptor (51). These two 
receptors contain in their structure the classical seven transmembrane 
domains, but not the TIR domain. Thereby, it is unlikely that these receptors 
could activate Cot/tpl-2 through the Myd88 adaptor. All these data open the 
possibility that Cot/tpl-2 take also part in other type of intracellular signaling 
pathways.   
 
Signal pathways activated by Cot/tpl-2 
 
 Both overexpressed wt Cot/tpl-2 and trunc Cot/tpl-2 are capable of 
increasing the activity of several MAP kinases pathways. Overexpression of 
wt or trunc-Cot/tpl-2 induce an increase in the MAP kinases pathways 
Erk1/Erk2, JNK (52), p38γ, and Erk5 (4). Cot/tpl-2, partially as a 
consequence of the up-regulation of the different MAP kinases pathways, 
induces the activation of several transcription factors, such as AP-1, NFAT 
and NF-κB.  
 Overexpression of Cot/tpl-2 induces AP-1 activity in different cell 
systems (53, 54). This activation is probably mediated by the capacity of Cot 
to stimulate c-Jun and c-Fos activities (4, 55). In this context, it has been 
proposed that the ability of Cot/tpl-2 to induce cellular transformation is 
dependent on its ability to activate these two transcription factors (4, 55).  
 Overexpressed Cot/tpl-2 also up-regulates the NFAT transcriptional 
activity (54). In fact, a physical interaction among both overexpressed 
Cot/tpl-2 and NFATc2 has been also demonstrated (56). In one hand, 
Cot/tpl-2 potentiates NFAT-induced transactivation (57), on the other one it 
has been also reported that Cot/tpl-2 induces an NFAT accumulation in the 
nucleus (58, 59). Since the NFAT transcription factors are regulated at two 
different levels, firstly at the level of subcellular localization and secondly 
at the level of the intrinsic DNA binding activity, it remains to be 
established, whether the reported accumulation of NFAT by Cot/tpl-2 in the 
nucleus, could be a consequence of the increased transactivation of NFAT 
triggered by the kinase, resulting in higher nuclear retention, or Cot/tpl-2 
could also have an active role in the modulation of the NFAT in/out 
shuttling of the nucleus.   
 Different groups have also shown that overexpressed Cot/tpl-2 induces 
the activation of the NF-κB, although the mechanism it still unclear. It has 
been claim that Cot/tpl-2 induces an increase in p65 NF-κB transcription 
factor activity by phosphorylating the residues S276 (60), S311(61),  or S536  
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(62), or  both  S468 and 536 (63). Several groups have stated that the NF-κB 
activation by Cot/tpl-2 is through the activation of the IKK complex (64-70), 
due  to the capacity of Cot/tpl-2 to activate NIK (63, 65), a kinase that 
mediates the activation of the IKK complex (71). Besides, it has been also 
proposed that Cot/tpl-2 is required to induce p105 NF-κB degradation (19, 
30) by phosphorylating p105 NF-κB in a different site than the IKK complex 
(32).  
 The cis-elements of these transcription factors modulated by Cot/tpl-2 
overexpression (AP-1, NFAT, and NF-κB) are conserved in many promoter 
regions, thereby, it should be expected that Cot/tpl-2 overexpression, would 
induce the transcription of many different genes (54, 57, 58, 72). However, 
more recent studies performed in cells; where the Cot/tpl-2 protein is knock-
out suggest that in a physiological context Cot/tpl-2 may be more specific 
than when overexpressed. This is in part due to the fact that Cot/tpl-2 share 
substrates with other kinases. Indeed, overexpression of the Cot/tpl-2 dead 
kinase mutant sequesters MEK-1, that physiologically is also phosphorylated 
by other kinases, such as c-RAF.  
 
Involvement of Cot innate and adaptive immunity 
 
 The physiological activation of Cot/tpl-2 has been extensively studied in 
macrophages after LPS stimulation.  Cot/tpl-2 is the unique MAP3K that 
activates Erk1/Erk2 in response to the activation of TLR4 by LPS in 
macrophages (9, 23, 73, 74) (Fig. 2) without modulating the activation of 
p38, JNK, Erk5, and NFκB (23). In TNFα- or LPS-stimulated macrophages, 
in CD-40- stimulated-macrophages or B cells, as well as in IL-1-stimulated 
HeLa cells, Cot/tpl-2 does not modulated JNK and p38 activation (10, 23, 
43). However in tpl-2-/- MEF cells not only Erk1/Erk2, but also JNK, and 
NF-κB activation are defective when stimulated with TNF whereas only 
Erk1/Erk2 activation is impaired when these cells are stimulated with IL-1. 
Thereby, it has been proposed that the signalling role of endogenous Cot/tpl-
2 is stimulus and cell type specific (60). 
 The ablation of Cot/tpl-2 expression in LPS-stimulated macrophages 
partially blocks TNFα (23) and IL-10 secretion (24), and reduces the 
expression of COX-2 (74). Cot/tpl-2 activation is also required to induce 
Erk1/Erk2 activation when bone marrow derived macrophages are activated 
with peptidoglycan, double-stranded RNA or loxoribine, that are ligands for 
TLR2, TLR3, and TLR7 respectively (24, 26). Cot/tpl-2 is also the sole 
MAP3K that activates Erk1/Erk2 pathway in B cells in response to anti-
CD40 and participates in the secretion IgE (43). In carcinoma Hela cells 
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Cot/tpl-2- MEK1-Erk1/Erk2 pathway is required to produce IL-8 and MIP-1β 
in response to IL-1 stimulation (10). On the other hand, and although Cot/tpl-
2 is involved in the intracellular signalling generated by the activation of 
TLR9 by CpG-DNA, it is not clear whether other MAP3K, besides Cot/tpl-2, 
upregulates the Erk1/Erk2 pathway in response to CpG-DNA stimulation  
(26, 75, 76).  
 The role of Cot in inflammation is not only confirmed by experiments 
performed in intact cells due to its capacity to modulate the production of  
cytokines/chemokines  involved in this process, but it also has been assessed 
“in vivo”. In fact Cot/tpl-2 KO mice have a reduction in caerulein-induced 
pancreatic inflammation upon tpl-2 ablation (77) and  it have  been also 
shown that Cot/tpl-2  plays a role in the  onset of Crohn’s  disease (78)(Fig.3) 
Besides, experiments performed with the Cot/tpl-2 KO mice, as well as with 
intact cells were Cot/tpl-2 is down modulated, have shown that this kinase 
modulates the strict balance between Th1 and Th2 cytokines. It has been 
reported that Cot/tpl-2 is an important negative regulator of Th1-type 
adaptive response due to its capacity to downregulate IL-12 production (75) 
(Fig. 3).  
 Antigen presenting cells from Cot/tpl-2 KO mice stimulated with CpG, 
an activator of TLR9, showed an increase in the IL-12 production (75, 76), 
and this  has been confirmed  “in vivo” by  performing  studies with the 
whole animal (75). More recently, it has been also shown, that antigen 
presenting cells from Cot/tpl-2 KO mice stimulated with LPS or CpG, 
showed not only an increase in IL-12 but also in the production of IFNβ, 
being  concomitant  with  a  reduction  in  the levels  of  IL-10, a  typical  Th2 
 
 
 
Figure 3. Cot/tpl-2 modulates Th1/Th2 response and inflammation. In the figure are 
summarized some data from the bibliography using mice null for the Cot/tpl-2 gene. 
The Cot/tpl-2 KO mice shows a decreased production of inflammatory cytokines such 
as TNFα or IL-1β and an increased production of cytokines characteristic of the Th1 
response like IL-12, IFNβ and decreased production of IL-10. 
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cytokine (76). However, further studies have to be carried on to determine the 
exact role of Cot/tpl-2 in polarizing the immune response to type Th1, since 
IL-12-stimulation  of CD4+ T lymphocytes of Cot/tpl-2 KO mice do not to 
produce IFNγ, another key cytokine  in the Th1 response (79). 
 
Cot/tpl-2 a target of anti-inflammatory drugs 
 
 Cot/tpl-2 and RAF isoforms are capable of activating the MEK1-
Erk1/Erk2 pathway, being Erk1/Erk2 a MAP kinase that phosphorylates 
multiple substrates. However RAF-MEK1-Erk1/Erk2 pathway is activated in 
response to proliferative signals, whereas Cot/tpl-2 mediates the intracellular 
signalling of PAMPs and pro inflammatory cytokines, indicating that Cot/tpl-
2 is involved in innate and adaptive immunity and thereby in inflammation. 
Besides, the Cot/tpl-2 physiological role can not be replace by any other 
protein, indicating that this protein is a very good target to develop new and 
improved anti-inflammatory drugs (80, 81). In fact, several groups and 
companies, have focused in the development of small organic compounds to 
specifically block the kinase activity by occupying the active center of 
Cot/tpl-2.  To date, 1,7-napthyridine-3-carbonitriles, quinoline-3-carbonitriles 
and  thieno[2,3-c]pyridines, have been reported as Cot/tpl-2 kinase inhibitors 
(82, 85). It has been shown, that the 7-amino substituted thieno[2,3-
c]pyridines are capable to inhibit activation of Erk1/Erk2 in bone marrow 
derived macrophages in response to LPS stimulation as well as TNFα secretion 
in human whole blood (85).   Among the quinoline-3-carbonitriles, it has 
been proposed that the 8-bromo-4-(3-chloro-4-fluorophenylamino)-6-[(1-
methyl-1H-imidazol-4-yl)met hylamino]quinoline-3-carbonitrile compound 
is capable to inhibit, at an oral dose of 50 mg/kg, the production TNF-α in a 
LPS-induced rat model (83).  
 More recently, it has appeared the possibility to obtain a specific 
ribozyme to degrade the Cot mRNA.  This catalytic RNA is an adenine-
dependent hairpin ribozyme that specific cleaves “in vitro” the mRNA of 
Cot/tpl-2 between bp +225 and +266 bp (86, 87). Further studies are required 
to determine whether this type of compounds or other improved ones will be 
useful to inhibit specifically the expression of Cot/ tpl-2 “in vivo”. 
 
Conclusion 
 
 Cot gene was identified in 1991, and since then we are beginning to 
understand its physiological role in biological processes. Today, there is also 
a very clear link between inflammation and cancer and Cot/tpl-2 is a good 
example of how a protein that is required to control immune responses 
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properly, playing a role in cell transformation when des-regulated. Now, it is 
also clear that this gene has a unique role in the development of the immune 
responses and in inflammation and thus Cot/tpl-2 is emerging as a very 
interesting target to arise new anti-inflammatory drugs.  However, and as it 
has been discussed here, there are still many questions unresolved  before to 
complete the picture of Cot/tpl-2 activation and function.  
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Abstract. The subfamily of WNK (With No K [lysine]) protein 
kinases is characterised by a unique sequence variation in the 
catalytic domain: a conserved lysine residue that is essential for 
catalytic activity in most eucaryotic protein kinases is located in an 
alternative position within the catalytic domain and this variation 
may result in unique substrate binding properties. The human 
genome contains four WNK genes, with different tissue-specific 
expression patterns. Mutations in WNK1 or WNK4 cause a 
hereditary hypertension syndrome due to increased renal salt 
retention. At the molecular level, WNK1, WNK3 or WNK4 have 
been shown to regulate different ion transporters in both the kidney 
and extrarenal tissues. Growing evidence has also revealed 
additional roles for WNK kinases in multiple signalling cascades 
related to tumour biology. There is strong evidence for a role as 
upstream regulators of MAPK cascades involved in cell 
proliferation control. In addition, a requirement of some WNK 
members for cell survival has been demonstrated. Here, we review 
the experimental evidence linking WNK kinases to tumorigenesis 
and discuss their role in major aspects of tumour biology: G1/S cell 
cycle progression, metabolic tumour cell adaptation, evasion of 
apoptosis, and metastasis.  
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Introduction 
       
 The phosphorylation of cellular proteins alters their function and is 
catalysed by protein kinases in response to extra- or intracellular stimuli. A 
superfamily of protein kinases has been recognized based on conserved 
sequence elements in their catalytic domains and human genome-wide 
analyses have concluded that there are 518 different protein kinase genes 
[1-3]. Of these, 478 genes present the classical eukaryotic protein kinase 
catalytic domain [4], while 40 are atypical kinases. Of the 478 classical 
kinases, 428 possess known or likely kinase activity, while the remaining 
50 proteins lack conserved key sequence elements. Among the 428 classical 
kinases, 365 fall into seven major families (TK, CAMK, AGC, CMGC, 
STE, TKL, and CK1), whereas 63 kinases present sequence variations in 
their catalytic domains and have been classified separately as 'Other' [3]. 
This group contains unique kinase genes or small subfamilies, including the 
WNK (With No [K] = lysine) subfamily. Phylogenetically, WNKs define a 
separate protein kinase branch, most closely related to the STE (mammalian 
homologs of the Saccharomyces cerevisiae STE families of 
serine/threonine kinases) and TKL (tyrosine kinase-like) family branches 
[1, 3]. 
 The unique sequence variation that characterises WNK protein kinases [5, 6] 
is the lack of a highly conserved catalytic lysine in subdomain II, important for 
the correct positioning of adenosine triphosphate (ATP) within the classical 
catalytic domain [4]. The crystal structure for the recombinant WNK1 kinase 
domain has been determined [7] and revealed that an alternative lysine from 
subdomain I reaches into the position normally occupied by the conserved 
lysine residue from subdomain II and therefore confers catalytic activity [5] 
(see Figure 1).  
 The sequence variation in the catalytic domain can be expected to induce 
conformational changes responsible for unique ATP and substrate binding 
properties of WNK kinases. Otherwise, the overall structure and folding of 
the WNK1 catalytic domain resembles that of other protein kinases with 
typical bilobal domain architecture [8]. 
 WNK proteins are serine/threonine kinases that undergo 
autophosphorylation and require phosphorylation of at least one serine 
residue within the WNK activation loop, S382 in WNK1, to become active 
[9, 10]. This serine is part of an activation site motif (S378FAKS382) that is 
conserved in MEK family kinases. Sequence alignment identifies 
homologue serine residues in positions 356, 308 and 332 for WNK2, 3 and 
4, respectively.  
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Figure 1. Sequence variation in the catalytic domain that characterises the WNK 
subfamily of protein kinases. The typical protein kinase catalytic domain is 
subdivided into 12 subdomains. A conserved lysine in subdomain II, which binds 
ATP, is absent in WNK kinases and functionally substituted by another lysine located 
in subdomain I [5, 7], as indicated.  
 
 Another primary level in the regulation of WNK kinase activity can be 
provided by the autoinhibitory domain encompassing about 70 residues just 
C-terminal to the catalytic domain and these are conserved in WNK protein 
kinases across species [9, 11]. 
 The characteristic catalytic lysine in subdomain I together with 7 other 
adjacent amino acid residues form an invariant WNK signature sequence [6] 
(see Figure 2). A database search using the WNK signature sequence 
revealed the existence of a variable number of WNK genes in animals and 
plants that are absent in uni-cellular organisms. The number of WNK genes 
increases from one WNK gene in C. elegans or Drosophila melanogaster to 
four different WNK genes in mouse and man, while the higher plant 
Arabidopsis thaliana has 9 WNK genes [6, 12, 13].  
 The human genome contains four WNK genes with chromosomal 
locations at 12p13.3 (WNK1), 9q22.31 (WNK2), Xp11.23-p11.21 (WNK3) 
and 17q21-q22 (WNK4). The human WNK1 gene contains 28 exons and 
extends over more than 150 kb, WNK2 is encoded by 31 exons that span 136 
kb, WNK3 contains 24 exons and spans 165 kb, whereas WNK4 is encoded 
by 19 exons contained within 16 kb of genomic DNA [6, 14, 15]. These 
genes differ in their tissue specific expression patterns. WNK1 is expressed 
in most human foetal and adult tissues; WNK3 is mainly expressed in brain, 
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liver and small intestine, WNK2 is mainly present in brain, heart and colon 
crypt, and WNK4 predominantly in the kidney, colon, skin, liver, and lung 
[5, 6, 14-19]. Expression analysis of WNK kinases has also revealed the 
existence of tissue-specific alternative promoter usage, alternative splicing 
and polyadenylation variants [6, 14, 15, 19-21].  
 
I II III IV V VIA VIB VII VIII IX X XI
N-terminal lobe
(ATP-binding)
C-terminal lobe
(Substrate binding)
WNK signature sequence      
GENE CATALYTIC SUBDOMAINS I+II GENE ID 
hs WNK1 LKFDIEIGRGSFKTVYKGLDTETTVEVAWCELQ 65125 
hs WNK2 LKFDIELGRGSFKTVYKGLDTETWVEVAWCELQ 65268 
hs WNK3 LKFDIELGRGAFKTVYKGLDTETWVEVAWCELQ 65267 
hs WNK4 LKFDIEIGRGSFKTVYRGLDTDTTVEVAWCELQ 65266 
mm WNK1 LKFDIEIGRGSFKTVYKGLDTETTVEVAWCELQ 232341 
mm WNK2 LKFDIELGRGSFKTVYKGLDTETWVEVAWCELQ 75607 
mm WNK3 LKFDIELGRGAFKTVYKGLDTETWVEVAWCELQ 279561 
mm WNK4 LKFDIEIGRGSFKTVYRGLDTDTTVEVAWCELQ 69847 
at WNK1 GRYNEVLGKGASKTVYRAFDEYEGIEVAWNQVK 819651 
at WNK2 GRYDEILGKGASKTVYRAFDEYEGIEVAWNQVK 821810 
at WNK3 GRYKEVLGKGAFKEVYRAFDQLEGIEVAWNQVK 823984 
at WNK4 GRFAEILGRGAMKTVYKAIDEKLGIEVAWSQVK 835947 
at WNK5 GRFREVLGKGAMKTVYKAFDQVLGMEVAWNQVK 824326 
at WNK6 IRYKEVIGKGAFKTVYKAFDEVDGIEVAWNQVR 821406 
at WNK7 IRYKEVIGKGASKTVFKGFDEVDGIEVAWNQVR 841339 
at WNK8 IRYDDVLGRGAFKTVYKAFDEVDGIEVAWNLVS 834204 
at WNK9 GRYNEVLGKGSSKTVYRGFDEYQGIEVAWNQVK 832881 
rn WNK1 LKFDIEIGRGSFKTVYKGLDTETTVEVAWCELQ 116477 
pt WNK1 LKFDIEIGRGSFKTVYKGLDTETTVEVAWCELQ 451739 
clf WNK1 LKFDIEIGRGSFKTVYRGLDTDTTVEVAWCELQ 477728 
gg WNK1 LKFDIEIGRGSFKTVYKGLDTDTTVEVAWCELQ 427925 
dm CG7177 FKYDKEVGRGSFKTVYRGLDTLTGVPVAWCELL 40391 
ce C46C2.1 LKFDEELGRGSFKTVFRGLDTETGVAVAWCELQ 177743 
       Invariant                                G G  K V    D      VAW        
 
Figure 2. Alignment of subdomains I and II of the catalytic domains of some WNK 
kinases from various species. The invariant WNK signature sequence is indicated below. 
Species abbreviations are: hs, Homo sapiens; mm, Mus musculus; at, Arabidopsis 
thaliana; rn, Rattus norvegicus; pt, Pan troglodytes; clf, Canis lupus familiaris; gg, 
Gallus gallus; dm, Drosophila melanogaster; ce, Caenorhabditis elegans (updated from 
Veríssimo and Jordan, 2001); NCBI sequence IDs are also given. 
 
 The four human WNK kinases are large proteins containing 2382, 2297, 
1743 or 1243 amino acids with predicted molecular weights of 251, 243, 192 
and 135 kDa, for WNK1, 2, 3 and 4 respectively [6, 14, 15, 21]. They share 
high homology within their kinase domains and the adjacent auto-inhibitory 
domain [9], however, homology outside their catalytic domains is low except 
for the presence of three short WNK homology regions (Figure 3).  
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Figure 3. Schematic representation of the four human WNK proteins. Catalytic, 
autoinhibitory and coiled-coil domains are shown as well as conserved regions of 
homology between WNK kinases. The white numbers indicate sequence identity of 
the respective catalytic domain with regard to the WNK1 sequence. 
 
 The most C-terminal homology region III contains a coiled-coil domain 
and WNK1 and WNK4 have at least one further coiled-coil domain outside 
the conserved regions. In addition, four short regions of unknown function 
are conserved between WNK1, WNK2 and WNK3. Multiple PXXP motifs, 
the typical binding sites for Src-homology 3 (SH3) domains [22], are also 
present in WNK protein kinases, suggesting a potential scaffolding function 
for these proteins [6, 23]. 
 In this chapter we will address the experimental evidence linking WNK 
kinases to tumorigenesis and discuss four main aspects: their roles in G1/S 
cell cycle progression, metabolic tumour cell adaptation, evasion of apoptosis 
and, finally, invasion and metastasis. 
 
1. Role of WNK kinases in cell cycle progression 
 
 Normal cells require extracellular growth stimulatory signals in order to 
leave the quiescent and enter a proliferative state. In epithelial cells the 
stimulation of cell proliferation is intimately linked to the receptor-mediated 
activation of the mitogen-activated protein kinase (MAPK) cascades. 
 
1.1. WNKs regulate MAP kinase cascades 
 
 The best characterized MAPK pathways in mammals involve the 
extracellular signal-regulated kinases 1 and 2 (ERK1/2), the p38 isoforms, 
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the c-jun N-terminal kinases (JNK1-3), and ERK5. In general, MAPK 
cascades consist of three protein kinase layers: MAPKs are phosphorylated 
and activated by MAPK kinases (MAP2Ks) which are in turn activated by 
phosphorylation by MAPK kinase kinases (MAP3Ks). Other kinases, 
including p21-activated protein kinases (PAKs), can act as upstream 
regulators (MAP4Ks) for these MAPK cascades and connect them with 
additional signalling pathways. MAPK signalling cascades regulate 
fundamental biological functions such as cell growth, proliferation, 
differentiation, migration and apoptosis and are found to be deregulated in 
approximately one third of all human cancers [24].  
 Sequence alignments using the catalytic domain of WNK1 showed that 
the closest human homologous kinases are the MAP3Ks MEKKs or Rafs and 
the MAP4K PAKs, which all display around 30 % sequence identity and 
50 % sequence homology [6]. It is therefore not surprising that effects of 
WNK kinases on various MAPK cascades have been observed. WNK1 was 
reported to be required for EGF-dependent stimulation of ERK5 but the 
activation of ERK1/2, JNK or p38 MAP kinases was not significantly 
affected. In vitro, WNK1 interacts with and phosphorylates MEKK2 and 
MEKK3, however, this phosphorylation does not seem to stimulate 
MEKK2/3 activity. In contrast, transfection of cells with either WNK1 or its 
kinase-dead mutant WNK1K233M stimulates MEKK3 autophosphorylation 
and activity towards its substrate MEK6. Apparently, WNK1 acts by protein-
protein interaction to assemble an ERK5 activation complex and thus acts as 
an upstream regulator of the ERK5 pathway (Figure 4). WNK1 was required 
for activation of ERK5 by EGF, in HeLa cells, but in the presence of high 
concentrations of EGF, this effect became less pronounced [25]. In 
agreement with these findings, the down-regulation of WNK1 in C17.2 
mouse neural progenitor cells also suppressed activation of ERK5 and greatly 
reduced cell growth [26]. 
 In contrast to WNK1, human WNK2 had no effect on ERK5 but 
modulated activation of ERK1/2. Experimental depletion of WNK2 or 
overexpression of a kinase-dead WNK2K207M mutant led to increased 
phospho-ERK1/2 levels but only when a basal ERK stimulation was present 
and not in serum-free culture conditions [19]. This increase in ERK1/2 
activation promoted cell cycle progression through G1/S and sensitized cells 
to respond to lower concentrations of EGF. From these data one might 
predict that loss of WNK2 expression can promote cell cycle progression in 
tumour cells. Interestingly, WNK2 expression is silenced in a significant 
percentage of human gliomas [27, 28, see section 5 below] suggesting that 
this pathway may be used in some tumour types to promote cell proliferation. 
The mechanism by which a reduction in WNK2 expression increased 
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ERK1/2 activation involves phosphorylation of MEK1 at serine 298, a 
modification that increases MEK1 affinity towards ERK1/2. Apparently, 
WNK2 affects Rac1 activation with subsequent stimulation of the Rac-
effector PAK1, the kinase responsible for MEK1 S298 phosphorylation [29] 
(Figure 4). Overexpression of WNK4 was also claimed to increase the 
phosphorylation of ERK1⁄2 and p38 MAPKs following EGF stimulation or 
hyperosmotic stress [30]. However, the mechanism of WNK4 involvement 
remains unclear and the corresponding effect of endogenous WNK4 was not 
addressed.  
 Together, these data demonstrate that WNK kinases can act upon 
different MAPK cascades and modulate cell proliferation. It may also be 
anticipated that this modulation is concerted because WNK kinases appear to 
regulate each others activities. For example, the recombinant kinase domain 
of WNK1 was shown to phosphorylate recombinant WNK2 and WNK4 
catalytic domains in vitro, in particular WNK4 on serine 332 in its activation 
loop [31]. WNK4 can also phosphorylate the catalytic domain of WNK1 and 
expression of the autoinhibitory domains of WNK1 and WNK4 are able to 
inhibit each others catalytic activities [11, 31]. Gel filtration profiles further 
indicate that endogenous WNK1 exists as a tetramer [31]. Although the 
functional role of oligomerization is still unclear, there is some evidence that 
the autoinhibitory domain of one WNK1 molecule may inhibit the catalytic 
activity of another WNK1 molecule within the tetramer [9, 31]. Additionally, 
given the presence of conserved coiled-coil protein interaction domains in all 
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Figure 4. Schematic representation of the role of human WNK1 and WNK2 in the 
cellular response to EGF. (Left side) Physiological activation of the ERK5 pathway is 
enhanced in the presence of WNK1. (Right side) Expression of WNK2 controls a Rho 
GTPase/PAK-mediated signalling cross talk that can increase ERK1/2 activation.  
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four human WNK proteins, it is likely that hetero-oligomers form under 
certain conditions. In this way, the activity of different WNK proteins on 
parallel MAPK cascades might be coordinated within a single complex [23].  
 WNKs also regulate upstream activators of MAPK pathways (MAP4Ks), 
such as those belonging to the STE20-related protein kinases. These consist 
of 10 subfamilies that include PAK and the germinal centre kinases (GCKs). 
The proline-alanine-rich kinase (SPAK) and oxidative-stress responsive 1 
(OSR1, also refered to as OXSR1) are members of the GCK VI subfamily 
and primarily known for their role in cell volume sensing and osmotic 
homeostasis. Given that cell size and volume are often linked to cell cycle 
progression, it is not surprising that these kinases have roles as upstream 
activators of MAPK pathways (MAP4Ks) [32, 33]. For example, SPAK is a 
known activator of the p38 and JNK cascades [34-36] and OSR1 acts 
upstream of CaMKII and p38 in C. elegans [37].  
 OSR1 and SPAK interact with WNK1, WNK3 and WNK4 [38-44] and 
WNK1 and WNK4 phosphorylate these proteins on two residues: T233 and 
S373 on SPAK and T185 and S325 on OSR1. Residues T233 or T185 are 
located in the activation loops of these kinases' catalytic domains and mediate 
their activation [38]. The molecular details of how the phosphorylation of 
SPAK and OSR1 by WNK kinases relates to cell proliferation have not yet 
been investigated. 
 As mentioned above, WNK2 also acts upon another STE20 member, 
PAK1, but direct phosphorylation does not seem to be involved. Rather, 
WNK2 affects activation of Rac1, a known upstream stimulator of PAK1 
[29] and active PAK1 phosphorylates MEK1 on S298, leading to increased 
activity of ERK1/2 MAPK [45-49].  
 
1.2. Effect of WNKs on receptor traffic 
 
 MAP kinases are activated in response to growth factor binding to their 
cell surface receptors and can either stimulate or inhibit cell proliferation. 
After ligand binding, most receptors become internalized into signalling-
competent endosomes and then either recycle back to the cell surface or 
become degraded in lysosomes as a mechanism to downregulate receptor 
signalling in cells [50, 51]. Vesiclular traffic can therefore modulate cellular 
signalling intensity and WNK4 has been proposed to promote cargo delivery 
to lysosomes. Expression of WNK4 inhibited the activity of the sodium 
chloride cotransporter NCC by diverting the channel to lysomal degradation 
[52, 53] and because this effect involved a general adaptor protein (AP) 3-
dependent endosomal sorting mechanism, WNK4 may also modulate the 
ratio of degradation of endocytosed growth factor receptors. This mechanism 
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is known to downregulate receptor signalling in cells and can have 
consequences for cell proliferation [50].  
 Similarly, WNK1 and WNK4 have been shown to stimulate clathrin-
dependent endocytosis of the renal outer medullar potassium 1 channel 
(ROMK1), thus inhibiting potassium secretion [54-56]. This process involves 
the interaction of WNK1 and WNK4 with the scaffold protein intersectin 1 
(ITSN1), which binds to specific proline-rich WNK motifs via its SH3 
domains and does not require WNK kinase activity [56].  
 Additional support of a role for WNKs in endocytosis comes from a 
genome-wide RNAi screen to determine the effect of human protein kinases 
on endocytosis. In this screen virus entry was used as a measure of clathrin-
mediated (vesicular stomatitis virus- VSV) or caveolin-dependent (simian 
virus- SV40) endocytosis and it was found that WNK4 interfered with VSV 
entrance whereas WNK2 inhibited caveolin-mediated SV40 uptake [57, 
Table S1]. 
 
1.3. WNKs as targets of insulin signalling and the PI3K/Akt 
pathway 
  
 There is substantial evidence that many tissues and derived cancer cells 
express insulin and insulin-like growth factor 1 (IGF1) receptors and that 
elevated circulating levels of IGF1 and insulin reflect a nutritional energy 
imbalance with increased cancer risk [58]. Insulin and IGF1 receptors are 
important activators of the phosphatidylinositol 3-kinase (PI3K)/Akt 
signalling network and increase the proliferation of neoplastic cell lines.  
 Following IGF1 treatment of cells, Akt is activated downstream of PI3K 
and phosphorylates WNK1 in its threonine residue 60, although this 
phosphorylation does not appear to affect WNK1 kinase activity, or its 
subcellular localization [59-63]. This WNK1 phosphorylation is dependent 
on PDK1, which phosphorylates Akt within its activation loop [64], and is 
blocked by PI3K inhibitors. IGF1 also activates the Akt-homologous serum- 
and glucocorticoid-induced protein kinase SGK1. While SGK1 is known to 
regulate sodium transport in response to aldosterone in the kidney, it also 
promotes degradation of the cyclin-dependent kinase inhibitor protein p27kip 
in other cell types [65].  
 Xu and collaborators proposed that WNK1 phosphorylation by PKB/Akt 
contributes to SGK1 activation and that WNK1 is required for SGK1 
activation by IGF1 [61]. There is evidence that SGK1 may in turn 
phosphorylate WNK1 on Thr60 and/or other sites and create a positive 
feedback [62].  
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 When 3T3-L1 adipocytes were treated with insulin, an increased WNK1 
phosphorylation was observed, and RNAi-induced depletion of WNK1 
enhanced insulin-stimulated thymidine incorporation by about 2-fold without 
significantly affecting insulin-stimulated glucose transport in these cells [60]. 
This observation suggests a negative regulatory role for WNK1 in insulin-
mediated proliferation control. 
 SGK1 apparently also phosphorylates WNK4 on serine residue 1169 in 
response to aldosterone [66] but a role related to cell proliferation has not 
been investigated yet.  
 
1.4. WNKs in transforming growth factor β signalling  
 
 The transforming growth factor (TGF) β transduces signals by 
stimulating the formation of heteromeric complexes of type I and type II 
serine/threonine kinase receptors which then phosphorylate and activate 
cytoplasmic transcription activators of the Smad family. Signalling from the 
TGFβ-Smad pathway often plays an anti-proliferative role in many cell types, 
acting as a tumour suppressor [67].  
 WNK1 and WNK4 kinase domains both interacted with and phosphorylated 
Smad2 in vitro. The siRNA-mediated knockdown of WNK1 reduced overall 
Smad2 levels but increased Smad2/3-dependent transcriptional responses [68]. 
This suggests that WNK1 imposes an inhibitory constraint on Smad2 and 
TGFβ signalling. Interestingly, a systematic mapping of the TGFβ receptor 
interactome revealed a link to another WNK1 substrate, the OSR1 protein 
kinase [69]. 
 
1.5. WNKs in calcium signalling  
 
 An increase in cytoplasmic calcium serves as a second messenger for 
calmodulin- and calcineurin-activated signalling pathways that promote 
cancer cell proliferation [70, 71].  
 One mechanism of increasing cytoplasmic calcium is uptake from the 
extracellular medium by calcium-channels, such as the transient receptor 
potential vanilloid (TRPV) channels and TRPV6 overexpression has been 
reported in carcinomas of the colon, breast, thyroid, and ovary [72]  
 Expression of WNK4 specifically enhanced TRPV5-mediated calcium 
uptake, which correlates with increased membrane expression of the channel 
[73], whereas WNK3 stimulated TRPV5 and TRPV6-mediated transport 
[74]. In contrast, WNK4 and WNK1 decreased cell surface expression of 
TRPV4, which plays a role in osmoregulation following hypotonic cell 
swelling [75].  
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 Additionally, WNK1 was also implicated in intracellular calcium 
sensing, because it selectively binds synaptotagmin 2 and phosphorylates the 
C2 domains, involved in calcium binding. WNK1 and synaptotagmin 2 co-
localize in secretory vesicles in an insulin secreting pancreatic β cell line and 
phosphorylation by WNK1 increased the amount of calcium necessary for 
synaptotagmin 2 binding to phospholipid vesicles [76]. 
 Together, these results show that WNK kinases can affect multiple 
signalling pathways related to cell proliferation; however, at present their best 
defined roles are as upstream regulators of MAPK cascades. 
 
2. WNK kinases and metabolic adaptation of tumour cells 
 
 Cell adaptation to the extracellular environment is required during the 
initiation of tumour formation when cells start to proliferate and in 
consequence experience suboptimal supply of oxygen and nutrients due to 
diffusion limits. In response, cancer cells upregulate the production of 
glycolytic energy leading to the generation of lactate and acidosis of the 
extracellular medium. Tumour cells have to compensate for this acid-induced 
toxicity in order to remain viable and continue to grow [77, 78].  
 
2.1. WNKs and glucose uptake  
 
 Malignant cells have accelerated metabolism and the increased 
requirements for ATP production are satisfied by aerobic glycolysis [79]. 
One adaptation is to increase glucose transport into malignant cells by 
overexpression of glucose transporters (GLUTs) [80] and elevated expression 
of GLUT1 has been described in many cancers.  
 In 3T3L1 adipocytes, the syntaxin 4-regulatory protein Munc18c 
functions in insulin-stimulated GLUT4 vesicle translocation and fusion [81]. 
A role for WNK1 has been reported in vesicle/granule exocytosis, because it 
forms a complex with Munc18c. WNK1 binds Munc18c via its kinase 
domain but does not phosphorylate it, suggesting a scaffolding function for 
WNK1 in recruiting Munc18c as a substrate for another kinase or 
phosphatase [82]. Interestingly, increased glucose supply decreased the 
expression of WNK4 in mouse kidneys, indicating the existence of a 
regulatory mechanism that links WNK expression to extracellular glucose 
concentrations [83].  
 Because synaptotagmins and Munc18c are implicated in a variety of 
membrane trafficking and vesicle fusion events, their interaction with WNK1 
provides a putative mechanism for how WNKs may regulate retention or 
insertion of plasma membrane proteins [76]. 
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2.2. Regulation of extracellular pH and the plasma membrane 
conductances  
 
 Mutations in the WNK1 and WNK4 genes were initially discovered to 
cause pseudo-hypoaldosteronism type II (or Gordon’s syndrome), a rare 
familial form of hypertension [14] characterised by increased renal salt 
reabsorption accompanied by hyperkalemia and metabolic acidosis due to 
impaired K+ and H+ excretion. Subsequently, a huge body of evidence has 
shown that WNK1, WNK3 and WNK4 are involved in the regulation of a 
variety of renal but also extra-renal ion channels (for WNK2 no such studies 
have been reported yet). Summarizing these studies, evidence links WNKs to 
the regulation of cell surface expression or channel activity of the 
cotransporters NCC, NKCC and KCC, the ROMK and Kir1.1 potassium 
channels, the CFTR chloride channel, the Cl-/HCO3- exchangers SLC26A6 
and A9, the epithelial sodium channel (ENaC), and the TRPV4 and TRPV5 
calcium channels [reviewed in 18, 84-86]. These data indicate that WNK 
kinases are important to maintain fundamental cell functions related to 
electrolyte homeostasis.  
 The regulation of electrolyte homeostasis is important for tumour cells 
and one relevant aspect is pH regulation. The extracellular environment in the 
tumour is more acidic than the intracellular pH (6.2–6.9 compared with 7.3–
7.4). The increased production and export of glycolytic lactate together with 
overexpression of the Na+/H+ exchanger NHE1, create a reversed pH gradient 
across the tumour cell membrane. Through NHE1 action, the inwardly 
directed sodium gradient can drive the uphill extrusion of protons, alkalinize 
intracellular pH and further acidify the extracellular pH. A supporting activity 
in pH regulation is provided by the chloride/bicarbonate (Cl–/HCO3–) anion 
exchangers of the SLC26A family [87]. The combined transport activities of 
NHE and SLC26A channels lead to electroneutral NaCl absorption with net 
H+ secretion. Recent findings suggest that the expression of the SLC26A 
family is regulated by WNKs. When expressed in Xenopus oocytes, WNK4 
inhibits the expression at the plasma membrane of SLC26A6 [17] and 
WNK1, WNK3 and WNK4 inhibit the expression of SLC26A9 [88], 
consequently decreasing channel activities.  
 Another aspect is the electrochemical gradient across the plasma 
membrane which most cells require to sustain nutrient uptake or release of 
metabolic products. For example, the electrochemical gradient for Na+ drives 
the uptake of nutrients and is in part maintained by the negative membrane 
potential. In case of enhanced Na+/H+ exchanger activity, as observed in 
tumour cells, the intracellular Na+ concentration increases so that the ATP-
consuming Na+/K+ ATPase becomes activated to exchange cytosolic Na+ for 
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K+. In consequence, K+ ions need to recycle through membrane potasium 
channels in order to keep the Na+/K+ ATPase going. A solid body of evidence 
documents that various types of tumours overexpress voltage-gated K+ 
channels, in particular the ether-a-go-go (EAG) and BK (Ca2+-activated K+ 
channels) subfamilies. These channels open in response to a depolarization of 
the cell membrane, thus allowing an efflux of K+ ions. Experimental 
overexpression of these channels promotes tumour cell proliferation, 
probably because it helps to maintain the membrane potential [89]. 
 Although WNK kinases have not yet been linked to the direct regulation 
of voltage-gated K+ channels, their known effects on channels involved in 
Na+, K+, Cl- and HCO3– homeostasis already indicate that these proteins play 
at least an overall regulatory role on electrochemical cell homeostasis and 
lead us to suggest that these channels may represent a further link between 
WNKs and tumour biology that should be explored.  
 
3. Role of WNK kinases in the evasion of apoptosis 
 
 The apoptotic program is a major barrier to tumour development that 
must be inactivated to achieve net tumour cell proliferation. A complex 
interplay between different pro- or anti-apoptotic factors determines whether 
cells survive or activate the cell death programme [90].  
 
3.1. WNK3 modulates caspase 3 
 
 Experimental data and mathematical models have suggested that 
apoptosis activation depends on molecular threshold values that trigger either 
the cell death pathway or maintain cell survival [91, 92]. Thus, either over-
production of anti-apoptotic factors, or loss of expression of pro-apoptotic 
factors, or changes in their activation status can shift the balance towards cell 
survival. WNK3 has been shown to act on this balance by promoting cell 
survival in a caspase-3-dependent pathway [21]. Suppression of endogenous 
WNK3 by RNA interference accelerated the apoptotic response of HeLa cells 
and promoted the activation of caspase-3. The mechanism of WNK3 action 
involves interaction with procaspase-3 and heat-shock protein 70. The 
prosurvival role was only in part dependent on the catalytic activity of 
WNK3 because a kinase-dead WNK3K159M mutant also interacted with 
procaspase-3 and increased cell survival to some extent. This indicates an 
adaptor or scaffold function for WNK3 within a protein complex that controls 
procaspase-3 activation. Accordingly, the level of WNK3 expression or 
activity may determine sensitivity or tolerance of cells towards apoptotic 
stimuli. 
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3.2. Genome-wide screening results 
 
 The role of protein phosphorylation in apoptosis induction was recently 
studied by systematic depletion of each human protein kinase or phosphatase 
in HeLa cells using RNA interference [93]. This approach identified 73 
kinases whose suppression increased the level of apoptosis by at least twofold 
over control, defining them as survival kinases. In this screen WNK1 and 
WNK3 kinases also scored positive, albeit below the threshold value 
(WNK1- 1.98 fold; WNK3- 1.58 fold), whereas WNK2 and WNK4 had no 
effect on cell survival [J. Blenis, Boston, personal communication]. These 
results are further supported by a genome wide screen for cell survival factors 
in Drosophila melanogaster. The single Drosophila WNK gene (designated 
CG7177; NM_141072) is most homologous to WNK3 and WNK1, and its 
depletion by RNAi affected cell survival in fly S2R+ cells [94].  
 Although WNK1 and WNK3 were detected in these screens, they did not 
stand out as essential genes for sustaining cell survival. However, these 
screens scored for spontaneous induction of apoptosis and a different 
physiological response can be expected when cells are exposed to conditions 
that challenge cell survival. For example, the single Caenorhabditis elegans 
WNK kinase (designated C46C2) was found essential for worm survival but 
only following hyperosmotic stress conditions [13]. It can be expected that 
the roles of WNK1 and WNK3 in cell survival will become more evident 
when cells face metabolic stress situations, including the above mentioned 
glycolytic acidosis and cell volume regulation.  
 
3.3. Putative role of WNK substrates OSR1 and SAPK  
 
 Which candidate signalling pathways could be involved in the anti-apoptotic 
function of WNK kinases? The survival under osmotic stress depends on OSR1 
[37]. As mentioned previously, OSR1 and SPAK interact with WNK1, WNK3 
and WNK4 (see section 1.2) and are key regulators of the NCC, NKCC and KCC 
ion channels involved in the regulation of ion homoeostasis and volume control 
in mammalian cells [95, 96]. Cells under hyperosmotic stress conditions are 
challenged to induce an apoptotic response and such conditions, including high 
concentrations of NaCl, KCl, glucose, sucrose, manitol or sorbitol, provoke a 
marked and reproducible increase in WNK1 activity [5, 9, 31] including towards 
its substrate OSR1 [10]. Thus, the expression or activity levels of WNK1 and 
WNK3 may determine the cellular capacity to cope with osmotic or acid-related 
stress. 
 In a yeast two hybrid screen with the SPAK C-terminal substrate binding 
domain, the apoptosis-associated tyrosine kinase (AATYK) was identified as 
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an interacting protein [97], and in myeloid precursor [98] or cerebellar 
granule cells [99], AATYK expression promotes apoptosis.  
 In addition, SPAK and OSR1 participate in other signalling pathways 
related to cell survival. Overexpression of the TNF receptor RELT led to 
activation of both the p38 and JNK survival pathways in 293 cells [35] and 
this was dependent on SPAK kinase activity, which is regulated by WNKs. 
Also, following extrinsic pro-apoptotic stimuli such as TRAIL receptor 
binding, SPAK is cleaved at two distinct sites by a caspase 3-like protease, 
which removes its substrate-binding domain. Accordingly, experimental 
depletion of SPAK expression by siRNA increased the sensitivity of HeLa 
cells to TRAIL-induced apoptosis [100]. Thus, down-regulation of SPAK 
activity is an important target to enhance the apoptotic effect of TRAIL, 
where WNK kinases may influence cell survival. 
 
4. WNK kinases in invasion and metastasis 
 
 Cancer cells can escape from the constraints of their tissue of origin and 
enter into the circulation to reach distant organs and eventually form 
secondary tumours, called metastases.  
 
4.1. Epithelial–mesenchymal transition 
 
 In many solid tumour types, the epithelial tumour cells switch to a highly 
motile fibroblastoid or mesenchymal phenotype, a process called epithelial–
mesenchymal transition (EMT). A well characterised inducer of EMT is TGFβ 
signalling [101, 102] that uses Smad-mediated gene expression to induce the 
transcription factors Snail and Slug. These repress expression of the E-cadherin 
gene required for epithelial cell adhesion, a hallmark phenotype of EMT [103]. 
Since WNK1 was shown to phosphorylate Smad2 in vitro and apparently 
negatively controls Smad2/3-dependent transcriptional responses and 
TGFβ  Signalling [68], this suggests that loss of expression or inactivating 
WNK1 mutations could promote EMT of epithelial tumour cells.  
 
4.2. Neuronal cell invasion 
 
 The ganglioside GD3 is a sialic acid-containing glycosphingolipid 
normally expressed during development but also in pathological conditions 
such as cancer. In neural tumour cells, WNK1 expression was found to 
correlate with that of GD3 [104]. In particular, experimental suppression of 
the GD3-synthase gene in F-11 tumour cells led to a reduced rate of cell 
migration and invasiveness [105], conditions under which a dramatic 
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decrease in WNK1 expression was observed. This suggests that WNK1 
may contribute to the invasive phenotype of F-11 cells but further 
mechanistic details are not yet available. 
 
4.3. Role of WNK-regulated Rho GTPases 
 
 Rho GTPases control the dynamics of the actin cytoskeleton and are 
important for cell migration and invasiveness [106]. WNK2 controls, through 
a yet unknown mechanism, the activation of the small GTPase RhoA, which 
in a reciprocal way regulates activation of Rac1 [29]. The suppression of 
WNK2 in cell lines leads to reduced RhoA, but increased Rac1 activation. It 
remains to be determined whether changes in WNK2 expression or activity affect 
RhoA/Rac1 activation in tumours, but in this sense, the reported epigenetic 
silencing of WNK2 in infiltrative gliomas [27] is highly suggestive. 
 A recent report also links WNK1 to Rho GTPases. In neuronal cells WNK1 
can be isolated in a complex with Rho-GDI and was proposed to mediate the 
regulation of Nogo66-induced RhoA activation and neurite outgrowth [107]. 
 Interestingly, a reciprocal relation between RhoA and Rac1 signalling 
has also been reported to mediate NHE1-dependent changes in motility and 
invasion of breast cancer cells [107]. For example, NHE1 has a crucial role in 
driving invasion, possibly by acting as an integrator protein that links the 
cytoskeleton and various metastasis-specific signalling complexes that 
mediate invasive activity. NHE1 can directly regulate cytoskeletal dynamics 
independently of its ion-transporting capabilities because it binds the ezrin, 
radixin and moesin (ERM) family of cytoskeleton regulators [109]. This 
feature of actin cytoskeleton remodeling has also been reported downstream 
of other ion channels [110], including some that are regulated by WNKs. 
 
5. Mutational mechanisms affecting WNK genes in tumours 
 
 If WNK signalling were important for tumour development, one can 
expect that genetic alterations affect either WNK gene expression or their 
coding sequence with consequences for protein activity.  
 
5.1. Changes in gene expression 
 
 The strongest evidence for such alterations was reported for WNK2. 
Expression of the human WNK2 gene is silenced in a large percentage of 
human gliomas due to extensive methylation in the CpG island encompassing 
the 5’ end of this gene [27]. Likewise, the WNK2 promoter was hyper-
methylated in 83% and 71% of grade II and III meningiomas, respectively 
and this was associated with decreased WNK2 expression in primary 
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tumours. In contrast, promoter methylation was rare in a total of 209 tumours 
from thirteen other tumour types [28]. 
 This finding makes WNK2 a candidate tumour suppressor gene in 
gliomas. WNK2 indirectly inhibits MEK1 and restrains growth-promoting 
signals through the EGF receptor. Thus, it is possible that the epigenetic 
silencing of WNK2 interacts on a functional level with genetic alteration of 
EGFR signalling, a common abnormality in glioblastomas especially due to 
EGFR gene amplifications [111]. It is interesting to note that colon tumours 
also show frequent hyper-stimulation of the EGFR signalling pathway and 
that a partial clone of WNK2 has previously been isolated as the colon cancer 
antigen SDCC43 [112]. An incomplete WNK2 fragment was also isolated as 
a T-cell recognized pancreatic cancer cell antigen P/OKcl13 [113]. 
 The other three human WNK genes share with WNK2 the presence of 
large CpG islands surrounding their promoter regions and extending into the 
first exons [6, 20, 15, 27]. This observation suggests some common 
mechanism of regulation under physiological conditions but also indicates 
that hyper-methylation of the WNK1, WNK3 or WNK4 promoters may exist 
in other tumour types.  
 In future studies, the presence of genomic deletions in WNK genes should 
also be explored because one mutation type that predisposes patients to 
Gordon syndrome is a deletion within intron 1 of WNK1. This is a very large 
intron of 58 kb which contains a kidney-specific repressor element [114] and 
its deletion results in WNK1 overexpression [14]. The structure of the WNK2 
and WNK3 genes is conserved with respect to a large intron 1 (44 kb and 22 
kb, respectively), raising the possibility that a similar mutational mechanism 
may lead to their overexpression. However, a homology search using the 
kidney-specific WNK1 repressor element C1 [114] did not identify any 
homologous sequences in introns 1 from the WNK2 and WNK3 genes 
[unpublished observation].  
 WNK expression studies will further need to test for the presence of 
alternative promoters. In WNK1 intron 4 an intragenic promoter generates a 
kidney-specific isoform (KS-WNK1) lacking kinase activity, which is thus 
functionally different from the long ubiquitous isoform (L-WNK1). 
Epigenetic changes could shift promoter usage in tumours and thus generate 
dominant-negative WNK isoforms, a possibility that remains to be explored 
as a potential mutagenic mechanism. 
 An additional avenue that requires more attention is the role of WNK 
alternative splicing variants. For example, one WNK1 variant lacks exons 11 
and 12 [6], two WNK2 transcripts exist that differ in their C-terminal exon 
with different C-terminal sequences [19], and for WNK3 two variants differ 
in usage of mostly brain-specific exons [15, 21]. Alternative splicing variants 
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can affect transcript turnover or encode protein isoforms. At present no 
simple structure/function relation exists to predict functional differences 
between two splicing variants from the same gene, however, many examples 
of variants have been documented that significantly differ regarding 
regulation or signalling activities [115-118]. Indeed, a recent report revealed 
that the two WNK3 variants have opposite effects on expression of the ion 
channel NCC [119]. 
 
5.2. WNK point mutations in tumours 
 
 In the last years, large-scale cancer genome sequencing efforts were 
conducted to determine the full spectrum of mutations in a given tumour. 
Among the provided lists of mutated genes a variety of point mutations in 
several WNK genes were identified in breast, colon, lung or brain tumours 
(Figure 5) [120-124].  
 No experimental evidence exists, however, showing whether the 
resulting missense or frameshift mutations have a functional impact on the 
corresponding WNK protein. It is possible that these mutations represent just 
'passenger' mutations in a genetically unstable cancer cell genome that are not 
causally implicated in oncogenesis [120]. 
 
Tissue Histology/Type Gene Zygosity cDNA Protein Mutation Reference
Breast  IDC WNK1 Het c.5395C>G p.Q1799E Missense 2,3,4
Breast  pleomorphic lobular ca WNK1 Het c.1255G>C p.E419Q Missense 2,4
Breast  pleomorphic lobular ca WNK1 Het c.6569C>G p.S2190C Missense 2,4
Lung  adenocarcinoma WNK1 Hom c.7086C>A p.F2362L Missense 1,4
Ovary  serous carcinoma WNK1 Het c.2829C>T p.Y943Y Silent 4
Colon  colorectal WNK1 c.3596A>G p.E1199G Missense 3
Brain  glioblastoma WNK1 Het c.5293G>A p.G1765S Missense 5
Brain  glioblastoma WNK2 Het c.3799G>A p.A1267T Missense 5
Colorectal  adenocarcinoma WNK2 Het c.1922delC p.P641fs*2 Frameshift deletion 4
Stomach  adenocarcinoma WNK2 Het c.4116delC p.S1373fs*5 Frameshift deletion 4
Lung  adenocarcinoma WNK2 Het c.5933G>T p.S1978I Missense 1,4
Lung  neuroendocrine carcinoma WNK2 Het c.4856G>A p.G1619E Missense 1,4
Ovary  serous carcinoma WNK2 Het c.1486G>T p.V496L Missense 4
Ovary  Mucinous carcinoma WNK2 Het c.6642delC p.T2215fs*31 Frameshift deletion 4
Glioma  glioblastoma WNK3 Het c.2784C>T p.H928H Silent 4
Lung  squamous cell carcinoma WNK3 Het c.2561C>G p.S854C Missense 4
Lung  large cell carcinoma WNK3 Het c.4599G>T p.L1533F Missense 4
Kidney  clear cell carcinoma WNK3 Het c.3809C>A p.T1270N Missense 4
Kidney  clear cell carcinoma WNK3 Het c.4900T>C p.S1634P Missense 4
Stomach  adenocarcinoma WNK4 Het c.1786delG p.V596fs*53 Frameshift deletion 4
Melanoma  metastatic WNK4 Het c.1402C>T p.L468L Silent 4
Melanoma WNK4 Het c.2974C>T p.P992S Missense 4
Melanoma WNK4 Het c.3154C>T p.P1052S Missense 4
Ovary  Mucinous carcinoma WNK4 Het c.1302C>G p.D434E Missense 4
Breast  IDC WNK4 Het c.441C>G p.F147L Missense 4
 References: 1= Davies et al., 2005; 2= Stephens et al., 2005; 3=Sjöblom et al., 2006; 4= Greenman et al., 2007; 5=Parsons et al., 2008  
 
Figure 5. List of WNK mutations identified in different unbiased cancer genome 
sequencing efforts (corresponding references are indicated).  
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6. Summary and perspective 
 
 Considering the reviewed data, the evidence for a role of WNK kinases 
in cancer cell signalling is just beginning to emerge. At present, experimental 
evidence is strongest concerning their role as upstream regulators of MAPK 
cascades, as modulators of Rho-GTPases and inhibitors of apoptosis (see 
Figure 6). The next few years will certainly shed light on further aspects of 
cancer biology that are affected by WNKs. It will be of particular interest to 
elucidate how their abundantly documented role on the regulation of activity 
or cell surface expression of ion channels can be related to tumour 
development. In order to understand the underlying signalling network, it will 
be important to systematically identify WNK interacting proteins and 
physiological substrate proteins, cellular phenotypes following WNK 
suppression, and the genetic changes affecting WNK genes during tumorigenesis. 
 
 
Figure 6. Schematic summary of major WNK-regulated cellular processes with a role 
in cancer cell biology. Arrows symbolise stimulation and t-shaped lines inhibition. 
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Abstract. Germ-line LKB1 mutations are responsible for Peutz-
Jeghers syndrome (PJS) and somatic mutations are involved in the 
development of some sporadic tumours, in particular lung cancer. 
The gene encodes the LKB1 protein with serine-threonine kinase 
activity, which is involved in the regulation of the cell energetic 
checkpoint through the phosphorylation and activation of AMP-
dependent kinase (AMPK) and other substrates. LKB1 is also 
involved in other important cell processes such as the control of 
cell polarity in various types of tissues. Here we provide an 
overview of the alterations of LKB1 in human cancer, Lkb1-mice 
models and what is currently known about the biological function, 
substrates and binding partners of LKB1 protein, with a special 
focus on cancer development.  
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Introduction 
 
      The human LKB1 gene, also known as STK11, spans 23 kb and is made 
up of nine coding exons and a final non-coding exon. LKB1 codes for an 
mRNA of ~2.4 kb transcribed in a telomere-to-centromere direction and for a 
protein of 433 amino acids and approximately 48 kDa. LKB1 is widely 
expressed in embryonic and adult tissues, albeit with some differences. In 
mouse, early embryos have high levels of Lkb1 expression in embryonic and 
extra-embryonic tissues and, along with progressive embryonic development, 
Lkb1 protein concentrates in the heart, esophagus, pancreas, kidney, colon, 
lung, small intestine and stomach (1, 2). In adult tissues, high levels of LKB1 
protein can be found in most epithelia, in the follicles and corpus luteum of 
the ovary, the seminiferous tubules of the testis, in myocytes from skeletal 
muscle, and in glial cells (2-3). The LKB1 gene gives rise to at least two 
transcripts (LKB1L and LKB1S) from an alternative splice site at exon 9 (4). 
Both isoforms are widely expressed in rodent and human tissues, although 
LKB1S is particularly abundant in haploid spermatids in the testis. LKB1 
maps to 19p13.3, a chromosomal region to which the autosomal dominant 
Peutz-Jeghers syndrome (PJS) (OMIM 175200) was first linked by genetic 
analysis. Individuals with PJS typically exhibit mucocutaneous melanin 
pigmentation and suffer from hamartomatous polyps in the gastrointestinal 
tract and an increased risk of developing cancer (5-6). Following the linkage 
of PJS to chromosome 19p13, the identification of germ-line-inactivating 
mutations at LKB1 in these patients was definitive in the conclusion that 
LKB1 is the gene causing the syndrome (7-8).  
 
The LKB1 protein kinase  
 
 LKB1 is a multi-tasking tumour suppressor serine-threonine kinase (9-
10) and is a member of the CAMK (Calcium/ Calmodulin Regulated Kinase-
Like) family of kinases. LKB1 orthologues include Xenopus laevis egg and 
embryonic kinase 1 (XEEK1)(11), mouse Lkb1 (12), Caenorhabditis elegans 
partitioning-defective gene 4 (Par-4)(13) and Drosophila lkb1 (dLKB1) (14). 
Par-4 and dLKB1 share 26% and 44% overall identity with human LKB1, 
respectively, and share 42% and 66% identity with the LKB1 kinase domain, 
respectively.   
 
Post-translational modifications 
 
 Phosphorylation is a post-translational modification that alters the 
chemical properties of a protein allowing it to recognize, bind, activate, or 
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deactivate substrate. Mouse Lkb1 is autophosphorylated on the residues 
Thr185, Thr189, Thr336 and, Ser404, and phosphorylated by upstream 
kinases on Ser31, Ser325, Thr366, and Ser431 (15-18). The residues Thr366, 
Ser404, and Ser431 in the mouse sequence correspond to residues Thr363, 
Ser402 and Ser428 respectively, of human LKB1 (19) (Figure 1).  
 
 
 
 
 
Figure 1. Post-translational modifications of murine LKB1 tumour suppressor 
kinase. The kinase domain is depicted in yellow, noncatalytic domains are depicted in 
orange and the nuclear localization sequence (NLS) is depicted in white. 
Autophosphorylation sites are depicted in black and sites phosphorylated by upstream 
kinases are depicted in red (modified from Alessi et al. 2006). 
 
 Currently there is no evidence that phosphorylation of LKB1 is necessary 
for its activity (15-16), thus the function of LKB1 may be indirectly 
regulated. LKB1 is phosphorylated at Ser431 by cAMP-dependent protein 
kinase A (PKA) and p90 ribosomal S6 kinase (RSK) (15-16). An earlier 
study suggested that phosphorylation at Ser431 is required for LKB1 
mediated growth arrest (16). However, a recent study reported that the LKB1 
mutants S431A, S431E, and the splice variant LKB1S, that lacks Ser431, 
retained the ability to cause cell cycle arrest (20), indicating that 
phosphorylation on Ser431 is not required for this function. A role for 
phosphorylation of Ser431 has been implicated in axon differentiation (21), 
and neuronal polarization (22). In Xenopus, the LKB1 homologue XEEK1, is 
also phosphorylated by protein kinase A (PKA), and increased PKA activity 
is important for maintaining the oocytes at the G2 phase of cell cycle (15). 
However, phosphorylation of Ser431 is not essential for LKB1 catalytic 
activity, since mutagenesis of this residue does not alter the ability of LKB1 
to autophosphorylate, or activate TP53 (16), AMP-activated protein kinase 
(AMPK) or brain-specific kinases 1 and 2 (BRSK1 and BRSK2 respectively) 
(20). Neither the cellular localization nor prenylation of LKB1 is affected by 
phosphorylation of Ser431.  Phosphorylation at Ser31, Ser325 and Thr366 
are not necessary for the catalytic activity of LKB1 since mutations to alanine 
to prevent phosphorylation, or to glutamic acid to mimic phosphorylation, or 
farnesylation 
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addition of phosphatases did not affect LKB1 autophosphorylation, and its 
ability to activate TP53 (17). On the other hand, LKB1 autophosphorylation 
at Thr336, is important for LKB1-mediated growth arrest in G361 cells. 
Activation of ataxia telangiectasia (ATM) by ionizing radiation, leads to 
double strand breaks, and phosphorylation of LKB1 on Thr366 (18) (Figure 1). 
Phosphorylation at this site also plays a role in LKB1 mediated cell cycle 
arrest. The significance of LKB1 autophosphorylation at Thr185, Thr189, 
Ser404 is currently not known. Moreover, the upstream kinase responsible 
for phosphorylating LKB1 at S31 and S325 is not known, but has been 
proposed to be AMPK, a proline-directed kinase (23), where in LKB1, a 
proline residue follows Ser325 (17).  
 A recent study indicates that LKB1 is acetylated on a minimum of nine 
lysine residues (24), with acetylation at Lys48 being the most significant. 
Sirtuin 1 (SIRT1), a NAD-dependent protein deacetylase, deacetylates LKB1 
at Lys48, resulting in an increased LKB1 interaction with STRAD.  This in 
turn shifts the LKB1 cytoplasmic to nuclear distribution ratio in favour of the 
cytoplasm, ultimately increasing LKB1 catalytic activity. Mutations of Lys48 
to Arg, to mimic effects of deacetylation, resulted in similar effects as 
overexpression of SIRT1. Overexpression of SIRT1, and consequently 
deacetylation of LKB1 Lys48, resulted in increased levels of phospho-Ser428- 
and phospho-Thr336- LKB1. Mutations of Lys48Arg displayed similar effects. 
As discussed above, phosphorylation of these residues (human Ser428 and 
Thr336) is required for LKB1 growth suppression function. 
 
LKB1 catalytically deficient mutants: Oncogenic mutants 
 
 A previous study from the Marignani laboratory demonstrated a novel 
function for LKB1 catalytically deficient mutants (25). Since these LKB1 
mutants are present in epithelial-derived cancers and PJS, it is important to 
understand the biological activity of these mutants within the context of 
disease. Marignani and colleagues discovered that LKB1 catalytically deficient 
mutants, such as SL26 and D194A, display oncogenic properties, whereby 
LKB1 mutants act as oncogenes or LKB1 mutants enhance expression of an 
oncogene (25). In a series of experiments, LKB1 catalytic deficient mutants 
(referred to as oncogenic mutants) enhanced the expression of the oncogene 
cyclin D1, which is required for cells to progress from G0 phase to G1 phase of 
the cell cycle. This study shows that the introduction of LKB1 oncogenic 
mutants into colorectal DLD1TP53-/-,P21WAF-/- cells resulted in elevated gene and 
protein levels of cyclin E, RB and cyclin D1, three proteins required for the 
progression of cells through S-phase of cell cycle. The cell cycle profile of 
these cells were unaltered following expression of ectopic TP53 or P21WAF, 
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suggesting LKB1 is capable of arresting cells in G1 independent of TP53 and 
P21WAF expression and LKB1 catalytic activity is required for this arrest, 
since LKB1 oncogenic mutants did not induce the G1 arrest.  
 In this same study (25), chromatin immunoprecipitation experiments 
were conducted to demonstrate that endogenous LKB1, but more importantly 
LKB1 oncogenic mutants, were recruited to response elements within the 
endogenous cyclin D1 promoter, namely the AP1, Sp1 and CRE binding 
protein/Ets sites, but not other sites, such as the E2F site. The authors postulate 
that in cancers where LKB1 is mutated, LKB1 oncogenic mutants are recruited to 
the promoter of cyclin D1, resulting in increased cyclin D1 expression, cell cycle 
progression and, cell division; perpetuating the uncontrolled cell growth 
characteristic of hamartomatous polyps. These findings represent the first 
characterized function for LKB1 oncogenic mutants. Interestingly, mutants of 
another tumour suppressor, TP53, have also been shown to exert oncogenic 
properties, and are therefore often referred to as ‘gain-of-function’ mutants (26). 
Future studies of mutant tumour suppressor proteins may lead to the 
discovery of other gain-of-function mutants, thereby providing insight into how 
mutants of tumour suppressor proteins may function in the context of disease. 
 
LKB1 interacting partners 
 
 After the discovery of LKB1 as the gene responsible for PJS, the 
discovery of LKB1 signalling partners was pursued. LKB1 interacts with 
numerous proteins, highlighting the multifunctionality of this protein 
(Figure 2), as discussed below. 
 
Brahma-related gene 1 (BRG1) 
 
 In an effort to identify a binding partner for LKB1, Marignani and 
colleagues (27) developed an in vitro expression cloning strategy. A HeLa 
cell cDNA library was in vitro transcribed and translated (TnT) in the 
presence of radiolabelled methionine. The TnT products were incubated with 
recombinant GST-LKB1 and GST fusion proteins, and subjected to a pull-
down using GSH beads. A single TnT pool containing a 35-kDa protein that 
bound specifically to LKB1 was further identified by sib-selection as 
Brahma-related gene 1 (BRG1). BRG1 is a member of the mammalian SWI-
SNF chromatin remodelling complex and contains ATP-dependent helicase 
activity required for chromatin remodelling.  
 To confirm the LKB1-BRG1 interaction in vivo, immunoprecipitation 
(IP) of LKB1 from Saos-2 cells was conducted, and BRG1 was identified in 
the IP complex, indicating endogenous LKB1 and endogenous BRG1 interact 
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in vivo. To identify the interface between LKB1 and BRG1, a series of LKB1 
and BRG1 truncations were generated. LKB1 was found to bind exclusively 
to the helicase domain of BRG1 while the N-terminus of LKB1 was found to 
be sufficient for LKB1 to bind the BRG1 helicase domain. Next, it was 
confirmed that the oncogenic mutant SL26 interacted with BRG1, indicating 
kinase activity is not required for this interaction. Functional studies 
determined that the association of LKB1 with BRG1 in the presence of DNA 
increases the ATPase activity of BRG1 approximately 6-fold compared to 
BRG1 alone. SL26 increased BRG1 ATPase function, indicating kinase 
activity of LKB1 is not required for BRG1-ATPase activity. Since LKB1 was 
previously shown to induce G1 growth arrest (28) and since BRG1 is involved 
in the retinoblastoma (RB)-dependent growth arrest pathway (29-30), 
Marignani and colleagues determined that LKB1 co-expressed with BRG1, 
induced growth arrest at the same level as BRG1 alone. However, co-
expression of SL26 and BRG1 lead to cell growth and proliferation (27), 
suggesting that LKB1 is required for BRG1-mediated growth arrest, and 
LKB1 kinase activity is required for this function.  
 
 
 
Figure 2. LKB1 interacting partner. A schematic representation of LKB1 interacting 
partners and signalling pathways. Dashed lines (---) indicate interacting partners, solid arrows 
(Æ) indicate phosphorylation, dotted arrows (-->) indicate downstream signalling effects. 
 
LKB1 interacting protein 1 (LIP1) 
 
 Smith and colleagues (31) used a yeast-two-hybrid screen to identify 
potential interacting partners for LKB1 and found the novel protein LKB1 
interacting partner-1 (LIP1). LIP1 is approximately 1,100 amino acids, with a 
molecular weight of about 121 kDa and was found to be ubiquitously 
phosphrorylate mTOR
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expressed in a wide variety of tissues. Co-immunoprecipitation experiments 
demonstrated that LKB1 and LIP1 interact in COS cells and LKB1 kinase 
activity was not required for this interaction since D194A catalytic deficient 
mutant co-immunoprecipitated along with LIP1. Kinase assays using the 
immunoprecipitated complexes showed that levels of LIP1 phosphorylation did 
not increase in the presence of LKB1, although low levels of LIP1 phosphorylation 
were seen. The authors suggest this is likely due to co-immunoprecipitation of 
an unidentified kinase, since similar levels of phosphorylated LIP1 were 
observed in the absence of LKB1. Thus LIP1 was determined not to be a 
substrate for LKB1. Immunofluorescent microscopy demonstrated that the 
LIP1 localized to the cytoplasm in punctuate structures, suggesting LIP1 may 
be localizing to a particular organelle. However, ectopic expression of LKB1 
and LIP1 led to the re-localization of LKB1 to the cytoplasm, co-localizing 
with LIP1. This study also showed that LIP1 co-immunoprecipitates with SMAD4, 
a TGFβ-regulated transcription factor. LKB1 does not directly interact with 
SMAD4; suggesting LIP1 acts as an adaptor between LKB1 and SMAD4. 
 Having shown that LIP1 facilitates in the re-localization of LKB1, the 
authors suggest that LIP1 may play a role in regulating LKB1 function by 
contributing to LKB1 subcellular localization, allowing LKB1 to act upon 
both nuclear and cytoplasmic substrates.  In summary, Smith and colleagues 
identified another LKB1 interacting partner, which regulates LKB1 function 
through partial control of LKB1 subcellular location.  
 
STRAD and MO25  
 
 Another series of studies, using a combination of yeast two-hybrid 
analysis and affinity purification experiments, have shown that LKB1 exists 
in a ternary complex with STE20-related adaptor (STRAD) (32) and mouse 
protein 25 (MO25) (33) in mammalian cells. STRAD is homologous to the 
STE20 family of kinases but lacks several key catalytic amino acid residues 
within its kinase domain (residues 58-401) (34), namely the glycine in the 
glycine-rich loop (subdomain I), the lysine residue of VAIK (subdomain II), 
the catalytic Asp residue of HRD (subdomain VIb), a conserved Asn residue 
(subdomain VIb) as well as the DFG motif in subdomain VII (35), thus is 
referred to as a pseudokinase (35, 36). Van Aalten and colleagues (35) 
reported the structure of STRADα in complex with MO25α, forming a 
heterodimer. STRADα was previously determined to bind to MO25α through 
its C-terminal Trp-Glu-Phe residues (WEF motif) (33), however, recent 
structural analysis confirms extensive interface with MO25α through seven 
structurally similar α-helical repeats that form a horseshoe shaped concave 
surface (36). Although STRADα lacks the prerequisite residue for catalytic 
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activity, STRADα adopts an active conformation when bound to ATP. While 
the affinity of STRADα for ATP is enhanced by MO25α, the binding of both 
MO25α and ATP to STRADα, are essential for the activation of LKB1 (36). 
LKB1-STRADα-MO25α heterotrimeric complexes (Figure 3) can be 
purified from mammalian cells, with each component in approximately equal 
stoichiometry (33). When in complex with STRADα and MO25α, LKB1 
becomes catalytically active, thus unlike most serine-threonine kinases LKB1 
does not require the phosphorylation of its conserved threonine in the T-loop 
for activity (32-35). Individually, STRADα and MO25α are expressed in 
both the cytoplasm and nucleus; however when co-expressed, both are 
located exclusively in the cytoplasm. Expression of LKB1 with STRADα and 
MO25α results in extensive re-localization of LKB1 to the cytoplasm (32-
33). Most oncogenic mutants of LKB1 that have been identified in human 
cancers are unable to interact with STRADα and MO25α (37), thus the 
majority of these mutants remain localized in the nucleus. The interaction of 
STRADα and MO25α with LKB1 increases the catalytic activity of LKB1 
approximately 10-fold (32). As previously mentioned, LKB1 induces a G1 
cell cycle arrest, while LKB1 oncogenic mutants cannot (28,38); this 
difference may be attributed to the fact that LKB1 oncogenic mutants do not 
interact with STRADα-MO25α, since the majority of mutations are localized 
to the kinase domain of LKB1. STRADα interaction is required for LKB1-
induced G1 arrest, since siRNA-mediated knockdown of STRADα expression 
prevented LKB1 from inducing G1 arrest (32).  LKB1 can also form a complex 
with heat shock protein 90 (Hsp90) and the Cdc37 kinase-specific targeting 
subunit for Hsp90 (39). It is likely that these are two separate complexes, since 
STRADα-MO25α immunoprecipitate with LKB1, but not with Cdc37 or 
Hsp90 (19). The authors of this study suggest that Hsp90 and Cdc37 may 
facilitate in the formation of the LKB1-STRADα-MO25α complex (39).  
 A more complex role for STRADα has recently been identified. A series 
of experiments by Dorfman and colleagues (34) demonstrated that STRADα 
plays an important role in the nucleo-cytoplasmic shuttling of LKB1. The 
authors showed that STRADα prevents LKB1 from binding to importinα/β, 
preventing LKB1 from entering the nucleus. Furthermore, STRADα exits the 
nucleus in a CRM1- (exportin1) mediated fashion. LKB1 is exported from 
the nucleus in complex with STRADα. LKB1 alone is not exported by 
CRM1. STRADβ can prevent the binding of LKB1 to importinα/β but cannot 
facilitate nuclear export of LKB1 through CRM1, indicating functional 
differences for STRADα and STRADβ. STRADα when in complex with 
LKB1 can also be exported from the nucleus by exportin7; this is the first 
protein identified as cargo for both CRM1 and exportin7. Both STRADα and 
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MO25α can passively diffuse in and out of the nucleus through nuclear pores. 
Due to the presence of various STRAD isoforms and splice variants, it is 
possible that when LKB1 is in complex with different STRAD isoforms, 
LKB1 localization will vary, providing another means of control of LKB1 
function. This was recently demonstrated by Marignani and colleagues (40) 
that identified eleven different STRADα isoforms isolated from human 
colorectal cancer cell lines, each of which differently interact with LKB1 and 
MO25α. Levels of LKB1 activity and localization also varied with the different 
STRADα isoforms. The authors of the study postulate that in PJS where LKB1 
expression is normal, the syndrome manifests due to the presence of a 
STRADα isoforms that render LKB1 catalytically deficient (40). 
 
 
Figure 3. Schematic representation of how STRADα/MO25α may interact to activate 
LKB1. The model is based on known mutagenesis and structural data detailed in 
Zeqiraj et al. 2009. Binding of either ATP and/or MO25a to STRADα induces 
STRADα to adopt a closed conformation, leading to the assembly of a fully active 
LKB1 complex. From Zeqiraj et al, PloS Biology, 2009. 
 
Other interacting partners of LKB1 
 
 In addition to the proteins described above, LKB1 has been reported to 
regulate the expression of transcriptions factors. LKB1 associates with LIM 
domain only 4 (LMO4), an adaptor that assembles transcription factors such 
as GATA-6 (41). LKB1 kinase activity enhances GATA-6 mediated 
transactivation in HeLa cells. Furthermore this study demonstrated that, in 
contrast to previous reports, LKB1 enhances the promoter activity of P21 WAF1 in 
the presence of LIMO4, GATA-6 and LDB1, in a TP53 independent manner 
(41). LKB1 along with its downstream kinase, the salt inducible kinase 
(SIK), regulates another transcription factor, cyclin AMP response element 
binding protein (CREB) by phosphorylating and repressing its coactivator, 
transducer of regulated CREB activity (TORC) (42).  It has been reported 
that Lkb1 null fibroblasts from mice exhibit high expression levels of signal 
transducer and activator of transcription 3 (Stat3)-regulated genes such as, 
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matrix metalloproteinase 2 (Mmp2), Mmp9, vascular endothelial growth factor 
(Vegf), insulin-like growth factor binding protein 5 (IGFBP5) and 
Cyclooxygenase-2 (COX-2) (43-44). This has been attributed to the suppression 
of the oncogenic transcription factor Stat3 by Lkb1 and its kinase deficient 
mutants, which interact with Stat3 and reduce its association with target promoters 
(46). An alternative mechanism for the enhanced expression of COX-2 in PJS 
hamartomas (47), has been ascribed to the regulation of the transcription 
factor polyomavirus enhancer activator 3 (PEA3) by LKB1. LKB1 associates 
with PEA3, induces its phosphorylation, and targets it to the ubiquitination 
and proteosome-dependent degradation pathway (48). Hence LKB1 plays a 
role in gene transcription through the regulating of transcription factors. 
 
LKB1 gene inactivation in human cancer  
 
 There is no doubt that LKB1 is an important tumour suppressor gene 
involved in cancer development. Its genetic inactivation is not only the cause 
of PJS but also a critical step in the development of some forms of sporadic 
tumours. Since PJS patients have an increased risk of developing several 
types of malignancies, mutations at LKB1 have been sought in a wide variety 
of sporadic tumours. Tumour-specific LKB1 alterations have been identified 
in many tumour types, although their frequency is apparently low (49). 
Intriguingly, in lung tumours of the non-small-cell lung cancer (NSCLC) 
type, especially adenocarcinomas, LKB1-inactivating mutations are 
commonly detected, occurring in from one-third to a half of cases (50-51). 
The type and pattern of mutations in LKB1 in the PJS and in lung cancer have 
been extensively reviewed elsewhere (49,52). These observations are fully 
consistent with the high frequency of loss of heterozygosity (LOH) at 
chromosome 19p13, reported in lung primary tumours and cancer cell lines 
(53). In tumours, frequent LOH at a particular chromosomal region constitutes 
a classic hallmark for pinpointing the location of a tumour suppressor gene. 
Thus, it can be concluded that LKB1 is one of the tumour suppressor genes 
targeted by the high frequency of LOH at chromosome 19p in lung cancer. 
More recently, another tumour suppressor on chromosome 19p13.2, BRG1 
(also called SMARCA4), has been found to be frequently inactivated by 
somatic mutations in lung cancer cell lines (54), indicating that LOH at 
chromosome 19p in lung cancer targets two distinct tumour suppressors (55). 
The reasons for the differences in the frequency of LKB1 mutations between 
lung tumours and other tumour types are not yet understood and are puzzling 
because lung cancer is not among the commonest tumours arising in PJS. 
There are several possible explanations for these differences, and these have 
been discussed elsewhere (49). 
LKB1 kinase in cancer   81 
 The pattern of mutations in LKB1 in tumours of sporadic origin and in 
those arising in PJS is that of a classic tumour-suppressor gene. First of all, 
mutations are homozygous, as predicted by Knudson’s two hit hypothesis (56). 
Usually, mutations or small deletions/insertions arise in one of the alleles while 
the remaining allele is lost by LOH. PJS patients are born with an LKB1 
alteration (first hit) and the remaining allele is altered (second hit) during 
tumour development. In contrast, in tumours of sporadic origin both alleles 
arise during tumour development. LKB1 mutations are scattered throughout 
exons 1 to 8, but no mutations in exon 9 have so far been identified. There is a 
large proportion of nonsense, indel, frameshift and intronic mutations in 
splicing-conserved sites, as well as large deletions. These changes predict the 
generation of truncated and, therefore, completely inactivated LKB1. Some 
missense mutations, which lead to aminoacid changes, have also been found, 
especially in PJS patients. Most of these are substitutions of highly conserved 
aminoacids in the kinase domain and abrogate the activity of LKB1 (52).  
 In lung cancer, LKB1 mutations occur preferentially in smokers and are 
found concomitantly with alterations at other cancer genes such as TP53, 
PIK3CA, MYC, CDKN2A and KRAS, but not with EGFR mutations (57-58). 
Moreover, LKB1 inactivation is less frequent in lung adenocarcinomas from 
patients of Asian origin (57-59), which exhibit a significantly higher 
frequency of EGFR alterations than found in lung adenocarcinomas arising in 
patients from western countries. 
 
LKB1 mouse models and cancer   
 
 Genetic mouse models have provided insight into molecular mechanisms 
by which LKB1 elicits its tumour suppressor function. The first Lkb1 mouse 
model was developed by Mäkelä and colleagues in 2001, targeted disruption 
of Lkb1 resulted in embryonic lethality at midgestation characterized by 
neural tube defects, and abnormal vasculature due to aberrant regulation of 
vascular endothelial growth factor (Vegf) expression (60). A second Lkb1 
gene knockout mouse model generated by Taketo and colleagues (61) 
characterized hamartomatous tumours in heterozygous Lkb1+/- mice that were 
histologically similar to PJS hamartomas. Analysis of the gastrointestinal 
hamartomas confirmed expression of wild-type Lkb1 and targeted Lkb1 allele, 
thus suggesting that the initiation and development of polyps was due to Lkb1 
haploinsufficiency and not due to Lkb1 loss of heterozygosity (61). In addition 
to gastrointestinal hamartomas, greater than seventy per cent of the male 
Lkb1+/- mice developed hepatocellular carcinomas (HCC) compared to 
approximately twenty per cent of the female Lkb1+/- mice (62). Furthermore, 
histopathology confirmed the presence of trabecular, pseudoglandular and 
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sarcomatous forms of HCC, that shared histological characteristics with 
human HCC and displayed biallelic inactivation of Lkb1(62).   
  Since knockout mouse models of the Lkb1 gene were found to be 
embryonic lethal, DePinho and colleagues developed a mouse model that 
carried a conditional Lkb1 allele (Figure 4) (43). Similar to previous models, 
conditional Lkb1-/- mice were embryonic lethal, while conditional Lkb1+/- 
mice developed polyps that were histologically similar to PJS polyps. Like 
the polyps from people with PJS (63-64), polyps from conditional Lkb1+/- 
mice were not positive for activating ras mutations however, Lkb1-/- mouse 
embryonic fibroblasts (MEFs) were sensitive to Ras-induced senescence and 
activated ras-mediated transformation (43). Inconsistent with previous Lkb1 
knockout models (60-61), 25% of the conditional Lkb1+/- mice displayed 
LOH at the Lkb1 locus. The reason for the discrepancy in Lkb1 LOH between 
Lkb1 knockout and conditional Lkb1 mouse models is not known. 
   
 
 
Figure 4. Targeting strategy and analysis of Lkb1. a) Lkb1 genomic structure and 
recombinant alleles. The 3' untranslated region (black bars), and noncanonical splice 
sequences (asterisks) are indicated. The transcript from the Lkb1 null allele eliminates 
exons 2–6, resulting in a translational frameshift (crosshatched bars). b) Southern 
analysis of DNA from ES cell clones showing targeting of the Lkb1 locus. c) Southern 
analysis of the lox, null (-), and wild-type (+) alleles. d) Southern analysis of DNA from 
Lkb1lox/- MEFs, untreated (-) or infected with a Cre retrovirus (+). e) Western analysis of 
Lkb1lox/- (-/-) and wild-type (+/+) MEFs after Cre expression, using antibodies to the 
amino (left) and carboxy (right) termini of Lkb1. From Bardeesy et al, Nature 2002. 
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 In 2005, Sakamoto and colleagues (65) generated mice conditional for 
expression of Lkb1 by replacing exons 5-7 of the Lkb1 gene with a cDNA 
cassette encoding exons V-VIII and IXb, flanked by loxP Cre excision 
sequence (Figure 5) (65). Surprisingly, male Lkb1fl/fl mice were sterile 
however a plausible explanation was made available several years later with 
the discovery of an alternative splice variant of Lkb1 located at exon IXa, 
referred to as Lkb1 short form (Lkb1S).  Lkb1S was found to be highly 
expressed in testis whereby male mice lacking Lkb1S were found to be sterile 
(66) and presented with defects in spermatogenesis (67). 
 
 
 
Figure 5. Generation of LKB1-deficient mice.  a) Diagram illustrating the positions 
of exons 3–8 (█) in the wild-type Lkb+Cre- allele. In the Lkb1flCre- allele, exon 4 of 
the Lkb gene is flanked with loxP Cre recombinase excision sites (▲), and exons 5–7 
encoding the catalytic domain of Lkb1 are replaced with a cDNA construct encoding 
the remainder of the Lkb1 sequence, as well as a neomycin (Neo) selection gene. The 
expression of the neomycin gene is driven by the Lkb1 promoter and it is made as 
fusion mRNA with Lkb1. Its translation is directed by an internal ribosome entry site. 
In the Lkb1flCre+ allele, exons 4–7 of the Lkb1 gene are deleted through action of the 
Cre recombinase, there by ablating functional expression of LKB1. The positions of 
the PCR primers used to genotype the mice are indicated with arrows. b) Breeding 
strategy employed to generate Lkb1fl/fl and Lkb1-muscle-deficient (Lkb1fl/flCre+/-) 
mice, where MCKCre denotes transgenic mice expressing the Cre recombinase under 
the muscle creatine kinase promoter. The number and percentage of each genotype 
obtained are indicated. From Sakamoto et al, EMBO J, 2005. 
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 The strategy used by the Alessi’s laboratory (65) to generate a floxed Lkb 
allele, resulted in no expression of testicular Lkb1S, thus explaining the 
sterility of these male mice. In addition to male sterility, protein expression in 
Lkb1fl/fl mice was found to be five- to ten-fold reduced compared to Lkb1+/+, 
indicative of a hypomorphic phenotype for homozygous Lkb1 mice, whereas 
Lkb1+/fl mice expressed two-fold less Lkb1 than Lkb1+/+ mice (65).  When 
Lkb1fl/fl mice were crossed with mice transgenic for Cre-recombinase under 
the muscle creatine kinase promoter (MCKCre), resulting progeny had Lkb1 
excised from skeletal and heart muscles prior to birth (68). AMPKα2 
activation was evaluated in Lkb1 lacking skeletal muscle and found to be 
significantly lower than AMPKα2 activity in skeletal muscle from wild-type 
or Lkb1+/fl mice (65), despite comparable AMPKα2 expression levels. 
Interestingly, AMPKα1 activity was modestly increased by 2-fold in Lkb1-
deficient muscle. These observations were explained by the possible 
contamination of nonmuscle cells in the sample preparations (65). Finally, 
since AMPK activation during muscle contraction regulates the balance of 
energy, ADP:ATP and AMP:ATP ratios were evaluated in contracting tibialis 
anterior and extensor digitorum longus muscles. In muscles lacking 
expression of Lkb1, ADP:ATP and AMP:ATP ratios were significantly 
elevated compared to wild-type, Lkb1+/fl, or hypomorphic Lkb1fl/fl mice.  
Overall, the work from Alessi and colleagues (65) confirms a critical role for 
Lkb1 in AMPK-mediated activation of skeletal muscle and energy balance.  
 The loss of LKB1 expression in pancreatic cancer is well described in the 
literature with neoplasms ranging from ductal adenocarcinomas, to 
intraductal papillary mucinous neoplasia and serous cytadenomas (69-70). 
Conditional ablation of Lkb1 expression in mice was conducted to determine 
the functional role of Lkb1 in the development of the pancreas (71). Genetic 
cross between conditional null allele of Lkb1 and transgenic Pdx1-Cre 
(expressed in pancreatic progenitors between E8-E12) resulted in initially 
normal development, however shortly after birth, these mice exhibited 
increased weight gain, elevated serum amylase, steatorrhea and by 10 weeks, 
all mice became increasingly cachetic and therefore euthanized (71). Analysis 
of the abdominal cavity revealed complete replacement of pancreatic tissues 
with cystic masses that closely resembled serous cystadenoma observed in 
PJS. The penetrance of pancreatic disease was complete in these mice 
compared to heterozygous Lkb1-Pdx1-Cre or wild-type mice (71). These 
findings confirm a functional role for Lkb1 in pancreas development. Since 
polarized organization of acina is necessary for directional secretion of 
zymogen from the pancreatic ductal network and given that LKB1 is reported 
to be involved in mediating cell polarity (13-14, 72), as it is discussed later, 
acinar development was evaluated in the Lkb1-Pdx1-Cre mice (71). There 
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was a loss of acinar polarity in pancreatic tissues from Lkb1-Pdx1-Cre at 
E18.5, as determined by loss of basal positioning of nuclei, lateralization of 
microvilli and a reduction/loss of tight and/or adherents junctions, was 
observed. Overall, the authors of this study establish a physiological role for 
LKB1 in pancreatic cellular polarity and the maintenance of ductal intregrity. 
 
LKB1 and AMPK: Cellular energetic metabolism and the 
cancer connection  
 
 As a tumour suppressor, the restitution of wild type LKB1 has the ability 
to suppress the growth of tumour cells that lack the LKB1 protein (28, 73). 
The molecular mechanisms underlying the tumour-suppressor function of 
LKB1 are still not completely understood, although it seems plausible that it 
depends on its serine-threonine kinase activity. The best characterized LKB1 
substrate is the AMP-activated protein kinase (AMPK), a so-called 'metabolic 
master switch'. An increase in the intracellular AMP:ATP ratio triggers the 
phosphorylation and activation of AMPK, which is allosterically activated by 
AMP and subsequently phosphorylated at Thr172 by upstream kinases such 
as LKB1 (74). Activation of AMPK modulates the activity of multiple 
downstream targets in normalizing ATP levels, e.g. stimulating fatty acid 
oxidation to generate more ATP and simultaneously inhibiting ATP-
consuming processes including fatty acid and protein synthesis (75). 
Enzymes essential for free fatty acid synthesis, including fatty acid synthase 
and acetyl CoA carboxylase (ACC), can be inhibited by AMPK by virtue of 
direct phosphorylation and/or regulation of transcription.  
 The upstream kinase that phosphorylates and activates AMPK (AMPKK) 
was a long-sought protein. The first evidence suggesting that LKB1 is an 
AMPKK came from the work by Hong et al. (76), who searched for kinases 
that triggered the phosphorylation/activation of Snf1, the homolog of AMPK 
in yeast. They identified three yeast kinases, Pak1p, Tos3p and Elm1p, that 
activate Snf1 kinase in vivo. Moreover, Tos3p was found to be able to 
phosphorylate and activate mammalian AMPK, suggesting functional 
conservation of the upstream kinases between yeast and mammals. Finally, it 
was shown that LKB1, which is related to Tosp3, is able to phosphorylate 
and activate AMPK in vitro and could be the long-sought mammalian 
AMPKK. Almost simultaneously it was described that LKB1, in a complex 
with STRAD alpha/beta and MO25 alpha/beta, activates AMPK via 
phosphorylation of Thr172. The heterotrimeric complex was essential for the 
proficient activation of AMPK in vitro and in vivo (74, 77). In further support 
of the AMPKK activity of LKB1, the AMPK-activating drugs 5-
aminoimidazole-4-carboxamide ribonucleoside (AICAR) and phenformin 
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does not activate AMPK in the cervical cancer-derived and LKB1-mutated 
HeLa cells or in lung cancer-derived LKB1-mutant cells, but activation can 
be restored by stably expressing wild type, but not catalytically inactive, 
LKB1 (33, 78). Finally, the comparison of the expression profiles among 
lung tumours according to LKB1 mutation status revealed that LKB1-mutant 
tumours has differential levels of many transcripts, including components of 
the PTEN/PI3K pathway as well as enzymes that participate in AMP 
metabolism, such as AMPD3 (adenosine monophosphate deaminase,  
isoform E) and APRT (adeninephosphoribosyl transferase) (79), further 
linking LKB1 function with that of AMPK.  
 How LKB1 and AMPK inactivation contribute to cancer development is 
still not completely clear. Abrogation of energetic checkpoints may be 
required for a cancer cell to ensure the maintenance of cell survival and 
growth in an environment with limited access to nutrients or oxygen. In a 
normal cell, these circumstances will trigger cessation of cell growth or 
apoptosis due to the compromised availability of ATP. Another link between 
the LKB1-AMPK pathway and cancer development is the tuberin protein, 
which is the product of the tuberous sclerosis complex 2 gene (TSC2), which 
represses of mTOR when activated by AMPK (80-81). Germ-line mutations 
of TSC1 or TSC2 genes cause the tuberous sclerosis syndrome, which has 
similarities with PJS, including the presence of hamartomas (82). Wild type 
LKB1 has been shown to be required for modulating AMPK activity and that 
of AMPK-downstream targets, including mTOR, in a variety of energetically 
depleted cancer cells (78, 80). 
In addition to cancer, LKB1 may be important in type II diabetes 
mellitus, a metabolic disorder characterized by resistance to the actions of 
insulin to stimulate skeletal muscle glucose disposal. The involvement of 
LKB1 in type II diabetes may arise from its function in the activation of 
AMPK. Deletion of LKB1 in the liver of adult mice abolished almost all 
AMPK activity and resulted in hyperglycemia with increased gluconeogenic 
and lipogenic gene expression (83). Furthermore, metformin, a drug widely 
prescribed to type II diabetes patients, lowers blood glucose concentrations 
by indirectly promoting AMPK activity (84). The effectiveness of 
metformin depends on the presence of LKB1 (83). Among the drugs that 
activate AMPK are AICAR and the biguanides, metformin and phenformin. 
All of these require LKB1 activity, and so therapies based on AMPK 
activators would be effective only in LKB1 wild type tissues. A recent 
population-based case-control study showed that type II diabetic patients 
treated with the AMPK activator metformin were less likely to get cancer 
(85), suggesting that AMPK activators could also be used in cancer 
prevention. Although the role of these compounds in cancer prevention looks 
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promising, their effectiveness in patients who have already developed cancer 
may not be so clear. 
 More recently, LKB1 and AMPK activity have also been related to 
SIRT1, a NAD-dependent protein deacetylase that regulates energetic 
homeostasis in response to nutrient availability. SIRT1 overexpression 
diminished lysine acetylation in specific lysine residues of LKB1 and 
concurrently increased its activity, cytoplasmic/nuclear ratio, association with 
the LKB1 activator STRAD and, as expected, increased AMPK and ACC 
phosphorylation (86). It has also been reported that resveratrol, a polyphenol 
that protects against metabolic disease by activating SIRT1, increased LKB1 
phosphorylation at Ser(428) and, thus, AMPK activity. These effects are 
abolished by pharmacological and genetic inhibition of SIRT1 (24). Taken 
together, these findings suggest that SIRT1 functions as a novel upstream 
regulator for LKB1/AMPK signalling. 
 Finally, the LKB1-AMPK signalling pathway has also been functionally 
associated with the BRAF oncogene. In melanoma cells, AMPK activation is 
suppressed by activated BRAF, V600E mutation. Conversely, downregulation 
of BRAF signalling triggers activation of AMPK. In these cells LKB1 was 
found to be phosphorylated by ERK and Rsk, two kinases downstream of 
BRAF, which compromised the ability of LKB1 to bind and activate 
AMPK (87). 
 
The role of LKB1 in the regulation of cell polarity 
 
 The identification of AMPK as a key substrate of LKB1 kinase activity 
provides definitive evidence that the abrogation of energetic checkpoints, 
probably with the purpose of maintaining energetically costly processes such 
as DNA replication and cell division, is an obligatory event for cancer 
development. However, LKB1 functions as a master upstream protein kinase 
of many AMPK-related kinases (88), indicating that LKB1 modulates other 
important cell processes. Some of these AMPK-related kinases are the 
MAP/microtubule affinity-regulating kinases (MARK1, MARK2, MARK3 
and MARK4) involved in microtubule stabilization, which may be related 
to the proposed role of LKB1 in cell polarity. The substrates of LKB1, their 
downstream targets and associated biological roles are summarized in 
Figure 2.  
 Watts et al. (13) provided the first hint about the role of LKB1 in the 
control of cell polarity. They observed that the maternally expressed par 
genes were asymmetrically distributed in the first cell cycle of 
Caenorhabditis elegans embryogenesis. Establishing asymmetries at this 
early stage is essential for determining the subsequent developmental fates of 
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the daughter cells. They found that the par4 gene of C. elegans encodes a 
putative serine-threonine kinase that was similar to LKB1 and to the Xenopus 
egg and embryo kinase, XEEK1. In support of this, the protein encoded by 
the homolog of par4 in Drosophila, lkb1, has also been implicated in 
embryonic polarity, since it is required for the early anterior-posterior (A-P) 
polarity of the oocyte and for the repolarization of the oocyte cytoskeleton 
that defines the embryonic A-P axis (14). Finally, in mammalian 
development, it has been reported that Lkb1 is asymmetrically localized to 
the animal pole of the mouse oocyte and that it associates with the 
microtubules at metaphase during oocyte maturation, indicating that Lkb1 
protein participates in the polarization of the mouse oocyte and in the 
regulation of the asymmetry of meiotic divisions during oogenesis (89).  
 LKB1 has also been associated with the polarization of adult somatic 
cells of a number of cell types. In human epithelial intestinal cells it has been 
observed that the inducible expression of STRAD activates LKB1, which 
leads the individual cells to the rapid remodeling of the actin cytoskeleton 
whereby, in the absence of cell-cell contacts, they form an apical brush 
border and redistribute junctional proteins in a dotted circle at the periphery 
of the brush border. This implies that LKB1 can induce complete polarity in 
intestinal epithelial cells (72). In addition, LKB1 is required for axon 
differentiation and specification during neuronal polarization in the mammalian 
cerebral cortex through the phosphorylation and activation of brain-specific 
kinase, BRSK (21-22). Finally, immunostaining of LKB1 in a variety of 
normal human tissues has revealed apical accumulation of this protein in 
several types of epithelial cells (3). LKB1 has also been shown to be essential 
for NSCLC polarity and to colocalize at the leading edge of the cell with the 
small rho GTPase cdc42 and its downstream binding partner, p21-activated 
kinase (PAK), two key components of the polarity pathway (90). The exact 
mechanism and downstream targets that mediate the role of LKB1 in the 
control of cell polarity are still under debate. Some observations suggest 
AMPK and its target non-muscle myosin regulatory light chain (MRLC; also 
known as MLC2), which is directly phosphorylated by AMPK at an important 
regulatory site (91). Since the microtubule affinity-regulating kinases 
(MARK1, MARK2, MARK3 and MARK4) are among the AMPK-related 
kinases phosphorylated by LKB1 they may also mediate the role of LKB1 in 
cell polarity. The MARK family phosphorylates microtubule-associated 
proteins (tau/MAP2/MAP4), causing detachment from microtubules, and their 
disassembly (92-94). Interestingly, aberrant phosphorylation of the microtubule-
associated protein tau is one of the pathological features of neuronal 
degeneration in Alzheimer’s disease, which points towards LKB1 being a 
candidate target for novel therapies against this neurodegenerative disease.  
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LKB1 in regulation of hormone receptor signalling 
 
 Clinical evidence suggests a role for the tumour suppressor kinase LKB1 
in the development of breast carcinoma (95-97). Early evidence in the 
literature suggests that a loss of LKB1 expression leads to papillary breast 
carcinoma (98). More recently, a study that evaluated the expression of 
LKB1 in 85 cases of breast cancers, the authors found that in a subset of 
high-grade in situ and invasive mammary carcinomas, the expression of 
LKB1 was completely lost as determined by immunohistochemistry (96). In a 
separate study, 116 patients with confirmed breast carcinoma were evaluated 
for LKB1 protein expression, of which expression was low in approximately 
one third of the patients compared to control population of women. The 
authors of this study concluded that low expression of LKB1 correlated with 
higher histological grade, tumour size, and presence of lymph node status 
(95). Both studies conclude that LKB1 expression profile may serve as a 
prognostic marker for breast carcinoma, however further investigation is 
warranted. These recent findings suggest a role for LKB1 in breast cancer 
however the molecular mechanism by which this occurs is not fully understood.   
 Recent work from the Marignani lab (98) highlight the discovery of a novel 
function for LKB1, coactivator of estrogen receptor alpha (ERα) signalling. In a 
series of experiments, LKB1 was discovered to bind to ERα, thereby enhancing 
ERα-mediated transcription. Furthermore, it was determined that LKB1 
catalytic activity contributes to enhanced ERα-mediated transcription and that 
LKB1 is recruited to the promoters of ERα-responsive genes. Clinical evidence 
suggests a role for LKB1 in breast cancer since low expression of LKB1 is 
correlated with poor clinical outcomes. This said the molecular mechanisms by 
which LKB1 is involved in mammary gland development and/or malignancies 
are not known. The significance of this work is the demonstration, for the first 
time, of a functional link between LKB1 and ERα, placing LKB1 in a coactivator 
role for ERα signalling, similar to the other tumour suppressors such as RB (99-
102), P21WAF/CIP (103-104), TSC2 (105) and BRG1 (106), that are reported to 
have coactivator function for hormone receptors.  This discovery broadens the 
scientific scope of LKB1 and lays the ground work for further investigation into 
the role of LKB1 in mammary gland development and tumourigenesis.  
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Abstract. Glycogen synthase kinase 3 (GSK3), originally 
recognized for its role in glycogen synthesis, is a multifunctional 
kinase involved in important biological processes such as insulin 
sensitivity, hematopoietic stem cell repopulation, survival of tumor 
cells, cytoprotection in normal and pathological neurons and in 
cardiomyocytes. Tissue-specific effects and segregated functions 
within intracellular compartments (mitochondria, nucleus, 
cytoplasm) further contribute to branch out the activity of GSK3. 
Due to the extensive properties of this kinase, novel drugs targeting 
GSK3 are under development for potential therapeutic use in 
neurological disorders, diabetes and cancer. Emerging evidence 
indicates that GSK3 is a central regulator of a stress-activated 
network acting in concert with metabolic sensors of the 
bioenergetic requirements of the cells. The crosstalk between the 
PI3K/AKT/mTOR, the p90 RSK/MAP kinase (ERK1/2, JNK, p38) 
pathways and other key regulators of intracellular homeostasis 
including the transcription  factors  hypoxia inducible  transcription  
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factor-1 (HIF-1), NFkB, Nrf2 and the LKB1/AMPK/malonyl-CoA fuel sensing 
pathway set the threshold of tolerance to stress through modification of glucose 
metabolism and redox balance. Modulation of GSK3 activity thus operates at the 
crossroad between cell survival and cell death and can arbitrate cell fate by promoting 
adaptive mechanisms that lead to cytoprotection against mild and transient stress, or 
to cell death under conditions of severe threat such as acute oxidative damage. This 
work provides an overview of recent findings on the role of GSK3 in tumor 
establishment and progression, with a special focus on the regulation of metabolic 
parameters related with energy and redox homeostasis in response to GSK activation 
or inhibition, which could be exploited as potential targets for cancer treatment. 
 
Introduction 
 
      GSK3 is a ubiquitous serine/threonine kinase that controls a wide range 
of cellular processes, including insulin sensitivity, glucose metabolism and 
cell survival through regulation of energy homeostasis. GSK3 is composed of 
two isoforms, GSK3α and GSK3β. GSK3 is a unique kinase normally active 
(unphosphorylated) in unstimulated cells and is negatively regulated by 
phosphorylation of GSK3α at Ser21 and GSK3β at Ser9 by AKT and other 
kinases of the AGC (protein kinase A, protein kinase G, protein kinase C) 
family including p90 ribosomal S6 kinase (p90RSK) [1] upon stimulation by 
growth factors. Thus, GSK3 activity is kept under control by survival signals 
propagated by growth factors mainly through the PI3K/AKT pathway upon 
AKT phosphorylation at Ser473. GSK3 is also regulated by activating 
phosphorylation of GSK3α and β at Tyr276 and Tyr216, respectively. 
Phosphorylation of GSK3α at Ser21 and GSK3β at Ser9 by AKT can show 
non-overlapping and even opposite effects, for example in cardiac 
hypertrophy [2].  
 As a downstream target of the PI3K/AKT survival pathway, the 
inhibition of GSK3 triggered by tyrosine kinase (RTK) and G-protein-
coupled receptors (GPCR) can block mitochondrial apoptosis [3,4]. This 
property is beneficial to protect from damage untransformed cells including 
neurons [5], cardiomyocytes [6,7] and pancreatic β cells [8]. Similarly, 
pharmacologic inhibitors of GSK3 can exert cytoprotective effects [9]. The 
cytoprotective activity of lithium chloride and numerous, more specific 
GSK3 inhibitors has been extensively studied in pathological neuronal cells 
[10,11] and in cardiomyocytes under stress [12].  
 Among other functions, GSK3 inhibition or, more recently, genetic 
deficiency has been shown to normalize glucose metabolism in animal models 
of insulin resistance [13] and to support pancreatic β cells survival [8], thus 
fostering the development of GSK3 inhibitors as antidiabetic agents [14]. 
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 In cancer, an important function of GSK3, in particular GSK3β, is to 
regulate the central step in the canonical Wnt/β-catenin signaling pathway. 
The overactivation of this pathway has been implicated in the pathogenesis of 
several types of tumors, such as colon and prostate adenocarcinomas [15].  
 GSK3 phosphorylation stimulated by hepatocyte growth factor (HGF) 
and insulin-like growth factor-1 (IGF-1) through the oncogenic AKT pathway 
can enhance tumor cell proliferation, motility, invasion and metastatic spread 
[16].  
 Since the formulation of the Warburg hypothesis on the generation of 
excessive lactate in the presence of oxygen by tumor cells, numerous studies 
have progressively unraveled a specific metabolic signature of epithelial cells 
in tumors characterized by glucose usage for energy production (aerobic 
glycolysis) [17]. GSK3 intervenes in key molecular events that regulate 
glucose metabolism such as binding of overexpressed hexokinase II (HK II) 
to mitochondria [18] and stabilization of HIF-1 [19]. 
 On the other hand, GSK3 has also been implicated in the inhibition of 
caspase 8-mediated apoptosis triggered by death receptors, thus GSK3 
inhibitors can potentiate cell death propagated through the extrinsic pathway 
[4,20]. More in general, new data add to mounting evidence that, at least in 
some cell types, GSK3 inhibition can be detrimental to tumor cell survival 
[21-23]. 
 This work will focus on seminal and recent studies that have shed light 
on GSK3 as an important node in a regulatory network involved in the 
adaptive response to critical extracellular conditions affecting intracellular 
homeostasis (Fig. 1). In particular we will discuss in which way the metabolic 
consequences of GSK3 activation or inhibition support cell survival or dictate 
cell death in cells under stress and, in particular, in transformed cells.  
 
1. GSK3 in cell survival and cell death: A matter of timing 
 
 GSK3 inhibition has been reported to induce cytoprotection in neuronal 
cells and cardiomyocytes. The cytoprotective properties of GSK3 inhibition 
appear particularly relevant in the context of the biological phenomenon 
defined as preconditioning [7] or hormesis [24] and in postconditioning, 
consisting of a series of adaptive responses to mild stress that protect cells 
against a subsequent, severe injury. These concepts have informed the 
improvement of therapeutic strategies in neuroprotection (neurohormesis) 
and cardioprotection to avoid the adverse effects of oxidative stress and 
necrotic cell death during reperfusion after cerebral or myocardial ischemia 
[7].  
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 One of the central events in reperfusion is the opening of the 
mitochondrial permeability transition pore (mPTP). This protein complex is 
formed, among other less well-identified subunits, by cyclophilin D and the 
voltage dependent anion channel (VDAC). The involvement of adenine 
nucleotide translocase (ANT), hexokinase II and creatine kinase has been 
recently questioned [25]. mPTP controls selective exchanges of ions and 
metabolites between the cytoplasm and mitochondria. Opening of the mPTP 
located in the inner mitochondrial membrane is an on-off process that leads 
to mitochondrial depolarization, ATP depletion and eventually mitochondrial 
swelling. Mitochondrial damage and mPTP opening at reperfusion is caused 
by a burst of ROS mostly originating as superoxide anion during mitochondrial 
respiration (probably at complex 1 and 3 of the mitochondrial respiratory 
chain) and elevated calcium levels. Hydrogen peroxide derived by the activity 
of superoxide dismutase (SOD) can in turn be transformed in highly reactive 
hydroxyl radicals that damage mitochondrial proteins and lipids.  
 Mild mitochondrial depolarization with limited production of ROS is one 
of the mechanisms of preconditioning that allows cells to better tolerate 
oxidative stress during ischemia/reperfusion injury. GSK3 plays a prominent 
role in preconditioning by elevating the threshold of tolerance to ROS 
damage, thus protecting mitochondrial membrane integrity against mPTP 
opening. Proteins forming the mPTP complex and antiapoptotic proteins 
regulating the susceptibility to the mitochondrial permeability transition such 
as Bcl2 may be the GSK3 targets involved in the cytoprotective effects [7].  
 The temporal dynamic of preconditioning is relevant to obtain the 
cytoprotective effect. Cells must have time to respond to the noxious stimulus 
by transiently perturbing mitochondrial respiration to produce a limited 
amount of ROS with prevailing signaling function. Then, following a 
biphasic kinetics, the adaptive response ensues. Several lines of evidence 
indicate that GSK3 inhibition is a key event integrating survival signals 
emerging from the stimulation of different molecular pathways including 
those mediated by insulin and IGF-1, PKC, PKA.  
 
1.1. The role of GSK3 in cardioprotection 
 
 A well-characterized experimental model of preconditioning governed by 
GSK3 inhibition has been described by Sollott and coworkers in 
cardiomyocytes [12]. The consequences of ATP depletion caused by 
impaired mitochondrial oxidative phosphorylation are particularly dangerous 
in cardiomyocytes that, differently from neurons, cannot rely on glucose as 
an energy substrate for ATP production and do not tolerate low pH due to 
lactic acid production by anaerobic glycolysis. The role of GSK3 has been 
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studied by analyzing the effects of different pharmacological inhibitors of the 
mPTP. Two pathways leading to inhibition of the mitochondrial pool of 
GSK3, which differ in their ability to confer transient or stable, memory-
associated protection against oxidative stress have been identified by using 
different pharmacological agents, including lithium chloride, insulin and 
mitochondrial ATP-dependent K+ channel openers [7,12,25]. Phosphorylation 
of GSK3β at Ser9 has been proposed to elevate the threshold for mPTP 
opening by preserving the binding of hexokinase II to the mPTP complex 
[18]. At present, the exact molecular mechanism through which GSK3 
inhibition elevates the threshold for mPTP activation remains undefined. 
However, based on the encouraging results that indicate GSK inhibition in 
preconditioning as a valuable tool to limit ischemia/reperfusion injury, this 
therapeutic approach deserves in depth exploration in further preclinical and 
clinical studies.  
 
1.2. The role of GSK3 in neuronal cell survival and death 
 
 The role of active GSK3 in neuronal cell death has been extensively 
studied in several models of neurotoxicity and neurodegeneration. Although 
the adaptations to limit neuronal cell loss and to maintain tissue integrity in 
the brain differ in acute damage such as ischemic/reperfusion and neurotoxic 
injury, and in chronic pathological conditions, some common mechanisms 
include oxidative stress and disruption of calcium homeostasis. These 
conditions eventually lead to impairment of mitochondrial function followed 
by apoptotic or necrotic cell death [26].  
 GSK3 has been found to regulate different molecular activators of the 
mitochondrial (intrinsic) apoptotic pathway [4]. In neuronal cells, GSK3 has 
been reported to phosphorylate Bax, favoring its mitochondrial translocation, 
and the mixed lineage kinase 3 (MLK3), a mitogen-activated protein kinase 
kinase kinase that activates the proapoptotic c-Jun N-terminal kinase (JNK) 
pathway [27,28]. The recent finding that Wnt-regulated GSK3β is implicated 
in cell death of cerebellar granule neurons induced by trophic factor 
deprivation assigns a new role to the Wnt GSK3 pool.  
 GSK3 overexpression or overactivation in the brain has been found in 
animal models of Alzheimer’s and Parkinson’s disease [29]. Most 
neurodegenerative diseases are characterized by impaired mitochondrial 
function and glucose hypometabolism. Of note, neuroprotection can 
apparently be achieved by metabolic changes enhancing glucose metabolism 
in neurons. Two main molecular mechanisms underlying neuroprotection by 
enhanced glycolysis have been identified: HIF-1 induction boosting glucose 
flux through glycolysis and the pentose phosphate pathway [30], and 
Roberta Venè & Francesca Tosetti 100
induction of HKII binding to mitochondria induced by GSK3 inhibition [31].  
Enhanced glucose metabolism can result in the production of reducing 
equivalents in the form of NADPH. This HIF-mediated mechanism has been 
identified as an adaptation to tolerate oxidative stress due to β-amyloid 
toxicity and to contribute to the selection of a β-amyloid-resistant phenotype 
[30].  
 Paradigmatic models of neuronal cell death upon trophic factor 
withdrawal show that GSK3 inhibition by growth factors is an essential event 
to preserve neuronal cell survival [32]. In accordance with the activity of 
other growth factors, NGF neuroprotection is linked to GSK3 inhibition 
through activation of PI3K/AKT signaling and the effects of NGF 
deprivation have provided an informative set of data on the mechanisms 
implicated in GSK-mediated cell death [28].  
 Lithium chloride has found application in psychiatry as a mood stabilizer 
in manic-depression illness (bipolar disorders) for over fifty years. In 1996, 
Woodgett and coworkers discovered that lithium chloride is a 
pharmacological inhibitor of GSK3 [33]. Since then, numerous GSK3 
inhibitors other than lithium, including alsterpaullone, kenpaullone, 
SB216763 and AR-A014418 have been synthesized and reported to protect 
neurons against a variety of stressful conditions. The effects of lithium and 
other GSK3 inhibitors at molecular level have been studied in in vitro and in 
vivo experimental models recapitulating oxidative neuronal damage found in 
Parkinson’s and Alzheimer’s disease and other injuries including hypoxia-
ischemia in the immature brain, oxygen-glucose deprivation, potassium 
deprivation, glutamate excitotoxicity. Some of the biological effects of 
lithium cannot be ascribed to GSK3 inhibition in that lithium can also inhibit 
inositol monophosphatase (IMP) and induce macroautophagy due to free 
inositol and myo-inositol-1,4,5-triphosphate (IP3) depletion [34]. This 
biological effect is therapeutically relevant in neurodegenerative disorders 
induced by intracellular self-aggregation and accumulation of peptides such 
as β-amyloid, α-synuclein, tau or mutant huntingtin, in neurofibrillary 
tangles, which are autophagy targets. Nevertheless, the neuroprotective 
properties of selective GSK3 inhibitors confirm that GSK3 plays a central 
role in neuronal survival and plasticity. Interestingly, other neuroprotective 
drugs such as valproic acid indirectly induce GSK3 phosphorylation [11].   
 GSK3 inhibitors belong to two categories:  ATP competitive inhibitors 
localized in the ATP-binding pocket (CHIR-99021, AR-A014418, SB216763, 
SB415286) and non ATP competitive compounds (TDZD8, TWS119). 
Lithium chloride competes with magnesium and causes Ser9 and Ser21 
autophopshorylation in GSK3β and GSK3α, respectively. Different GSK3 
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inhibitors including AR-A014418, SB216763, SB415286, do not interfere 
with GSK3α/β phosphorylation at Ser21 and Ser9. Thus, the effects of the 
pharmacological inhibition of GSK3 on downstream targets can be 
independent of phosphorylation induced by PI3K/AKT and other AGC 
kinases (Fig. 1).  
 The question of why dysregulated, hyperactive GSK3 appears 
particularly damaging in neurons remains to be answered. The identification 
of oxidative stress as one of the most important event in the pathogenesis of 
classical models of neuronal injury by neurotoxic agents such as amyloid-β 
peptide and glutamate excitotoxicity and the use of pharmacological 
inhibitors of mitochondrial damage to maintain neuronal cell survival has 
provided important information about the requirements of this highly 
specialized cell type with unique biological functions.  
 Several recent reports suggest that, among other factors, neuronal GSK3 
activation appears particularly harmful due to the unique set of stress-related 
GSK substrates in this cell type. As an example, active GSK3 plays a pivotal 
role in Alzheimer’s disease by increasing tau phosphorylation and β-amyloid 
production [35]. 
 Most of the GSK3 inhibitors, except for CHIR-99021, show low affinity 
and weak inhibition for other kinases [1]. Nevertheless, GSK3 inhibitors 
represent a promising category of therapeutic agents in neurodegenerative 
disorders and, consequently, in recent years the search for more specific 
GSK3 inhibitors to avoid side effects due to off-site targeting has been 
intensified [14]. 
 
1.3. The opposing roles of GSK3 in tumors 
 
 Over-activation of survival signaling pathways mediated by AKT and 
NFkB is a common feature of tumor cells. In recent years, great efforts have 
been made to advance the search for synthetic or naturally occurring 
antitumor drugs able to selectively inhibit protein kinases regulating cell 
survival pathways. The clinical utility of highly selective protein kinase 
inhibitors, however, has been questioned. To overcome the emergence of 
molecular resistance to specific inhibitors, it has been proposed the 
alternative strategy of pointing to multi-targeted protein kinase inhibitors or 
cocktails of selective antagonists [36]. Another possibility is the targeting of 
multifunctional kinases that act as master regulators of different and cross-
talking signaling pathways. This appears to be the case for GSK3. In some 
tumor cell types active GSK3 mediates mitochondrial apoptosis, while in 
others it negatively regulates cell death induced by death receptors and 
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caspase 8, thus GSK3 has been shown to enhance cell death induced by 
TRAIL [4]. Thus, the effects of GSK3 inhibition on tumor cell survival 
depend on cell type-specific contexts. The increasing interest in histone 
deacetylase (HDAC) inhibitors as neuroprotective and cardioprotective drugs 
[11,37] and, at the same time, as promising anticancer agents underscores the 
evidence that GSK3 inhibition by lithium chloride, valproate and other 
HDAC inhibitors can lead to opposite outcomes in different cellular contexts. 
Evidence from in vitro and in vivo studies with specific GSK3 inhibitors like 
AR-A014418 confirm this observation: AR-A014418 has been indicated as a 
potential therapeutic tool in neurodegenerative disorders, however it 
potentiates the activity of anticancer drugs in glioblastoma and melanoma 
cells [38] and other tumor cell types [4]. Similarly, the regulation of NFkB by 
GSK3 exerts antiapoptotic effects in pancreatic cancer cells [39], while it 
induces cell death in astrocytes [40]. We have shown that GSK3 inhibition 
modulates the threshold of sensitivity to anticancer synthetic triterpenoids in 
prostate adenocarcinoma cell lines. We observed that GSK3 inhibition or 
genetic depletion changes the shape of cell death from apoptotic to necrotic 
by enhancing caspase 8 activity and mitochondrial and nuclear apoptosis 
mediated by downstream caspase 9 and caspase 3 [22]. 
 The activation of the Wnt/βcatenin pathway can promote tumor 
progression. Active GSK3β phosphorylates and promotes β-catenin 
proteosomal degradation by the destruction complex formed by the 
adenomatous polyposis coli (APC) and Axin proteins. This process inhibits 
Wnt-stimulated TCF/LEF-dependent transcription and accumulation of an 
oncogenic, transcriptionally active form of β-catenin [41]. In those tumor cell 
types in which the role of active GSK3β in the Wnt/β-catenin pathway 
prevails over other functions, the inhibitory phosphorylation of GSK3β can 
thus be functional to tumor progression through the stabilization and 
activation of β-catenin. Recently, multiple proteins have been identified as 
potential candidates for GSK3-regulated phosphorylation and Wnt-regulated 
proteasomal degradation, thus broadening the range of cellular activities 
controlled by the Wnt/GSK3 destruction complex. These targets, besides β-
catenin-mediated transcription, are involved in cellular functions including 
RNA processing, cytoskeletal dynamics, and cell metabolism [42]. Several 
recent excellent reviews have exhaustively treated the role of GSK3 and the 
Wnt-β-catenin pathway in the control of cell fate [43], therefore this topic 
will not be discussed further in this review. 
 The paradoxical effects produced by the same compound in different 
pathological contexts occur despite some neurodegenerative disorders like 
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Alzheimer’s disease, diabetes and cancer show common pathophysiological 
traits including mitochondrial dysfunction, excessive generation of ROS, a 
precarious redox equilibrium due to altered expression of antioxidant 
enzymes and insulin resistance. The first consideration is that pathological 
neurons, cardiomyocytes and pancreatic β cells are not transformed cells; 
secondly, they are non-proliferating, post-mitotic cells. These observations 
could imply that untransformed and rapidly proliferating, transformed cells 
adopt different metabolic rearrangements to cope with similar pathological 
manifestations. Here we will illustrate some of the metabolic changes 
resulting from GSK3 modulation and will discuss several hypothesis on why 
the attempt to restore intracellular homeostasis can produce diverging effects 
in untransformed and in transformed cells. 
 
2. Linking the metabolic effects of GSK3 with cytoprotective 
and anticancer properties 
 
 It is now established that the metabolic control of intracellular 
homeostasis is intimately linked to cell signaling networks integrating 
information from environmental changes or intracellular pathological events 
such as peptide or protein aggregation and tangle formation in neurons, 
endoplasmic reticulum (ER) stress due to glucose deprivation, or oncogene 
activation in cells living in chronic stressful conditions. In particular AKT, 
mTOR, GSK3, FoxO and sirtuins (Sirt 1-3) belong to a signaling network 
acting in concert with energy sensors such as AMP-activated protein kinase 
(AMPK) and transcription factors including the hypoxia inducible 
transcription factor 1 (HIF-1) and NF-E2-related factor 2 (Nrf2) capable of 
producing metabolic and redox adjustments in response to the bioenergetic 
requirements of the cells. While short-term damage elicits adaptive responses 
usually functional to cell defense and repair, long-term activation of 
homeostatic molecules, for example HIF-1, AKT/GSK3 and Nrf2, can help 
cells to substantially reprogram metabolism in pathological directions (Fig. 1).  
 
2.1 GSK3 supports the glycolytic phenotype 
 
 The glycolytic phenotype of most tumor cells is supported by the 
overactivation of the PI3K/AKT/GSK3 pathway that can confer resistance to 
apoptosis. Other specific cell types such as immune cells with intense 
biosynthetic  activity  show  an  hypermetabolic  state  and  preferentially  use 
glucose as a primary energy source [44].  However, it is not clear whether the 
glycolytic switch may have a causative role or be a consequence of 
transformation.  The observation  that  metabolic  diseases  characterized  by 
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Figure 1. Redox imbalance is a common trait of different pathological conditions 
including cardiovascular diseases, neurodegeneration, metabolic disorders, diabetes, 
and cancer. One of the main line of antioxidant defense against oxidative stress 
involves the activation of cell signaling pathways regulating energy expenditure and 
adjustment of glucose metabolism. The enhanced transcriptional activity of Nrf2 
following GSK3 inhibition provides a battery of antioxidant enzymes, while HIF 
induction of glycolytic enzymes can compensate the impairment of mitochondrial 
ATP production. This mechanism is effectively involved in neuroprotection. In 
cardiomyocytes, a central event apparently necessary to protection against 
ischemia/reperfusion injury is the limitation of mPTP, which can be obtained by 
GSK3 inhibition. In tumor cells under constitutive oxidative stress, the perturbation of 
a precarious redox equilibrium by ROS induction or GSH depletion can lead to cell 
death and represents a promising anticancer strategy. Different redox-active drugs 
have been shown to enhance GSK3 phosphorylation. Due to the up-regulation of GSH 
and antioxidant enzymes consequent to GSK3 inhibition, this event could be an 
attempt to counteract oxidative stress. 
 
altered glucose balance and defective mitochondrial energy production 
including insulin resistance and obesity are risk factors for some types of 
cancer suggest that impairment of glucose homeostasis is important in the 
early phases of cancer development [45]. On the other hand, the 
hypermetabolic state of frank tumor cells showing activated oncogenes like 
ras and myc indicate that glycolysis supported by AKT could be an 
adaptation to cope with the high bioenergetic requirements of tumor cells due 
to oncogene activation and increased ROS production.  
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 Emerging evidence is elucidating the link between glucose metabolism 
and inhibition of tumor cell death. GSK3 can regulate glucose metabolism 
through multiple mechanisms, with varied effects in normal and tumor cells 
[14,46]. During growth factor deprivation, but in conditions of enhanced 
glucose metabolism, GSK3 inhibition by protein kinase C can stabilize the 
antiapoptotic Bcl-2 family protein Mcl-1, which is degraded by a GSK3-
mediated mechanism [47].  
 Overexpression of HKII and enhanced binding to mitochondria promotes 
glucose consumption and exerts an antiapoptotic effect. It has been reported 
that active GSK3 can phosphorylate HK II, thus inhibiting its binding to 
mitochondria, and trigger cell death in tumor cells [48]. As a result of AKT 
activation by growth factors, the inhibitory phosphorylation of GSK3 
promotes binding of HK II to mitochondrial outer membrane, an event that 
enhances glucose metabolism. [18,49]. This same adaptive mechanism 
involving HK II overexpression and binding to mitochondria, with the 
consequent enhancement of glucose metabolism, can be also due to chronic 
inhibition of GSK3 and plays an opposing, neuroprotective role in neuronal 
cells treated with the mitochondrial complex I inhibitor rotenone [23,31,48].  
 GSK has been shown to mediate HIF-1α stabilization upon ROS-induced 
RhoB activation in hypoxic conditions [50], or during early hypoxia in other 
experimental models [51], thus reinforcing glucose utilization through HIF-
mediated transcription. Conversely, in prolonged hypoxia GSK3 
dephosphorylation and activation contributes to HIF-1α degradation [19] and 
probably hypoxic cell death.  
 
2.2 GSK3 in regulation of energy balance 
 
 Cross-talk and reciprocal regulation between GSK3 and AMPK, a major 
molecular mediator of energy balance within the cell [52], plays a key role in 
cellular and systemic metabolic regulation. AMPK is a heterotrimeric 
complex that is composed of a catalytic α-subunit, a β-subunit, and a γ-
subunit that binds AMP. Low energy levels in the cell due to oxygen or 
glucose deprivation or enhanced ATP consumption are sensed as a decreased 
ATP/AMP ratio. Allosteric AMPK activation by AMP binding is 
accompanied by phosphorylation of the active site by upstream kinases 
including the tumor suppressor LKB1 and calmodulin-dependent kinase 
kinase-β (CaMKKβ). AMPK then phosphorylates various substrates 
including metabolic enzymes, transcription factors and co-activators to 
inhibit energy consuming biosynthetic pathways, first of all protein synthesis 
promoted by mTOR activation, along with lipid and carbohydrate 
biosynthesis, while it activates catabolic reactions to preserve ATP. The 
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metabolic effects of AMPK inhibition by AICAR or metformin, include 
improved glucose uptake and glycolysis and lipid metabolism [53]. AMPK 
phosphorylates AcetylCoA carboxylase 1 and 2 (ACC1, ACC2), blocking 
fatty acid synthesis and improving fatty acid oxidation. It has been recently 
demonstrated that AMPK is inhibited upon binding of glycogen to its β-
subunit [53]. In this way, through the modulation of glycogen binding, 
AMPK can also sense and control the availability energy stores. AMPK 
inhibitors such as metformin are in clinical use for the treatment of the 
metabolic syndrome, dyslipidemia and diabetes. Activation of AMPK 
triggers a phosphorylation cascade involving the tuberous sclerosis complex 
proteins (TSC1 or hamartin, TSC2 or tuberin), that inhibit the mTOR 
activator Rheb, and leading to mTOR inhibition. In conditions of critical 
energy levels due to low ATP, glucose or oxygen, AMPK and GSK3 
cooperate to activate a pro-survival pathway by blocking mTOR activity. In 
different non-tumorigenic cell lines including HEK293, MEF, 293T, AMPK 
directly phosphorylates TSC2 on serine residues 29–32 and primes serine 
residues for subsequent phosphorylation by GSK3 [54]. AMPK has been 
shown to induce AKT-mediated Ser9 phosphorylation of GSK3 in HepG2 
cells that is required for inhibition of cAMP-response element (CRE)-
dependent genes, such as phosphoenolpyruvate carboxykinase C (PEPCK-C) 
[55]. Conversely, in both hyppocampal neurons and the neuroblastoma cell 
line SH-SY5Y both the AMPK inhibitors AICAR and phenformin induced 
AKT and GSK3 dephosphorylation [56]. 
 AMPK activation not only limits ATP-consuming biosynthetic processes, 
but also inhibits cell growth and proliferation by inducing the accumulation 
of cell-cycle inhibitors such as p53, p27 and p21. Based on the evidence of 
the proapoptotic effects on energy demanding cancer cells, AMPK inhibitors 
have received attention as potential antineoplastic drugs [53].  
 In conclusion, GSK3 signaling essentially contributes to the network 
involving modulation of mTOR and AMPK activation, all integrating at the 
level of the TSC2 complex, in order to arrange growth control with energy 
availability within the cell (Fig. 2).  
 Other major metabolic changes affecting energy balance in tumor cells 
involve the diversion of lipogenesis by fatty acid synthase (FAS) to enhance 
cell survival at the expenses of energy storage [57] and myc-stimulated high rate 
glutamine metabolism to support anabolic growth [58]. Several reports show that 
GSK3 plays a role in these key tumor-specific metabolic adaptations. Active 
GSK3 has been reported to down-regulate the transcriptional activity of adipocyte 
determination and differentiation-dependent factor 1 (ADD1)/SREBP1c that 
controls FAS expression [59] and to phosphorylate and promote degradation of 
a Drosophila homologue of c-myc upon priming by casein kinase I (CKI) [60]. 
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Figure 2. The main intracellular stress-sensitive signaling pathways converge on 
GSK3 regulation. Dissection of the different branches of the network by the use of 
pharmacological inhibitors including the MEK inhibitors PD98059 and UO126, the 
PI3K inhibitors wortmannin and LY294002, the mTOR inhibitor rapamycin and the 
p90 RSK inhibitor BI-D1870 served to set the hierarchical order of the single 
molecular components of the network. Although targeted genetic depletion is a 
straight forward approach to assign a role to the different molecular components, the 
therapeutic perspectives to modulate the activity of the network foresee the use of 
protein kinase inhibitors. The reciprocal regulation and feed-back inhibition or 
activation in the network are not represented for simplification, but contribute to 
finely tune the duration and the effectiveness of the adaptive signals aimed at 
preserving cell survival as a first goal. If the intra- and extracellular conditions do not 
allow the completion of the survival programs, the attempts to balance adverse 
conditions result in a futile cycle and cells will eventually undergo cell death. 
 
2.3. GSK3 in intracellular redox regulation  
 
 One of the most remarkable properties of active GSK3 is to modulate the 
activity of the transcription factor Nrf2, a major regulator of redox 
homeostasis [61]. This property directly links the neuroprotective effects of 
GSK3 inhibition with the antioxidant defenses of the cells. A pool of nuclear 
Nrf2 is constitutively present in unstressed cells to maintain basal levels of 
transcription of antioxidant phase II genes regulated by the cis-acting element 
antioxidant response element (ARE). To maintain homeostasis, part of Nrf2 
is negatively regulated by Keap1 which promotes its ubiquitylation and 
degradation in the cytoplasm. In conditions of redox imbalance due to 
enhanced production of hydrogen peroxide and ROS, or decreased 
antioxidant defenses including GSH, cytoplasmic Nrf2 is stabilized and, 
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following translocation, contributes to the nuclear active pool. ARE 
activation by a transcriptional complex formed by Nrf2 and small Maf 
proteins induces the expression of antioxidant proteins including heme 
oxygenase (HO-1), NADPH:quinone oxidoreductase (NQO1), thioredoxin 
(Trx) and enzymes involved in GSH metabolism such as glutathione S-
transferase A1/A2 (GST A1/A2), glutathione peroxidase (GPx), γ-glutamyl 
cysteine ligase (γGCL). The induction of this last enzyme causes an adaptive 
elevation of intracellular GSH. Once normal levels of GSH are reached, a 
negative feed-back operated by GSH itself inhibits further GSH synthesis by 
γGCL. Active GSK3 has been reported to phosphorylate Nrf2 [62]. This post-
translational modification excludes Nrf2 from the nucleus, thus limiting the 
expression of Nrf2-dependent genes. Thus, upon GSK3 inhibition, Nrf2 can 
activate the transcription of ARE-regulated phase II antioxidant enzymes. As 
a consequence, GSK3 inhibition can enhance GSH utilization in cells with 
overall antioxidant effects. Importantly, persistent oxidative stress has been 
shown to inhibit cytoprotective Nrf2 activation by GSK3 in neuronal cells 
[63], confirming the neuroprotective effects of GSK3 inhibition. 
 Nrf2 plays a relevant role in tumorigenesis. Nrf2 promotes detoxification 
and cytoprotection against oxidative, electrophilic and xenobiotic stress and 
its activation has been implicated in prevention of tumor development and 
progression in numerous animal models. Nrf2 is apparently a major 
molecular target of cancer chemopreventive compounds, in particular of 
chemopreventive phytochemicals or their synthetic derivatives [64]. In 
established tumors, Nrf2 targeting by different anticancer agents induce 
caspase-dependent and independent cell death essentially by glutathione 
depletion and redox imbalance [65]. In some tumor cell types, Nrf2 
activation, as judged by induction of HO-1, occurs in cells undergoing cell 
death [66]. Therefore, while the cytoprotective and antioxidant response in 
normal or preneoplastic cells in the early phases of transformation elicits an 
antitumor effect by preserving cell survival and tissue integrity, the same 
response may apparently contribute to cell death in established tumor cells. 
 Several lines of evidence indicate that GSK3 itself is sensitive to redox 
regulation [62,63,67,68]. Of note, key molecular targets of survival pathways with 
proinflammatory and proangiogenic activity including the nuclear transcription 
factors NF-κB and HIF, AKT and mTOR are redox-sensitive molecules (Fig. 1).  
 Different redox-active pharmacological agents and intracellular 
conditions that perturb intracellular redox homeostasis modulate GSK3 
activity [67]. The modification of intracellular redox conditions toward a more 
oxidized state, as already discussed in the case of GSH metabolism regulated 
by Nrf2, can affect, in particular, GSK3 intracellular localization and activity. 
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The molecular events following GSK3 inhibition, including induction of phase 
II genes such as heme oxygenase, elevation of intracellular GSH and of 
enzymes related with GSH metabolism, indicate that GSK3 inhibition exerts a 
cytoprotective effect against oxidative stress (Fig.3). This cytoprotective 
response is apparently evoked by transient, acute stress in untransformed as 
well as in tumor cells. A different condition seems to be established in chronic 
degenerative disorders, where oxidative stress becomes a permanent condition 
that necessitates metabolic adaptations, and active GSK3 accumulates in 
neuronal cells with detrimental effects on cell survival. Time-dependent effects  
 
 
 
Figure 3. The expression of antioxidant enzymes such as heme oxygenase-1 (HO-1) 
and a set of stress-inducible Nrf2-regulated genes stimulated by GSK3 inhibition 
requires the coordinated activation of ancillary pathways providing energy substrates 
and cofactors necessary to guarantee the proper functioning of the antioxidant 
machinery. The expression of antioxidant enzymes requires transient up-regulation of 
G6PD providing reducing equivalents in the form of NADPH, concomitantly with 
enhanced glucose uptake. The attempt to mount an antioxidant adaptive response 
against oxidative stress can be elicited in normal and stressed untransformed cells, as 
well as in cells under selective pressure imposed by tumorigenic conditions such as 
chronic inflammation, and in frank tumor cells. The final outcome changes depending 
on the intracellular bioenergetic state and microenvironmental conditions that must be 
permissive to effectively obtain cell repair and survival. 
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have been described for ERK1/2. Transient ERK activation can induce an 
adaptive elevation of intracellular GSH [69]. However, sustained ERK 
activation can both lead to oncogenic adaptations or to cell death [70]. Several 
lines of evidence suggest that the consequences of transient versus sustained 
GSK3 inhibition can have similar effects in some cellular contexts.  
 
2.4. GSK3 as a molecular target of redox-active phytochemicals 
 
 Emerging evidence indicates that natural or synthetic derivatives of 
phytochemicals interfere with key redox-regulated events in tumorigenesis 
and tumor-predisposing conditions such as metabolic disorders including 
hyperinsulinemia, obesity and diabetes, and in aging [71]. Remarkably, 
several redox-active dietary phytochemicals have shown neuroprotective [72] 
and cardioprotective effects [73] in preclinical studies. It is now established 
that metabolic disorders, besides defining risk factors for cardiovascular 
diseases and diabetes, also increase the risk for cancer. Starting from the 
natural compounds, novel synthetic derivatives are under development for the 
production of more effective drugs with increased therapeutic efficacy. This 
class of compounds are presently under intense pre-clinical and clinical 
scrutiny for potential use in diabetes, neurodegenerative and cardiovascular 
disorders and in cancer treatment [74]. Nrf2 is a major target of cancer 
chemopreventive and cytoprotective phytochemicals and their synthetic 
derivatives [64]. Few data are presently available on the involvement of 
GSK3-mediated Nrf2 activation in the mechanism of action of these 
compounds. However, owing to the fact that Nrf2 regulation by GSK3 could 
explain several of the cytoprotective effects of GSK3 inhibition in different 
pathophysiological contexts, here we will briefly mention recent reports on 
the involvement of Nrf2 in the activity of model phytochemicals which 
appear promising therapeutic agents: resveratrol, sulforaphane and curcumin.  
Resveratrol, a polyphenol found in red grapes, has shown a range of 
remarkable biological properties in preclinical models of aging that resemble 
the beneficial metabolic effects of dietary restriction [75]. Similarly to other 
phytochemicals with potential application in long-term cancer chemoprevention, 
resveratrol shows both cytoprotective and anticancer properties. GSK3 
inhibitory phosphorylation induced by resveratrol has been shown to protect 
against mitochondrial damage induced by arachidonic acid [76], and to be 
implicated in cardioprotection [77]. Induction of Nrf2-regulated antioxidant 
genes depending on GSK3 inhibition induced by sulforaphane has been 
shown to protect hyppocampal neurons against lethal kainate-induced 
oxidative stress [78]. Curcumin and sulforaphane activate an antioxidant 
defensive response mediated by Nrf2-induced GPx expression [79]. 
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3. Effects of GSK3 on stem cells 
 
 An unexpected function of GSK3 recently discovered is to regulate 
embryonic stem cell (ESC) pluripotency and self-renewal. GSK3 inhibition 
has been shown to sustain the expression of three molecular targets involved 
in stem cell repopulation: the pluripotent state-specific transcription factors 
Oct-3/4, Rex-1 and Nanog [80]. GSK3 regulates different signaling pathways 
implicated in HSC function, including Wnt, Hedgehog and Notch pathways. 
Interestingly, GSK3 inhibitors were found to modulate genes regulated by 
Wnt, Hedgehog and Notch pathways selectively in hematopoietic stem cells 
(HSC) of the primitive hematopoietic compartment, while mature cells were 
unaffected [81]; most importantly, GSK inhibitors were toxic to MLL leukemia 
cells [82]. Again, GSK3 can act in opposite ways in cells of the same origin 
depending on transformation. Similarly to the role of GSK3 in different 
intracellular compartments and molecular complexes, the partition of GSK3 in 
subcellular pools appears a regulatory mechanism per se in stem cell renewal 
[83]. The PI3K/AKT pathway and c-myc sustain ESC self-renewal. GSK3 
phopshorylates and induce degradation of c-myc, thus antagonizing ESC self-
renewal. The mechanism operating in mouse ESC depends on GSK3 
phosphorylation by AKT that excludes shuttling of GSK3 into the nucleus and 
causes phospho-GSK3 accumulation in the cytoplasm. In this way AKT 
neutralizes the antagonizing effect of GSK3 on ESC self-renewal. 
 
Summary 
 
 The regulation of cell survival occurs through the activity of interrelated 
sensing systems that monitor, among others, nutrient and glucose availability, 
the level of tissue oxygenation and redox homeostasis. NF-κB, HIF, FOXO, 
Sirt1, PI3K/AKT/mTOR/ GSK3 and the MAP kinases ERK1/2, JNK and p38 
belong to a signaling network deciphering the overall metabolic state of the 
cell. The cross-talk between the different branches of the network results in 
the activation of effector mechanisms that engage both pro-survival and pro-
death pathways in adverse environmental conditions. The modulation of 
these pathways propagates information to effector systems involved in 
glucose metabolism, energy expenditure and redox homeostasis that allow 
cells to adapt to transient environmental changes, with an overall positive 
effect on cell survival. Under conditions of chronic stress, however, the 
persistent activation of these salvage pathways to which GSK3 belongs can 
contribute to the transcriptional reprogramming involved in tumor 
insurgence, stabilization and progression. Active GSK3 phosphorylates and 
promotes the degradation of substrates involved in molecular pathways 
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including Wnt/βcatenin and Hedgehog/MYCN in normal cells, thus blunting 
important oncogenic signaling. However, GSK3 overactivation has 
apparently detrimental effects on cell survival. Under physiological 
conditions, GSK3 is kept under negative control by cell survival signaling 
triggered by trophic factors and supported by adequate energy availability. In 
different pathological conditions, such as neurodegenerative and 
cardiovascular disorders, GSK3 shows excessive accumulation and over-
activation, thus its inhibition exerts cytoprotective effects. In cancer, GSK3 
probably plays a different role during the early phases of tumorigenesis and 
in established tumor cells. Several lines of evidence indicate that 
dysregulated GSK3 inhibition, depending on constitutive activation of AKT 
and other oncogenes, can support tumor-associated metabolic adaptations 
such as the glycolytic switch and can play an antiapoptotic role by preserving 
mitochondrial integrity in stressful conditions. On the other hand, Nrf2, 
which can be activated upon GSK3 inhibition, has been identified as a major 
target of several cancer chemopreventive drugs, providing a cellular defense 
against tumorigenic oxidative damage. The up-regulation of Nrf2-regulated 
antioxidant enzymes following GSK3 inhibition, while accounting for the 
cytoprotective effects against cell death in brain cells, can confer resistance to 
anticancer cytotoxic agents. Paradoxically, different drugs inducing GSK3 
inhibition, including several phytochemicals or their synthetic derivatives, 
specific pharmacologic inhibitors and HDAC inhibitors, have shown 
promising anticancer effects in preclinical models. One hypothesis to explain 
the opposing roles of GSK3 inhibition is that different effects depend on the 
bioenergetic requirements of the cells. In cells that rely on oxidative 
phosphorylation for energy production and in cells that can tolerate the use of 
glycolysis as an alternate source of ATP, such as neuronal cells, GSK3 
inhibition exerts cytoprotective effects. GSK3-mediated cytoprotection can thus 
be beneficial in cells that are not subjected to oncogenic stimulation, while can 
promote cell survival in tumorigenic cells. Once the metabolic reprogramming 
that leads to stabilization of tumor cells, first of all the glycolytic switch, is 
fully realized, GSK3 inhibition in sensitive cells might perturb a precarious 
equilibrium characterized by a high metabolic rate fueled by enhanced glucose 
metabolism and adaptive adjustments of redox balance to tolerate increased 
ROS production. An emerging therapeutic approach highlights the possibility 
to exploit specific metabolic adaptations such as enhanced glucose usage, 
elevated production of reactive oxygen species and antioxidant enzymes to 
selectively target tumor cells [84]. GSK3 pharmacologic targeting could offer 
the opportunity to investigate the application in oncology of drugs already in 
use for the treatment of neurological disorders, which have been proved to be 
safe upon long-term administration.  
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Abstract. Plk3 is a member of the Polo-like kinase family. It has 
multiple biological functions including the regulation of cell cycle 
progression, cell cycle checkpoint control, cellular response to 
hypoxia, and apoptosis. Deregulated Plk3 is also strongly 
implicated in tumorigenesis. Aberrant expression of Plk3 is 
detected in tumors of various origins. Plk3 knockout mice develop 
tumors in multiple organs at an advanced age. In the past, much of 
the attention regarding the role of Plks in tumor biology has been 
primarily directed toward Plk1. The importance of Plk3 in tumor 
biology and its value as a target for therapeutic intervention has not 
yet been fully appreciated. Recent progress on Plk3 research has 
revealed new roles that may lead to better understanding of this 
elusive protein kinase in regulating stress responses and 
suppressing tumorigenesis.  
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Introduction 
 
      Serine/threonine (Ser/Thr) protein kinases play a central role in tumor 
biology. Deregulated kinase activities and/or their expression frequently lead 
to perturbation in cell growth control and differentiation, resulting in tumor 
formation. A prominent example is B-Raf kinase, whose oncogenic mutations 
contribute to the development of numerous human malignancies [1]. As 
deregulated kinase activities are often the main reason for their oncogenicity,  
small chemical compounds have been developed as potential anticancer drugs 
that target the kinase activities of various Ser/Thr protein kinases [2]. On the 
other hand, regulatory domains of protein kinases have also been explored as 
anti-proliferative or anticancer drugs [2]. Given the sheer number of genes 
encoding unique Ser/Thr protein kinases in the mammalian genome and the 
necessity of developing target-specific chemical compounds for cancer 
therapies, it is imperative for us to understand the biochemical and biological 
properties of various protein kinases in growth control and their deregulation 
in tumorigenesis.  
 Polo-like kinases (Plks) are a family of Ser/Thr protein kinases that, among 
other functions, regulate cell cycle progression, apoptosis, and stress responses 
[3-6]. These kinases, when deregulated, have been strongly implicated in tumor 
initiation and development [7, 8]. Therefore there is considerable interest in 
exploring these kinases as targets for cancer drug development [9] although the 
major efforts have been devoted primary to Plk1 [10, 11]. Compared with that 
of Plk1, the biological role of Plk3 is much less clear. In this chapter, we 
attempt to summarize the work on characterization of Plk3 and discuss its 
significance in suppressing genomic instability and tumor angiogenesis.  
 
Polo-like kinases 
 
 Polo-like kinases were named after Polo, a fruit fly (Drosophila 
melanogaster) Ser/Thr protein kinase that is involved in mitosis and meiosis 
[12]. Polo was originally discovered from a polo mutation that is associated 
with mitotic and meiosis defects in fruit fly [13]. It was subsequently found 
to be a highly conserved kinase [14]. Polo thus serves as the founding 
member of a family of evolutionarily conserved Ser/Thr protein kinases. Polo 
is an essential component of the cell cycle machinery and its kinase activity 
and expression level are tightly regulated during the cell cycle [3, 15]. 
Mutations of the polo gene lead to abnormal mitosis and meiosis [3].  
 The counterparts of Polo kinase in the budding yeast and the fission yeast 
are CDC5 and Plo1, respectively [16]. As with the fruit fly, these proteins 
have a pivotal role in the mitotic stage of the cell cycle [16]. In mammals, the 
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Plk kinase family consists of four members including Plk1, Plk2, Plk3, and 
Plk4. These proteins all share significant sequence homology to Polo [17]. 
Structurally, all Plks are comprised of a highly conserved kinase domain at the 
amino–terminus and a Polo box domain (PBD) at the carboxyl-terminus [5, 17] 
(Fig. 1). PBD is critical for the kinase subcellualr localization as well as the 
substrate recognition by Plks [5]. The biological functions of mammalian Plks, 
however, are more diverse than that of their counterparts in lower eukaryotes. 
Plk1 is the most studied and its functions are more in line with those of Polo in 
the regulation of mitosis [6]. Plk1 expression peaks at G2/M phases, consistent 
with its role in mitosis [18]. The functions of Plk2, Plk3, and Plk4, however, 
are much less understood. Available evidence indicates that these proteins may 
have more diverse functions than that of Plk1 [6]. This notion is reinforced by 
findings revealing that these proteins have expression patterns quite different 
from those of Plk1 during the cell cycle [18]. In addition to the potential 
role in mitosis, Plk2, Plk3, and Plk4 appear to have functions in regulating the 
G1/S transition, S phase progression [19, 20], centrosome dynamics, stress 
responses [20-24], and/or synaptic activities [25]. Plks, or their deregulated 
activities, have also been strongly implicated in tumor development, 
especially Plk1, Plk3 and Plk4 [7, 8, 26, 27]. 
 
 
 
Figure 1. Basic Structures of Plk Family Members. 
 
Polo-like kinase 3 (Plk3) 
 
 Mouse Plk3 was initially identified as a fibroblast growth factor-
inducible kinase (Fnk) from NIH 3T3 cells in a differential display analysis 
[28]. The human counterpart was independently isolated and named Prk as a 
proliferation related kinase [29]. The amino acid sequence of human Plk3 
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shares 36% and 33% overall identity to Plk1 and Polo, respectively [29]. Plk3 
has the structure of a typical Plk family member, with an N-terminal kinase 
domain and a C-terminal PBD with two Polo boxes [17] (Figure 1).  
 Plk3 is considered an immediate early response gene, whose expression 
does not depend on de novo protein synthesis [18, 28, 29]. Its mRNA 
expression level reaches the maximal level one hour after stimulation with 
fibroblast growth factor or serum addition to the serum-starved NIH 3T3 cells 
and returns to the basal level 8 hours post-stimulation [18, 28, 30]. Plk3 
protein level is fairly constant in mitogen-stimulated cells throughout the cell 
cycle [18, 21, 30]. A recent report, however, showing that Plk3 protein level is 
also cell cycle-regulated with a pattern similar to that of its mRNA, peaking at 
the G1 phase [19]. The kinase activity of Plk3 also oscillates during the cell 
cycle [31]. Immunocomplex kinase assays show that whereas the Plk3 kinase 
activity is low in G1 and G1/S phases, it dramatically increases during late S/G2 
and remains at a moderate level at M phase [31]. Plk3 activity is also subjected 
to regulation by a variety of stress conditions [21, 23, 24, 32, 33].   
 
Plk3 and tumorigenesis 
 
 Tumorigenesis is a cellular transformation process that causes 
uncontrolled cell division and proliferation, resulting in a disease phenotype 
in multi-cellular organisms. Perturbations of many biological processes that 
control cell proliferation, apoptosis, stress responses, and angiogenesis have 
the potential to trigger malignant transformation [34].  
 The association of Plk3 with tumor development was first revealed when 
the human Plk3 (Prk) was examined in human primary tumor samples [29]. 
In contrast to Plk1, whose activity and expression are generally positively 
correlated with tumor formation, Plk3 activity or expression is often 
negatively correlated with tumor development. Thus, Plk3 is commonly 
regarded as a tumor suppressor [7, 8]. This notion has been confirmed by a 
mouse genetic study [22]. Compared with wild-type littermates, Plk3 null 
mice are prone to the development of malignancies in several organs [22].  
 Through analysis of more than a dozen of lung cancer patient samples, 
Plk3 mRNA was found to be significantly downregulated in a majority of 
lung carcinoma samples [29]. This abnormal mRNA expression appears to be 
a result of reduced PLK3 mRNA transcription [29], suggesting that reduced 
Plk3 expression may be associated with tumor development. This notion is 
supported by the observation that although three polymorphisms were 
identified from 40 lung tumor cell lines, no missense or nonsense mutations 
were found in Plk3 [35]. Thus, mutations of Plk3 coding sequences appear to 
be rare in lung cancer. 
Polo-like kinase 3 in normal and tumor biology    121 
 Reduced expression of PLK3 also occurs in human head and neck cancer 
[36]. In a survey of primary head and neck squamous-cell carcinomas 
(HNSCC) from 35 patients, 26 samples have reduced PLK3 mRNA levels 
compared with corresponding normal tissues. Two samples have an 
undetectable level of PLK3 expression [36]. This connection of PLK3 
expression with head and neck cancer is reinforced by the finding that the 
PLK3 gene is located at chromosome 8p21 where high frequency of loss of 
heterozygosity happens in many human cancers [36-38]. 
 Plk3 is also implicated in the development of colon cancer [39]. 
Expression of PLK3 mRNA is significantly lower in rat colon tumors that 
have been induced by azoxymethane than it is in the corresponding normal 
tissues [39]. Moreover, PLK3 mRNA levels in rat colon tumors appear to be 
influenced by diet since tumors isolated from rats fed high fat diet 
supplemented with fish oil exhibit less reduction in PLK3 expression than 
those isolated from rats fed the same diet supplemented with corn oil [39].  
 A positive correlation between Plk3 expression/activity and cancer 
formation has also been reported. An immunohistochemical study shows that 
Plk3 is expressed at a moderately high level in cystadenomas [40]. More than 
5% of ovarian carcinomas are Plk3-positive whereas Plk3 expression was 
low in normal ovarian surface epithelium and borderline tumors [40]. In 
addition, LFM-A13, an inhibitor of Plks with a significant inhibitory activity 
toward Plk3, is able to delay progression of MMTV/neu transgenic mouse 
model of HER2 positive breast cancer [41].  
 
Plk3 and cell cycle progression 
 
Plk3 in regulating G2/M phases 
 
 Plk3 is involved in regulating multiple phases of the cell cycle. In most 
cells, Plk3 is predominantly located around the nuclear membrane in 
interphase of the cell cycle [42]. It concentrates at the centrosomes in a 
microtubule-dependent manner [42]. During mitosis, Plk3 is closely 
associated with spindle poles and mitotic spindles [42]. A significant amount 
of Plk3 can also be found in midbody in telophase [42]. Plk3 overexpression 
induces rapid cell cycle arrest at the M phase followed by apoptosis, likely as 
a result deregulation of microtubule dynamics and centrosomal function [42]. 
The subcellular localization of Plk3 to the centrosomes, spindle poles and the 
midbody is driven by the PBD domain of the kinase [43]. Both Polo boxes of 
Plk3 are required for its localization [43]. Interestingly, overexpression of the 
PBD domain alone can cause significant cell cycle arrest and abnormal 
cytokinesis [43]. This is consistent with another report that overexpression of 
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Plk3 inhibits cell proliferation and colony formation as a result of incomplete 
cytokinesis [44].  
 The functional conservation of Plk3 is clearly illustrated by two lines of 
evidence.  Human PLK3 transcripts greatly enhance progesterone-induced 
meiotic maturation of Xenopus oocytes, whereas the corresponding antisense 
PLK3 transcripts inhibit the maturation process [31]. In S. cerevisiae, ectopic 
expression of human Plk3 was able to rescue the temperature-sensitive 
phenotype of a CDC5 (the yeast Plk homolog) deficient strain of the budding 
yeast [31]. These studies thus strongly suggest that Plk3 may also regulate the 
onset and/or progression of mitosis and meiosis. 
 Plk3 phosphorylates and regulates the subcellular localization of Cdc25C 
phosphatase [45, 46], a key regulator of the G2/M transition by 
dephosphorylating inhibitory phosphorylation sites of CDK1 thereby activating 
the master regulator of mitosis [47]. Plk3 directly interacts with Cdc25C and 
phosphorylates it in vitro at Ser216 [45], a residue critical for binding to 
scaffold protein 14-3-3 when phosphorylated [48, 49]. Binding of Cdc25C to 
14-3-3 sequestrates Cdc25C to the cytosol, thereby effectively inhibiting its 
function in the nuclei [50]. Plk3 is also found to phosphorylate Ser191 and 
Ser198 of the Cdc25C [46]. Similar to Ser216, phosphorylation of these two 
residues also promotes accumulation of Cdc25C in the nuclei [46]. Thus, 
serine to alanine mutation of Ser191 prevents the nuclear accumulation [46]. 
Consistent with this observation, ectopically expressed Plk3 promotes the 
accumulation of Cdc25C protein in the nuclei whereas Plk3 knockdown with 
RNA interference inhibits its nuclear accumulation [46]. Together, these 
findings indicate that Plk3 is an important regulator of the cell cycle at the 
G2/M transition.  
 
Plk3 in regulating G1/S phases 
 
 Plk3 also mediates the G1/S transition and is required for the S phase 
entry [19, 51]. Plk3 protein levels are regulated during the cell cycle that 
peak at the G1 phase [19, 51], consistent with the expression pattern of Plk3 
mRNA [18, 28, 30]. Knockdown of Plk3 by transfecting siRNA prevents 
cells from entering the S phase of the cell cycle [19]. Mechanistically, Plk3 
appears to be required for cyclin E expression since Plk3 depletion 
significantly reduces cyclin E levels [19]. Regulation of cyclin E by Plk3 
appears to be mediated through a posttranscriptional mechanism [19]. It has 
been proposed that Plk3 may regulate cyclin E levels by modulating the 
activity of phosphatase Cdc25A [19], which is a potential target of Plk3 
[52]. Cdc25A is known to regulate the activity of the cyclin E/Cdk2 
complex [53, 54]. 
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 Plk3 also phosphorylates proteins that are important for regulating DNA 
replication [20, 55]. Plk3 but not Plk1 can phosphorylate topoisomerase IIα at 
Thr1342 [55]. Topoisomerase IIα has an essential role in DNA 
replication/transcription, cell cycle regulation, cell proliferation, and cancer 
development [56]. Although the functional significance of Thr1342 
phosphorylation remains poorly understood, this finding may reveal a potential 
new mechanism by which cell proliferation and tumor formation is differentially 
regulated by Plk3 and Plk1 [55]. Moreover, Plk3 interacts with and 
phosphorylates p125, the major subunit of DNA polymerase δ (Pol δ), and the 
phosphorylation occurs on Ser60 [20]. The significance of the physical 
interaction and phosphorylation of Pol δ by Plk3 remains to be elucidated. It 
is speculated that the phosphorylation may regulate the subcellular localization of 
Pol δ because the region of p125 contains a nuclear localization signal. 
  
Plk3 in Golgi fragmentation 
 
 Fragmentation of the Golgi apparatus in mammalian cells is an essential 
step in mitosis entry. It is a process in which Golgi stacks are reversibly 
disassembled into small vesicles and tubules during mitosis to ensure correct 
partitioning of the Golgi content between daughter cells [57]. Several lines of 
evidence show that Plk3 is involved in the Golgi fragmentation process [58-
60]. Plk3 is found to localize at the Golgi apparatus in interphase of the cell 
cycle; it disintegrates and redistributes in a manner similar to that of Golgi 
stacks [59]. Nocodazole, a drug that disrupts microtubules and induces 
mitotic arrest and Golgi fragmentation, activates Plk3 [59, 60]. Plk3 interacts 
with Golgi-specific protein giantin; a Golgi-specific poison brefeldin A 
disperses Plk3 signals in a manner similar to that of the Golgi apparatus [59]. 
Ectopic expression of wild-type but not the kinase-defective mutant of Plk3 
leads to marked Golgi breakdown [59, 60]. Subsequent studies show that 
MEK1, a MAP kinase kinase known to mediate Golgi fragmentation, 
interacts and activates Plk3 [60].  Plk3 also colocalizes with phosphorylated 
MEK1 at the spindle poles [60]. Activation of Plk3 by nocodazole and Golgi 
fragmentation induced by Plk3 can be blocked by specific MEK1 inhibitors 
[60]. These results indicate that Plk3 is an essential regulator of Golgi 
fragmentation during mitosis and that MEK1 is an upstream activator of Plk3 
in mediating this process.  
 A recent study identifies vaccinia-related kinase1 (VRK1) to be the direct 
downstream target of Plk3 in regulating Golgi fragmentation [58]. VRK1 
interacts and colocalizes with the Golgi complex and Plk3 throughout mitosis 
[58]. Plk3 phosphorylates VRK1 at Ser342 of the C-terminal region and this 
phosphorylation is necessary for VRK1 to mediate Golgi fragmentation. 
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Thus, a serine-to-alanine point mutation abolishes the capability of VRK1 to 
promote Golgi fragmentation induced by Plk3 or MEK1 [58]. Furthermore, 
both VRK1 kinase activity and phosphorylation by Plk3 at Ser342 are 
necessary for its function in Golgi fragmentation. Moreover, knockdown of 
VRK1 by siRNA or overexpression of kinase-dead VRK1 also inhibits Plk3 
or MEK1-induced Golgi fragmentation [58]. Combined, available evidence 
has revealed the MEK1→Plk3→VRK1 signaling axis in the regulation of 
Golgi fragmentation in mitosis.  
    
Plk3 in regulating apoptosis 
 
 Apoptosis or programmed cell death is a controlled suicidal process that 
is vitally important in maintaining homeostasis of tissues in multicellular 
organisms [61]. Apoptosis serves as a tumor suppressing mechanism by 
which old, abnormal, and/or excessive cells in tissues are removed [34, 62, 
63]. Dysregulated apoptosis often contributes to tumor development [34, 63].  
 The role of Plk3 in apoptosis was initially revealed in the study of 
ectopically expressed Plk3 [32, 44]. Ectopic expression of Plk3 causes cell 
cycle arrest followed by chromatin condensation and apoptosis of cultured 
cells [32, 42, 44]. Plk3 appears to mediate apoptosis through a kinase-
dependent and a kinase-independent mechanism [42, 64]. It is also shown to 
induce apoptosis in a biphasic manner: a rapid apoptosis that requires Plk3 
kinase activity and p53, and a delayed onset apoptosis that is independent of 
Plk3 kinase activity and p53 [64]. Consistently, kinase defective Plk3 is less 
capable of inducing apoptosis compared to wild type Plk3 [42, 64].  
 Plk3 promotes the kinase-independent apoptotic function mainly through 
its C-terminal Polo box domains because ectopic expression of the Polo box 
domains alone is sufficient to induce apoptosis [32, 43, 44]. However, 
another study has identified the first 26 amino acids at the N-terminus of Plk3 
to be essential for induction of apoptosis when it is overexpressed [64]. DNA 
damage- or superoxide-induced apoptosis requires the kinase activity of Plk3 
[32, 64]. Plk3 phosphorylates tumor suppressor protein p53 at Ser20 in 
response to these stimuli and induces apoptosis through the p53-mediated 
proapoptotic pathway [32, 64]. Moreover, Plk3 can induce apoptosis through 
disrupting microtubule integrity [42].  
 Plk3 has been identified as a key component in NF-κB-dependent 
apoptosis [64]. A κB enhancer element is identified at the promoter region of 
PLK3 gene [64]. This element is responsible for NF-κB mediated Plk3 
expression in response to a panel of known NF-κB activators, including 
chemotherapeutic drug Doxycycline [64]. Plk3 appears to play an essential 
role in Doxycycline-induced apoptosis, since knockdown of Plk3 expression 
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with siRNA dramatically inhibits Doxycycline-induced apoptosis [64]. 
Increase of Plk3 levels alone does not seem sufficient for apoptosis because 
TNF-α strongly activates Plk3 expression but fails to induce apoptosis [64]. 
Thus, Plk3 is necessary but not sufficient for NF-κB-mediated apoptosis.  
 
Plk3 in stress responses 
 
Plk3 in DNA damage response 
 
 Genotoxic stresses such as ultraviolet light and ionizing radiation 
generate reactive oxygen species (ROS). ROS induces DNA damages and 
mutations that lead to genomic instability, thereby promoting tumor 
formation and progression [65, 66].  ROS are known to regulate DNA 
damage responses through the activation of p53, which leads to cell cycle 
arrest, apoptosis or replicative senescence [67]. ATM (mutated in ataxia 
telangiectasia) functions as an upstream regulator of p53 that is activated by 
oxidative stresses [68]. ATM regulates phosphorylation of p53 directly or 
indirectly and is thought to be a sensor for oxidative stresses [68].  
 Plk3 is activated by and mediates cellular responses to DNA damage that 
produces ROS [21, 23, 32, 69, 70]. Genotoxic agents such as hydrogen 
peroxide (H2O2), ionizing radiation, methylmethane sulfonate, ultraviolet 
light, and adriamycin strongly activate Plk3 [21, 32, 69, 70]. This is different 
from Plk1 whose activity is inhibited by these agents [32]. Plk3 mRNA is 
also inducible by ionizing radiation [33]. Plk3 activation induced by 
genotoxic agents is ATM-dependent [21, 32, 69], Thus, H2O2 and ionizing 
radiation mimetics are unable to activate Plk3 in ATM-deficient cells [21, 
69]. Furthermore, inhibition of ATM using caffeine blocks adriamycin- or 
ionizing radiation-induced Plk3 activation [21, 32]. Plk3 is phosphorylated 
when treated with ionizing radiation and this phosphorylation is also ATM-
dependent [21]. Further experimentation, however, fails to detect direct 
phosphorylation of Plk3 by ATM, indicating that ATM may promote Plk3 
phosphorylation and activation through another kinase(s) [21]. One of the 
candidate kinases that phosphorylates Plk3 appears to be Chk 2, which is 
known be activated by ATM in response to genotoxic stresses [21]. 
 The downstream effecter of Plk3 in mediating DNA damage responses is 
p53 [21, 32, 69]. Plk3 is able to phosphorylate p53 in response to DNA 
damage [21, 32, 69]. Activation of Plk3 by H2O2 is accompanied by 
phosphorylation of p53 at Ser9, Ser15, and Ser20 residues [69]. 
Phosphorylation of p53 at these residues in response to H2O2 correlates with 
its transcriptional activity since the level of p21, whose expression is 
positively regulated by p53, is also elevated [69]. Further analysis reveals that 
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phosphorylation of Ser20, but not other residues, after H2O2 treatment is 
dependent on Plk3 [69]. Furthermore, H2O2 fails to induce Ser20 
phosphorylation of p53 in a Plk3-deficient cell line; the kinase-defective Plk3 
suppresses H2O2 –induced Ser20 phosphorylation [69]. Phosphorylation of 
Ser20 of p53 is confirmed in an in vitro assay using recombinant Plk3 and 
p53 proteins [32]. Ser20 of p53 is also a target of protein kinases Chk1 and 
Chk2 that are downstream components of ATM and are essential for DNA 
damage checkpoint control [71, 72]. Plk3 is thus proposed to work in parallel 
with Chk1 and Chk2 to reinforce DNA damage checkpoint responses or to 
preferentially mediate certain types of DNA damage insults [32]. Plk3 is also 
found to directly regulate Chk2 and vise versa [21, 70]. Chk2 interacts 
directly with and activates Plk3 both in vitro and in vivo; this interaction is 
enhanced after DNA damage [70].  Intriguingly, Plk3 also phosphorylates 
Chk2 and contributes to its full activation [21]. Collectively, these results 
underscore the dynamic role of Plk3 in the DNA damage checkpoint control. 
 
Plk3 in hypoxic stress responses  
 
 Tumor progression and metastasis require blood supply to provide 
oxygen and nutrients to the newly formed tumor masses.  The formation of 
new blood vesicles or angiogenesis is therefore essential for tumor growth 
[73, 74].  Cellular responses to hypoxia play an important role in tumor 
growth since hypoxia triggers tumor angiogenesis [75]. Hypoxia-inducible 
factors (HIFs) are the key sensors and regulators of hypoxic responses, 
which, upon induction by hypoxia, promote expression of multiple genes 
essential for mediating angiogenesis. Among the HIF-activated gene products 
are: fibroblast growth factor (FGF), vascular endothelial growth factor 
(VEGF), and glucose transporters [75].     
 Plk3 can be activated by hypoxia [24]. Hypoxia-activated Plk3 increases 
the activity of AP-1 transcription factors and promotes apoptosis [24]. A 
recent study has demosntrated that Plk3 is involved in controlling HIF-1α 
levels in response to hypoxic conditions [22]. Specifically, compared with 
wild-type mouse embryonic fibroblasts (MEFs), PLK3 null MEFs exhibit a 
hyper-sensitive response to the treatment with hypoxia or with nickel ions 
and contain an elevated level of HIF-1α but not of HIF-1β [22]. Consistently, 
expression of VEGF-A is also higher in PLK3-/- MEFs than that in wild type 
MEFs [22]. More importantly, PLK3 null mice display an increased tumor 
incidence; tumors developed in these mice display an increased vasculature 
[22].  Transfection analyses also confirm the role of Plk3 in regulating the 
stability of HIF-1α [22]. Ectopically expressed Plk3 is able to suppress the 
expression and nuclear accumulation of HIF-1α in HeLa cells [22]. The 
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inhibition of HIF-1α nuclear translocation appears to be dependent on its 
kinase activity since overexpression of Plk3 kinase domain alone is sufficient 
to suppress HIF-1α accumulation in the nucleus under hypoxic conditions 
[22].  
 The exact mechanism by which Plk3 regulates HIF-1α levels and its 
activities remains to be elucidated. HIF-1α is a very labile protein that is 
rapidly degraded under normoxia via the proteosome [76]. After 
hydroxylation, which is an O2-sensitive process, hydroxylated HIF-1α is 
recognized by von Hippel-Lindau factor (VHL, a ubiquitin  E3 ligase) for 
polyubiquitination and subsequent proteasomal degradation [77]. HIF-1α 
degradation can also be positively controlled by direct phosphorylation. 
GSK3β phosphorylates HIF-1α in the oxygen-dependent degradation domain, 
resulting in its destabilization via a VHL-independent but proreasome-
dependent process [78]. Given that HIF-1α is super-induced by hypoxia or 
hypoxic mimetics in PLK3 null MEFs [22], it is tempting to speculate that 
Plk3 may regulate HIF-1α protein stability via a phosphorylation-dependent 
process as well. 
 
 
 
Figure 2. Plk3 Regulatory Network. 
 
Conclusion remarks 
 
 The relationship between Plk3 and normal or abnormal cell proliferation 
has been established since its initial identification. To date, interest in the role 
of Plk3 in tumor biology has lagged behind that of Plk1, a structurally close, 
and perhaps functionally-related component. Earlier work has focused 
primarily on the role of Plk3 in cell cycle regulation. Recent studies suggest 
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that Plk3 may have broader functions. The potential role of Plk3 in mediating 
hypoxic responses is particularly interesting since it can lead to the discovery 
of a new player important to the regulation of tumor angiogenesis. Despite 
extensive research efforts in the past decade, Plk3 remains largely an elusive 
protein kinase in terms of its physiological substrates and biological 
functions. Much needs to be done in order to obtain a clear picture on Plk3’s 
roles in normal biology, as well as to explore it as a potential anti-tumor 
target. Summarized in Figure 2 is the current knowledge about molecular 
interactions between Plk3 and cellular gene products in the regulation of 
normal and abnormal biological processes.  
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Abstract. VRK (vaccinia-related kinase) is a group of three 
proteins in the human kinome. These proteins, mainly VRK1 and 
VRK2, have been studied in the context of their substrates and 
interacting proteins in order to identify and characterize their 
signaling pathway, as well as their effect on other signaling 
pathways. VRK1 is mostly a nuclear kinase that specifically 
phosphorylates p53, c-Jun, ATF2, CREB, BAF and histone H3. 
VRK1 is an early response gene and is implicated in regulation of 
cell cycle progression. VRK1 is activated in response to DNA 
damage phosphorylating p53, which is stabilized and activated; this 
active p53 induces a downregulatory mechanism of VRK1 that 
permits the reversal of p53 induced effects. The activity of nuclear 
VRK1 is regulated by its interaction with the Ran small GTPase. 
Also, VRK1 is a downstream component of the signaling pathway 
of MEK-Plk3 that induces Golgi fragmentation in mitosis.  VRK2  
 
 
Correspondence/Reprint request: Dr. P.A. Lazo, IBMCC-Centro de Investigación del Cáncer, CSIC-
Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain  
E-mail: plazozbi@usal.es; 
Marta Sanz-García  et al. 136
has two isoforms; VRK2A is cytosolic and bound to endoplasmic reticulum and 
mitochondrial membranes. VRK2B is a shorter isoform free in cytosol and nucleus. 
VRK2A affects cellular signaling by interaction with scaffold proteins, as JIP1. The 
JIP1-VRK2A signalosome blocks the incorporation of JNK, preventing its activation, 
and thus reducing the stress response to inflammatory cytokines as interleukin-1β and 
to hypoxia. 
 
1. The vaccinia-related kinase (VRK) family 
 
 The completion of the human genome project has led to the identification 
of 518 proteins that constitute the human kinome [1]. Approximately half of 
them are not well characterized regarding the signaling pathways in which 
they are integrated, and their biological functions. But in most likelihood they 
can probably account for the specificity and regulation of many biological 
functions.  VRK (vaccinia-related kinases) were classified as a new group of 
Ser-Thr kinases in the human kinome [1], and originally were identified as 
two human EST, VRK1 and VRK2, which have homology to catalytic region 
of the B1R kinase of vaccinia virus [2] that is expressed early in viral 
infection since it is required for viral DNA replication [3-5]. The VRK gene 
family appeared late in evolution. In lower eukaryotes, D. melanogaster 
(NHK-1) and C. elegans (Vrk1), there is only one member, and no ortholog 
has been identified in unicellular eukaryotes, like yeasts S. cerevisiae or S. pombe. 
In mammals there are three members, two of which (VRK1 and VRK2) are 
catalytically active [6-8], and a third one, VRK3, is not active and might 
function as a scaffold protein [9]. The VRK catalytic domain is distantly 
related to the casein kinase group, forming an early divergent branch in the 
human kinome [1], but the conservation of the kinase domain is weak and has 
substitutions in several key residues in this domain [10]. These proteins 
maintain the structure of the kinase domain, but the rest of the protein is very 
divergent among them, suggesting that the CK1-like catalytic domain 
recombined early in evolution with other proteins to form a divergent protein 
family with new regulatory properties, affecting interactions, regulation, and 
subcellular localization. In one of these recombination events the kinase 
domain was picked up by pox viruses (vaccinia, variola, smallpox) and 
generated the B1R protein, which is the only kinase in poxviruses genome; 
B1R is required for poxvirus replication and its inactivating mutations can be 
partially recovered by overexpression of mammalian VRK1, or VRK2 
proteins, indicating that in poxvirus there was an additional functional 
divergence due to viral life requirement [11]. Structurally, the three VRK 
proteins differ in their regulatory region located C-terminal for VRK1 and 
VRK2 and N-terminal for VRK3. These regulatory regions are unrelated 
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among them and have no homology to any known feature identified in other 
proteins. The length of the regulatory region is variable. It is approximately 
one hundred amino acids in VRK1 and two hundred aminoacids in VRK2, 
thus their subcellular localization and regulation is likely to be different 
among mammalian VRK proteins and those of lower eukaryotes. The relative 
conservation of catalytic domain of VRK proteins indicates they can have an 
overlap of potential substrates. 
 The catalytic domain of these kinases have some key substitutions which 
make them differ from other closely related kinases, nevertheless two of them 
VRK1 and VRK2 are catalytically active and have a 56 % sequence identity 
[6, 8, 12]. These differences might be exploited for the design of VRK 
specific inhibitors [13], which may be achieved by determination of their 
crystal structure. The crystal structure of the catalytic domain of VRK2 and 
VRK3, with 38 % sequence identity and without any significant difference, 
has been determined providing the framework for future inhibitor 
development [10]. 
 Human VRK1 gene is located on the chromosomal region 14q32.2. This 
gene has a polymorphism, marker rs722869, that in combination with other 
nine polymorphisms in other genes has proven very useful and is included in 
the most informative set to study the identification of human continental 
population structure and genetic ancestry [14]. VRK1 gene expression has 
been studied in hematopoietic murine development, and its highest 
expression coincides with the time of maximum cellular expansion in days 
E11.5  to  E13.5 [15].   Endogenous  VRK1  protein  is  detected  in  different 
 
 
 
Figure 1. Structure of the three human VRK proteins. ATP: ATP binding site; KD: 
kinase domain; Plk: consensus target for Plk3. NLS: nuclear localization signal. BAB: 
Basic-acid-basic region. TM: transmembrane region. 
Marta Sanz-García  et al. 138
intracellular compartments, suggesting that localization is regulated and that 
it might play different functional roles depending on its localization. VRK1 
has a canonical nuclear localization signal (KKRKK) in residues 356 – 360, 
which accounts for its nuclear localization [6, 8]. In interphase the 
endogenous VRK1 has a granular aspect, probably forming aggregates, 
dispersed within the nucleus, and in mitosis it is dispersed throughout the cell 
and does not bind to chromatin. In some cell types the endogenous VRK1 
protein is mostly cytosolic presenting a particulate appearance, and a minor 
fraction is nuclear [16], but the underlying cause is unknown. Also there is a 
subpopulation in the Golgi apparatus where VRK1 colocalizes with giantin 
where it participates in the control of Golgi fragmentation, and perhaps in 
VRK1 recycling [17]. This differential distribution is tissue specific [16]. 
These different locations of human VRK1 are also detected in human normal 
tissue biopsies. For example in testes and esophagus VRK1 is detected as 
nuclear with all antibodies. However in small intestine or kidney, a nuclear 
and a cytosolic subpopulation are detected depending on the antibody used 
[16]. The factors determining, and regulating, these different subcellular 
localizations are unknown.  
 The human VRK2 gene has 14 exons and can generate two different 
transcripts by alternative splicing, one lacking exon 13 that contains a 
termination codon, encoding two proteins of 508 (VRK2A) or 397 (VRK2B) 
aminoacids respectively. The largest protein is called VRK2A, and the other 
is VRK2B [12], both are identical up to residue 393 and have a common 
kinase domain. The VRK2A protein has, at the end of its carboxy terminus, a 
hydrophobic region of 17 aminoacids that anchors the protein to membranes 
in endoplasmic reticulum and mitochondria. VRK2A colocalizes with 
calreticulin and calnexin indicating its presence in the endoplasmic reticulum 
[12]; it also colocalizes with mitotracker, a lipidic marker of mitochondria 
[12]. VRK2B, lacking its hydrophobic tail, is free in the cytosol and the 
nucleus of the cell. The shorter isoform B is more similar in size to VRK1, 
lacking the membrane anchor sequence, and detected in those cells where 
VRK1 is mostly cytosolic, suggesting they might have some functional 
redundancy, but how their expression is coordinated is not known. Therefore, 
although both proteins might have similar or identical kinase properties, their 
natural substrates may be different due to their different subcellular 
localization. Additional variants of VRK2 have been identified by RT-PCR, 
but the expected corresponding proteins have not been detected and may 
represent splicing intermediates. Many cell types have been studied for the 
expression of both isoforms, such as normal B-cells, several lymphoma cell 
lines and several frequently used carcinoma cell lines such as HeLa, A549, 
H1299, MCF7, among others. All of them expressed both messages [12]. All 
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of them express VRK2A protein, but the level of the VRK2B protein was 
variable, and in some cell lines was not detectable [12]. 
 The human VRK3 gene is located on 19q13.33, and codes for a protein 
with a degenerate kinase domain located in the carboxy terminal region that 
has no kinase activity due to critical aminoacid substitutions [8]. Its crystal 
structure has revealed important structural differences that make it unable to 
bind ATP [10]. VRK3 non-functional kinase-dead domain maintains its 
overall structure so that it can function as scaffold for other proteins [10]. The 
VRK3 protein is detected in the nucleus and has a bipartite nuclear 
localization signal [8, 9].  
 In humans the expression of VRK proteins has been detected in all 
tissues studied; but not all cells in a tissue express these proteins. The reason 
for this heterogeneous expression is not yet known, but it may be associated 
to the proliferation and differentiation state of individual cells. In normal 
epithelium higher levels are detected near the basal layer, and the intensity of 
the signal decreases as the cell matures [18]. 
 
2. Biological roles of VRK proteins 
 
 The biological information available on the three VRK proteins is very 
limited, and most of it was obtained by studying the human proteins in two 
main directions. One of them implies the characterization of the signaling 
pathway in which VRK proteins are implicated, either by substrate 
identification or by interaction with other proteins. The other is directed at 
their effect on some biological response, such as hypoxia, interleukin1β or 
DNA damage. In both situations it is expected that information will expand 
as these proteins acquire more relevance in the context of tumor biology, and 
start to attract more attention. In the case of VRK1 some of its targets have 
been identified, including several transcription factors (Fig. 2), which can 
serve as starting points to characterize the VRK pathway by itself, or their 
interaction with other pathways. 
 In this review we will summarized the different biological processes 
where VRK proteins have been shown to participate. 
 
3. VRK proteins and cell signaling 
 
3.1. VRK2 downregulates the response to hypoxia or interleukin-1β 
mediated by JNK 
 
 Many biological processes induced by growth factors, stress responses 
send signals that activate gene expression. These signals are channeled by a 
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protein complex of mitogen-associated protein kinases (MAPK) which are 
activated by two additional kinases, MAPKK and MAPKKK, ordered as 
consecutive steps. MAP kinases represent the core of multiple signaling 
pathways in response to a variety of stimuli, ranging from growth factors to 
stress responses. The response implies multiple biological effects such as 
proliferation, apoptosis, growth arrests and senescence among others [19, 20]. 
For each of these steps there are multiple kinases, making up multiple 
combinations that are very likely to determine the specificity of the 
responses. The three kinases are often anchored on a scaffold protein; the best 
known are JIP1, of which there are four members, and KSR1 [21]. But there 
are also other less well known scaffolds. The levels and subcellular 
localization of scaffold proteins are critical to determine the distribution of a 
signal among different signaling pathways, and the asymmetry of this signal 
distribution can determine the final biological effect. These complexes might 
be further regulated by additional proteins that might interact, activate or 
inhibit the signal transmission; among these proteins are the two VRK2 
isoforms. Therefore signal specificity is likely to be determined by 
interactions between components of the core signaling pathway with other 
proteins, most of which have not yet been identified, but is an emerging field. 
Among these proteins, VRK2A and VRK3 have been shown to interact and 
regulate MAP kinase signaling in response to different types of stimulation. 
 
3.2. VRK2 downregulates MAP kinase signaling and JNK activation 
 
 Many biological processes are controlled by regulation of the activity of 
mitogen-activated protein kinases which function like a central hub where 
signals are received and distributed to exert specific roles. MAPK (mitogen-
activated protein kinases) are implicated in a large number of cellular 
responses to growth factors and stress signals of different types. MAPK 
signals are transmitted by a complex of three consecutive kinases and for 
each step there are several possibilities. The combination of these kinases 
contributes to signal specificity. The three consecutive MAP kinases are 
assembled on scaffold proteins, of which there are several types [21]. These 
modules permit the organization of specific signal transmission and can be 
further modulated by specific interactions with other proteins. One of these 
new regulators is VRK2, which by its interaction with scaffold–MAPK 
complexes can alter the balance between different pathways responding to a 
common signal. Signals regulating proliferation are mainly transmitted by the 
RAF-MEK-ERK proteins assembled on the KSR1 scaffold, while signals 
implicated in stress responses are channeled by the TAK1-MKK4/7-JNK 
complex assembled on JIP proteins [21]. The effect of VRK proteins on 
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signaling by scaffold proteins has been studied using two different 
experimental systems; one based on the response to stress mediated by the 
JNK (c-Jun N-terminal kinase) pathway and the other in response to growth 
factors such as EGF and mediated by the ERK pathway. The best 
characterized one is the complex assembled on JIP1. JIP1 interacts with JNK 
and MKK4, or MKK7, as the third and second kinase respectively. However, 
responses to a common stimulation using this complex may vary depending 
on cell type, and the reasons for the difference are not known, but are likely 
to be related to additional proteins which might modulate the signalosome or 
signaling complex. The JIP1 scaffold protein is usually thought of as a 
monomer to which different kinase can bind. However, it is known that JIP1 
can also be associated to membranes and form large complexes [22]. In our 
laboratory we have identified that JIP1 form complexes with a size of 1200 
kDa, which includes the VRK2A protein [23, 24]. These complexes can 
incorporate VRK2, and the composition of the complex can be altered if cells 
are stimulated [23].  
 
 
 
Figure 2. Model of the complexes assembled on the JIP1 scaffold protein which can 
incorporate VRK2 protein and is modulated by interleukin-1β or hypoxia.  
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 The VRK2A protein subpopulation that is anchored on the endoplasmic 
reticulum (ER) [12], colocalizes with JIP1 on the ER which suggest that they 
can interact and modulate MAPK signaling [24]. JIP1 by interacting with 
ER-anchored VRK2 can be incorporated and form larger complexes; JIP1 up 
to now has been thought of as a monomer, and by this incorporation in 
membrane complexes JIP1 can be compartmentalized instead of being free in 
the cytosol. The formation of these complexes provides the cell with two 
different signaling alternatives, depending on location and aggregation state, 
and probably with different substrates. The formation of the signalosome is 
likely to be assembled on VRK2A protein anchored to membranes, because it 
is not formed by the VRK2B isoform that is free in the cytosol and nuclei 
(Fig. 2). The presence of VRK2A is a major requirement to induce the 
oligomerization state and assembly of the signalosome. In the presence of 
VRK2A complexes are very large (1000 kDa), but when VRK2A was 
knocked down the complexes were disassembled, and many of its 
components were detected as free or forming smaller and incomplete 
complexes [23, 24]. The effect of VRK2-JIP1 interaction has been studied 
under two types of stimulation, one in response to the inflammatory 
interleukin-1β (IL-1 β)[24] and the other in response to hypoxia [23], IL-1 β  
and hypoxia induce the formation of a large complexes of more than 1000 
kDa, known as signalosomes, and containing MAPK and JIP1 protein, and 
among its components is present the VRK2A [23, 24]. In the complex 
VRK2A directly interacts with JIP1 and TAK1. The stable interaction of 
VRK2A with JIP1 can alter the composition of MAPK bound to JIP1. 
Binding of VRK2A to JIP1 does not affect JIP1 interaction with TAK1 or 
MKK7, but reduces its binding to JNK, and thus limits the potential 
activation of c-Jun dependent transcription, which can not be activated 
because JNK is inactive (Fig. 2).  
 
3.3. VRK3 downregulates ERK activity by interaction with the 
VHR phosphatase 
 
 The nuclear VRK3 protein is able to downregulate ERK signaling by a 
mechanism different from the one involving VRK2 and MAPK. Because 
VRK2 is not catalytically active it can only function by mediating protein-
protein interactions, where it plays a scaffold role. The effect of VRK3 on 
MAPK signaling has been characterized by its role in modulating nuclear 
signals mediated by ERK. ERK (extracellular regulated kinase) is a MAPK 
that has been implicated in the control of proliferation and cell growth [25, 
26]. ERK is the last kinase in the MAPK complex responding to EGF, 
ERBB2, Ras and Raf, which is most commonly assembled on the KSR1 
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scaffold. Activation of the pathway by growth factors (EGF) or oncogenes 
(ERBB2, RasG12V, or BRAFV600E) induces a phosphorylation of ERK (p-ERK) 
that has substrates in the cytosol and in the nucleus. Among its cytosolic 
targets is p90RSK (ribosomal S6 kinase) that activates pleiotropic response 
associated to cell growth and increase in cell mass [27]. The activated p-ERK 
is translocated to the nucleus and mainly phosphorylates a large number of 
transcription factors including ETS, ELK1, Pax6 or c-FOS among others, and 
their relative levels and activation might condition activation of one type of 
response or another. One of these pathways is represent by ERK 
(extracellular-signal regulated kinase). These kinases are regulated by 
phosphorylation and the level of phosphorylation is control by proteins 
known as mitogen-activated protein kinase phosphatases (MKPs), the 
expression or stabilization of MKP activity thus negatively controls ERK 
activation forming a feed-back regulatory mechanism [28]. In this context, 
the VRK3 protein, the least known member of the VRK family, appears to 
control the level of ERK activation [9, 29]. This effect is indirect and 
mediated by an interaction with the VHR (vaccinia H1-related). In the 
nucleus VHR dephosphorylates ERK resulting in its inactivation. The nuclear 
binding of VRK3 to VHR increases its phosphatase activity, and for this 
process the kinase activity is not necessary, thus this effect is postactivation 
in the cytosol and therefore its role is to mediate a downregulation, or 
silencing, the nuclear action of phospho-ERK [9, 29]. In this context, VRK3 
functions as a scaffold protein that binds to the VHR phosphatase, which 
removes the phosphate from an activated MAPK, as is the case of ERK, and 
thus inhibits or downregulates its nuclear signal.  
 
4. Modulation of transcription factors by VRK proteins 
 
4.1. VRK1 activation of transcription factors can cooperate or be 
an alternative to MAPK signals  
 
 Among the phosphorylation targets of hVRK1 there are transcription 
factors that are generally regulated by MAPK signaling. Some of these 
transcription factors can be directly phosphorylated by VRK1 and VRK2B 
isoform resulting in enhancement of their transcriptional activity, including   
c-Jun [30], ATF2 [31], CREB [32] and p53 [6]. The nature of these 
transcription factors reveals potential functional implications for VRK 
proteins. ATF2, CREB and c-Jun are members of the bZIP family of proteins 
that can bind to the AP-1 sites to regulate gene expression [33]; this 
activation is mediated by dimers of these proteins, and depending on the two 
partners the specificity of the gene selected can be determined. 
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 The c-Jun protein, a component of the AP1 transcription sites, is 
activated by phosphorylation by JNK (c-Jun N-terminal kinase) in response 
to stress signals that regulate apoptosis, proliferation and development [34, 
35]. The phosphorylation of c-Jun by VRK1 results in the transcriptional 
activation of Jun independently of the JNK signal. The oncogenic c-Jun can 
be directly phosphorylated by VRK1 and VRK2B in residues Thr63 and 
Ser73, which are the same as those phosphorylated by JNK (N-terminal 
kinase of c-Jun), activating c-Jun dependent transcription [30]. Thus, in 
situation of suboptimal stimulation, the two kinases might have an additive 
effect (Fig. 3) and reach maximum c-Jun transcriptional activation [30]. This 
generates an interesting situation in which c-Jun phosphorylation might be 
inhibited by the action of cytosolic VRK2A that blocks its activation as a 
consequence of VRK2A interaction with the JIP1 scaffold protein [24], thus 
the stress signal response is blocked, as is the case in hypoxia response [23], 
but at the same time permits its activation by a different route mediated by 
VRK1, which is regulated in a different way that remains to be identified, but 
which is associated with entry into cell cycle or responses to DNA damage. 
 
 
 
Figure 3. Diagram illustrating the different substrates identified for the human VRK1 
kinases and the overlap of its signals with other signaling pathways [6, 30-32]. 
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 The ATF2 and CREB transcriptions factors are implicated in pleiotropic 
responses. VRK1 phosphorylates ATF2 in Ser62 and Thr73 and activates 
transcription [31]. These two residues are very proximal to those targeted by 
JNK, Thr69 and Thr71; all within the same region (Fig. 3). These slightly 
different positions might regulate ATF2 by differential interaction properties 
with other transcriptional cofactors, and thus affect the specificity of gene 
transcription. Furthermore, these differences in phosphorylation target can 
generate a potential cooperative activation by suboptimal stimulation of each 
kinase, VRK1 and JNK, or respond alternatively to one signaling route or the 
other. But also the ATF2 residues targeted by VRK1 are the same as those 
targeted by calmodulin-dependent kinase IV or protein kinase A [31], 
permitting cooperation between more than one signaling pathways [31]. Thus 
at least four signaling routes can converge on ATF2 (Fig. 3). 
 Another target of VRK1 is CREB, a factor identified in response to 
cAMP. The CREB transcription factor can also be activated by 
phosphorylation in Ser133 by VRK1, and is required for transcription of 
cyclinD1 (CCND1), VRK1 forms part of the transcriptional complex of this 
gene in the G1 phase of the cell cycle. This CREB activation was previously 
known as an effect mediated by a cAMP-response element in CCND1 
promoter [32].  Thus two transcription factors responding to cAMP, ATF2 
and CREB, are regulated by VRK1, but the functional interaction between 
VRK1-mediated pathway and cAMP responses are not known. 
 
4.2. Regulation of p53 by VRK1, a novel regulatory loop between 
VRK1 and p53 in response to DNA damage mediated by DRAM 
 
 The tumor suppressor p53 was the first target identified for VRK 
proteins. VRK proteins can stabilize and regulate p53 by a unique 
phosphorylation of Thr18. VRK1 [6, 36] and VRK2 [12] phosphorylate p53 
specifically is Thr18, a residue that is critical to maintain the loop structure in 
its N-terminal tansactivation domain (TAD). The stabilization is a 
consequence of the disruption of the hydrogen bond between Thr18 and 
Asp21 in p53 necessary to maintain the structure of the loop that binds to 
Hdm2/Mdm2 [37, 38]. This Thr18 is the critical residue controlling the 
selection of binding partner by p53 TAD, its phosphorylation increases seven 
fold its binding to transcriptional coactivators, such as p300 [39], and 
dephosphorylated p53 interacts preferentially with Hdm2. The effect on p53 
interactions is very consistent with the consequences of phosphorylation; 
when p53 is phosphorylated in Thr18 there is a reduction in ubiquitination 
and an increase in acetylation, as well as in transcriptional activity [36]. This 
Thr18 specific phosphorylation changes by three orders of magnitude the 
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differential binding from Hdm2 to p300 and TAZ1 [39]. Other well-known 
residues such as Ser15 or Ser20 have a much weaker contribution to selection 
of binding partner and play a secondary role in this context, although they are 
the most characterized in response to DNA damage by the ATM/CHK2 [40, 
41]or ATR/CHK1 pathways [42].  
 The stabilization of p53 by VRKs renders a p53 molecule that cannot be 
degraded and thus accumulates in the cell; a persistent accumulation of p53 
will not permit life because it induces either a blockade of cell cycle 
progression or apoptosis. In addition, the VRK1 protein that functions as a 
p53 activator is very stable with a half life of four days thus if activated it 
will maintain p53 in a non-degradable and stabilized form. These 
characteristics suggested that regulation of VRK proteins level probably 
requires an active mechanism of protein degradation, which will permit p53 
downregulation at the same time. Therefore it is very likely that an 
autoregulation between p53 and VRK1 must exist. There was an initial 
observation which suggested that such potential mechanism was functioning 
because in cell lines that have a high level of p53 there was a lower level of 
VRK1 compared with cell lines that have a smaller amount of p53, and a 
higher level of VRK1 [43]. In experimental systems, overexpression of p53 
was always followed by a reduction in VRK1 level [43]. The drop in VRK1 
protein was not accompanied by a reduction in VRK1 gene expression 
suggesting it was an indirect effect of p53. Nevertheless, this downregulation 
was dependent on p53 transcriptional activity, probably by regulating the 
expression of a not yet identified protein that is the one that targets VRK1 for 
degradation [43]. 
 The structural requirements of the p53 molecule required to induce VRK 
downregulation have been identified using different p53 variants containing 
mutations, deletions or conformational mutants [43]. The N-terminal TAD 
(trans activation domain) was studied with the p53L22Q/23WS conformational 
mutant, phosphorylation mutants in all its Ser or Thr residues; none of them 
affected VRK1 downregulation  [43]. The p53 DNA binding domain was 
studied using the three most common mutations detected in sporadic or 
hereditary (Li-Fraumeni syndrome) human cancer. The conformational 
mutant p53R175H, or the p53R248W and p53R273H DNA-contact mutants. All 
these mutants were unable to induce downregulation of VRK1 levels [43]. 
Thus a functional p53 DNA binding domain is necessary and supports the 
requirement of p53 transcriptional dependence of this VRK1 downregulation. 
 The VRK1 protein is not ubiquitinated by Hdm2, or other ubiquitin 
ligases, as demonstrated by its insensitivity to either overexpression of mdm2 
or to proteasome inhibitors [43], suggesting that the proteasome pathway is 
not implicated in VRK1 downregulation. Alternatively, downregulation of 
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VRK1 is sensitive to inhibitors of late-endosome to lysosome transport such 
as chloroquine [43], and to inhibitors of lysosomal protease activity. These 
results suggested that p53 induces the expression of a protein that regulates 
VRK1 and targets it for lysosomal degradation.  This protein is DRAM, a 
lysosomal membrane protein of 238 aminoacids and has six transmembrane 
domains equally spaced [44]. DRAM expression is dependent on activation 
of transcription by p53, and expression is lost in case of common p53 
mutations in human cancer, such as p53R175H, p53R248W and p53R273H. These 
requirements are identical as those for VRK1 downregulation induced by 
p53, thus DRAM is a candidate to be its mediator, and its overexpression of 
DRAM downregulates VRK1. The induction of DNA damage by ultraviolet 
light results in accumulation of p53, followed by expression of DRAM and 
downregulation of VRK1. Thus p53 has a double autoregulatory loop to 
control its intracellular levels, activated p53 is phosphorylated and induces 
HDM2 and DRAM gene expression. But hdm2 ca not degrade p53 if it is 
phosphorylated, thus the removal of VRK1 by its lysosomal degradation 
mediated by DRAM permits the accumulation of unphosphorylated p53 that 
is now susceptible to ubiquitination by hdm2 and can be degraded in the 
proteasome (Fig. 4). 
 
 
 
Figure 4. Autoregulatory loop of VRK1 dependent on p53. Phosphorylated p53 
activates transcription of Mdm2 that downregulates p53 and of DRAM that 
downregulates VRK1. 
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5. VRK proteins in processes required for mitosis 
 
5.1. VRK1 expression and cell cycle 
 
 Expression of VRK1 and VRK2 was originally associated to 
proliferation, because of their expression in proliferating tissues such as 
testis, thymus, and fetal liver [2] and in the rapid proliferation stage of B-cell 
development in murine embryos [15].  
 The expression of human VRK1 gene is regulated in cell cycle 
progression. Serum withdrawal results in endogenous VRK1 gene silencing in 
human fibroblast, parallel to the loss of phopho-Rb, and also in loss of 
expression dependent on the human VRK1 gene promoter coupled to a 
luciferase reporter [45]. Addition of serum induces expression of VRK1 RNA 
at the same time as MYC, FOS and CCND1 (cyclinD1), indicating VRK1 is 
an early response gene. Knock-down of endogenous VRK1 results in lack of 
induction of cyclin D1 and a cell cycle block, early in G1 [36, 45]. 
 In human head and neck squamous cell carcinomas (HNSCC), VRK1 
protein is expressed at high levels and positively correlates with several 
proliferation markers such as Ki67, cyclins B1 and A, cdk2, cdk6 and cdc2. 
In addition in human lung carcinomas, there were higher levels of VRK1 in 
those tumors that have a p53 mutation, consistent with an inactivation of the 
p53 dependent autoregulatory loop [46]. 
 
5.2. VRK1, in the control of nuclear membrane formation 
 
 The VRK1 and VRK2 proteins, as well as the vaccinia virus B1R kinase, 
phosphorylate the BAF1 protein (barrier to autointegration factor 1), a 10 
kDa protein that forms dimers. The BAF1 protein binds to DNA in a non-
sequence specific manner [47], and to proteins containing LEM domains, 
which are present in the inner nuclear membrane [48]. VRKs and B1R 
phosphorylate residues Ser4 or Thr2/Thr3 in the N-terminal domain of BAF1. 
The phosphorylated BAF1 presents a reduction in its binding to DNA and 
LEM-containing proteins [49]. Phosphorylation of BAF1 in Ser4 delocalizes 
emerin and interferes with emerin binding to lamin A, both in mitosis and 
interphase [50]. The overexpression of VRKs reduces BAF1 interaction with 
nuclear chromatin and results in its dispersal [49]. Nuclear disassembly is a 
process necessary for cell cycle progression, thus BAF1 phosphorylation by 
VRK1 might be dependent on functional changes in the activity of VRK1, a 
kinase that is regulated in cell cycle, and required for G0 exit and G1 
progression [45], and its knock down causes a block of cell cycle progression 
[36, 45]. VRK1 is expressed as the cells enter the cycle from G0 to G1 and 
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the highest levels are achieved at G1/S transition [18]. The VRK1 protein is 
very stable and therefore is ready to act when the nuclear envelope has to 
disintegrate in order to permit chromosome segregation. The C. elegans   
Vrk-1 protein, a unique ortholog of human VRK proteins, also 
phosphorylates the BAF1 protein and affects nuclear membrane structure 
[51]. But C. elegans Vrk-1 protein is much larger, 610 aminoacids, 
completely unrelated to that of human VRK1 protein.. The conservation is 
restricted to the kinase domain, but there is no relation between their 
carboxyterminal regions. Thus C. elegans and human VRK1 have a common 
substrate, but probably a different regulation because of their different         
C-terminal region. Vaccinia virus B1R kinase also has among its substrates 
the BAF protein that is required in vaccinia life cycle at a time when 
disintegration of the nuclear envelope takes place, and this function can be 
partially rescued by overexpressed human VRK1 in virus with B1R 
mutations [49].  
  
5.3. Regulation of VRK1 activity by interaction with Ran and 
nuclear dynamics 
 
 The enzymatic activity of VRK1 can be regulated by different 
mechanisms that can affect either its kinase activity or its substrate 
specificity. These regulatory mechanisms include either protein interactions 
or covalent modifications. Using a proteomics based approach several 
interacting proteins have been identified and some of them have already been 
validated and are now components of emerging VRK signaling pathways. 
 The first allosteric regulator of VRK proteins is the small GTPase Ran, 
the only nuclear member of the large Ras GTPase family. Ran stably interacts 
with the three VRK proteins, but only the Ran interaction with VRK1 has 
been characterized [52]. Small GTPases have two forms depending on the 
bound nucleotide; inactive or bound to GDP, and active or bound to GTP. 
Ran-GDP is mostly located in the cytosol and participates in the nuclear 
transport mechanism; Ran-GTP, is located in the nucleus, and the nucleotide 
exchange from Ran-GDP to Ran-GTP is mediated by the action of RCC1 its 
GEF (Guanine exchange factor) in the nucleus. During mitosis Ran-GTP can 
form a concentration gradient, with the highest concentration near condensed 
chromosomes [53]. VRK1 contributes to chromatin condensation by 
phosphorylation of histone H3 [52, 54]. Ran-GTP binds to VRK1 but does 
not alter its activity, but VRK1 binding to Ran-GDP inhibits VRK1 kinase 
activity [52], permitting the formation of a nuclear gradient of VRK1 activity 
in the nucleus depending on its partner interactions. VRK1 will be activated 
near the chromosomes, where it can participate in chromatin condensation by 
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phosphorylation of histone H3 [54], a phosphorylation that is lost by 
knocked-down of VRK1 [52]. A diagram of the regulation of VRK1 by the 
Ran small GTPase is shown in Fig. 5. 
 Also some histones are substrates of VRK proteins. NHK (nucleosomal 
histone kinase), is the unique VRK ortholog in Drosophila melanogaster, and 
phosphorylates mitotic histones H2A which is required for acetylation of H3 
[55-57], a phosphorylation also required for mitotic progression [58]. Human 
VRK1 is able to phosphorylate histone H3 in Ser10 resulting in chromatin 
condensation, and cooperating with Aurora B, a process also required for 
progression of mitosis [54]; this phosphorylation of H3 can be inhibited if 
human VRK1 interacts with RanGDP [52]. 
 
 
 
Figure 5. Interaction between VRK1 and Ran. Effect on VRK1 kinase activity 
depending on the loading state of the small GTPase Ran. [52]. 
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5.5. The MEK-Plk3-VRK1 pathway: Specific phosphorylation of 
VRK1 in Golgi fragmentation 
 
 Golgi fragmentation is a necessary process during mitosis in order to 
redistribute this organelle into daughter cells. The regulation of this 
fragmentation is not well known, but mitogenic signals mediated by MAP 
kinases, particularly MEK1, that induce Golgi fragmentation [59-62], 
representing an upstream component. A step downstream of MEK1 is 
mediated by plk3 (polo-like kinase 3) [63], a member of the plk protein 
family [64]. There is a subpopulation of VRK1, detected with a specific 
antibody, which is partially located in Golgi colocalizing with markers such 
as giantin of GM130 [17], which suggests VRK1 might participate in 
processes regulating Golgi functions. VRK1 participates in this process as a 
downstream target of Plk3, since VRK1 has a consensus sequence for 
phosphorylation by Plk proteins. Plk3 phosphorylates VRK1 in Ser340 [17]. 
Knocking-down VRK1, or the use of a catalytically inactive VRK1K179E, 
blocks Golgi fragmentation induced by either MEK1 or Plk3 [17]. Thus, one 
of the cytosolic VRK1 roles is to contribute to Golgi fragmentation in G2/M 
in mitosis, as a new downstream step of this pathway in mitosis (Fig. 6). 
 
 
 
Figure 6. VRK1 is a downstream step in the signaling pathway required for Golgi 
fragmentation in mitosis [17]. 
 
Conclusions 
 
 VRK proteins are a group of new human serine-threonine kinases 
forming a distinctive branch in the human kinome. Among its targets there 
are a variety of transcription factors implicated in the response to DNA 
damage, such as p53, or stress responses such as p53 or c-Jun. VRK1 
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participate in several biological processes including regulation of cell cycle 
entry and progression, response to DNA damage, nuclear envelope assembly 
and Golgi fragmentation. VRK2 also modulates signaling by MAPK 
pathways playing and inhibitory role after its incorporation in a signalosome 
with scaffold proteins. The VRK signaling pathway is still partially 
characterized and is expected that its contribution to cell and tumor biology 
will increase significantly in a near future. 
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1. Background  
 
      Cancer cells proliferate unlimitedly. Therefore, targeting the proliferative 
capacity of cancer is one of the smartest ways to treat cancer. In this vein, 
understanding the basis of mitosis is essential for the advanced treatment of 
cancer, let alone its importance in basic biology. Indeed, recent progress in 
anti-cancer strategy has come from the development of a group of inhibitors 
targeting mitosis.  
     Opposed to meiosis, mitosis aims to preserve its genome during 
proliferation. In mitosis, genetic information of the parental cell is passed to 
two daughter cells through equal segregation of the replicated genome. Thus, 
the genetic integrity in proliferating cells is guaranteed through accurate 
chromosome separation in mitosis. 
      Mitosis is an ordered process orchestrated by a series of mitotic kinases 
and associated proteins. Sets of checkpoint mechanisms ensure the accurate 
segregation of the replicated genomes.  Prior to mitosis, G1 restriction point, 
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G1/S checkpoint, G2 checkpoint ensures that any type of DNA damage is 
repaired before entry into mitosis. p53 plays the pivotal role in interphase 
checkpoints; hence numerous anti-cancer strategies have focused to activate 
the p53 pathway.  
 In mitosis, failure in the bipolar attachment of microtubule spindles to 
even one chromosome would result in loss or gain of chromosomes in 
daughter cells, resulting in massive alteration of genetic information. 
Therefore, spindle assembly checkpoint has evolved in eukaryotes to ensure 
that not a single chromosome is left behind in mitosis. Errors in this process 
can be detrimental; deformity in development, abortion, Down’s syndrome, 
neurodegenerative disorders, and cancer. 
 Principal strategy of anticancer agents was the stabilization or destabilization 
of microtubule polymerization. This effectively controlled mitotic cells, the cancer 
cells, and not the quiescent normal cells. These include taxanes and vinca 
alkaloids. Recently, mitotic kinases emerged as the target for anti-cancer therapy.  
 
 
 
Figure 1.  Dynamic localization of mitotic kinases. At the prophase, Plk1 recruits 
Aurora A and B kinases to the centrosomes and chromosome arms respectively. 
BubR1 is recruited to the outer kinetochores after nuclear envelope break-down 
(NEBD). During prometaphase, Plk1 and Aurora B converge to the kinetochores; 
Aurora B to the inner centromeres and Plk1 to the outer kinetochores. At the 
metaphase when all the chromosomes are attached to the bipolar spindles and under 
proper tension, BubR1 is degraded and anaphase begins. At the anaphase, Plk1 and 
Aurora B are relocalized to the midzone and regulate cytokinesis. With completion of 
cytokinesis, Plk1 and both Aurora kinases banish. 
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Table 1. Inhibitors for Aurora kinases and Plk1 in clinical trials. 
 
Aurora kinase inhibitors 
Company Name Remarks 
Astex Therapeutics AT9283 Phase I-II trials, Aurora A/B inhibitor 
AstraZeneca AZD1152 Phase I-II trials, Aurora B/C inhibitor 
 ZM447439 Preclinical development, Aurora B inhibitor
Cyclacel CYC116 Phase I trials, pan Aurora inhibitor 
GlaxoSmithKline GSK1070916 Phase I trials, selective Aurora B/C inhibitor
Millenium MLN8054 Phase I trials, Aurora A inhibitors 
 MLN8237 Phase I-II trials, Aurora A inhibitors 
Pfizer PHA-739358 Phase II trials, pan Aurora inhibitor 
 PHA-680632 Aurora A inhibitor 
 PF-03814735 Phase I trials, Aurora A/B inhibitor 
Sunesis Pharmaceuticals SNS-314 Phase I trials, pan Aurora inhibitor 
Vertex / Merck VX-680 (MK-0457) Phase I-II trials, Aurora A/B inhibitor 
 
Plk1 inhibitors 
Company Name Remarks 
Boehringer Ingelheim BI 2536 Phase I-II trials 
 BI 6727 Phase I-II trials 
GlaxoSmithKline GSK461364 Phase I trials 
Nippon Shinyaku HMN-214 Phase I trials 
Onconova ON01910Na Phase I-II trials 
 
 As illustrated in Figure 1, mitosis is orchestrated by several mitotic 
kinases at distinct cellular locations. Thus, malfunction in any of these key 
kinases can activate the spindle assembly checkpoint and ultimately end up in 
apoptosis in an as-yet-undefined mechanism. Among these mitotic kinases, 
Aurora kinases and Polo-like kinases have proven to be effective targets for 
cancer therapy; specific inhibitors are on clinical trials (Table 1).  
 In this chapter, we will review on how mitosis is regulated by key 
kinases, such as Aurora kinases, Plk, and BubR1, and discuss on the potential 
of the recently developed anti-cancer drugs. The future of anti-cancer strategy 
based on the understanding of mitosis and its novel mechanisms will also be 
discussed. 
 
2. Aurora kinases  
 
 Aurora kinases are Serine/Threonine kinases that are associated with 
microtubule apparatus and chromosome in mitosis. While cyclin-dependent 
kinse-1 (CDK1) and Polo-like kinase-1 (Plk1) trigger cell division and work 
as global controllers of mitosis, Aurora kinases directly regulate mitotic 
events largely at three critical points; at the mitotic entry building up 
centrosomes for the bipolar spindle formation, at the prometa- to metaphase 
orchestrating amphitellic attachment of spindles to kinetochores, and during 
cytokinesis delaying abscission until chromosome segregation is complete. In 
yeasts, a single Aurora kinase exists, Ipl1 [increased in ploidy] in the budding 
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yeast and Ark1 [Aurora related kinase] in fission yeast. In metazoans Aurora 
A and B were discovered; Aurora A is prominently localized at the 
centrosomes whereas Aurora B is localized at the inner kinetochores early in 
the mitosis and relocalized to the midbody during cytokinesis (Figure 1). 
Yeast Ipl1 is localized at the chromosome to midbody and forms a complex 
with INCENP-Survivin (Sli15-Bir1) similar to mammalian Aurora B. 
Reminiscent of their localization, Aurora A plays a crucial function in the 
centrosome maturation and bipolar spindle formation whereas Aurora B is 
involved in the chromosome condensation, microtubule-kinetochore 
attachment, and cytokinesis. Vertebrates have a third Aurora kinase C; the 
expression of Aurora C is restricted to the testis and shows similar 
localization and function as Aurora B.  
 
2.1. Structure 
 
 Aurora kinases have a variable N-terminal domain, a highly conserved 
protein kinase domain and a regulatory C-terminal domain. Aurora A and 
Aurora B kinases share over 60% amino acid identity and structural 
similarities. The substrate binding surface of Aurora A and Aurora B 
catalytic domain is almost identical except for a few amino acid residues. The 
difference is responsible for the binding of a unique partner for each kinase; 
Aurora A to Tpx2 and Aurora B to INCENP. A single amino acid 
substitution, Gly-198 of Aurora A with the Aurora B equivalent Asn residue 
disrupts Tpx2 association and confers INCENP binding for the mutant 
Aurora A [1]. The exchange of binding partner leads to the localization of 
Aurora A at the inner centromeres and midzone. More importantly, Aurora A 
G198N compensates the loss of Aurora B. These indicate that the basis for 
the divergent function of Aurora A and B is their interaction partners. Aurora 
A-Tpx2 complex and Aurora B-INCENP complex have distinct structure and 
different substrate specificities [2,3] Autophosphorylation of Thr-288 in 
Aurora A stimulated by Tpx2 and Thr-232 in Aurora B by INCENP are 
required for the full activation of kinase activities as well. The variable N-
terminus mediates many protein-protein interactions for Aurora A and Aurora 
B kinases. C-terminal D box and N-terminal A box are responsible for 
APC/Cdh1 dependent degradation during mitotic exit [4] for both kinases. 
 
2.2. Function of Aurora A 
 
 Aurora A is prominently localized at the centrosomes and along the 
microtubules during mitosis.  At the centrosome, Aurora A is involved in the 
centrosome separation and centrosome maturation. Aurora A also regulates 
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centrosome-dependent and independent spindle assembly. In the absence of 
Aurora A, mitotic entry is significantly delayed, implicating Aurora A in cell 
cycle progression as well. Also important is that Aurora A locus is frequently 
amplified and the expression elevated in cancer cells including breast and 
colon. We will discuss the role of Aurora A in the regulation of centrosome 
and bipolar spindle formation, mitotic entry, and its oncogenic potential. 
 
2.2.1. Centrosomal function 
 
 The first discovery of Aurora A kinase was made in Drosophila, in 
search for mutations that affect centrosome cycle [5]. In the aur mutant 
embryos, two centrosomes were paired and acted as a single pole to nucleate 
monopolar spindles. Those embryos had circular chromosome arrangements 
around a large centrosomal structure, resembling aurora in the polar region. 
Centrosomes and the pericentriolar materials (PCM) function as a main 
microtubule nucleation center in animal cell division. A single centrosome 
comprises of two centrioles perpendicularly arranged. In G1-S phase, 
centrosomes duplicate in concert with DNA replication, giving rise to two 
centriole pairs surrounded by PCM. In late G2-prophase, the two paired 
centrosomes undergo maturation, expanding PCM to nucleate sufficient 
mitotic microtubules.  Centrosome separation occurs before or after nuclear 
envelope break down (NEBD) depending on the cell types. After NEBD, the 
centrosomes nucleate microtubule asters to form bipolar spindles around 
metaphase chromosomes. In all organisms examined, Aurora A inhibition 
resulted in defects in centrosome maturation, failing to build up enough PCM 
components such as γ-tubulin. In C. elegans, Aurora A depleted air-1(RNAi) 
embryos and somatic cells failed to accumulate γ-tubulin and additional PCM 
components at the centrosome [6]. In flies, aur mutant sensory organ 
precursor cells failed to recruit γ-tubulin, Centrosomin [7], and Minispindles 
(XMAP215 homolog) . In HeLa cells, RNAi for aurora A impaired gamma-
tubulin recruitment and induced split centrioles [8]. The failure to recruit 
enough PCM components may perturb in centrosome separation and bipolar 
spindle formation. 
 Apart from the role in centrosome maturation, Aurora A plays a direct 
function in mitotic spindle formation. In animal cells, centrosome-dependent 
and chromosome-dependent spindle assembly pathways exist and Aurora A 
is an important player in both. In centrosome-dependent spindle assembly, a 
link between Aurora A and the spindle formation is found in TACC, a highly 
transforming acidic-coiled-coil-containing protein. TACC is a substrate of 
Aurora A whose centrosomal targeting relies on Aurora A. TACC forms a 
complex with TOG/XMAP215 protein which directly binds to microtubules. 
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Aurora A mediated recruitment of TACC-TOG complex to centrosomes 
stabilizes microtubule minus ends by counteracting microtubule-destabilizing 
kinesins. Involving Aurora A’s function in centrosome maturation and 
bipolar spindle formation several upstream and downstream factors were 
identified in various model systems. Although the contribution and exact 
function of those factors are not fully defined, Barr and Gergely [9] put 
together those factors in a model where, the kinase CDK11 is responsible for 
the localization of Plk1, which in turn recruits Aurora A to the centrosome. 
Centrosomal Aurora A phosphorylates factors like PAK1, Tpx2 and Ajuba, 
all of which facilitate Aurora A autophosphorylation. The active Aurora A 
kinase recruits downstream factors like TACC and Ndel1. Ndel1 is known to 
restore many defects caused by Aurora A depletion.  
 In the chromosome-dependent spindle assembly, microtubules assemble 
around chromosomes which can be readily shown in oocytes of many animal 
species. This pathway is known to require the activity of Ran-GTP. In fact, 
microtubule nucleation takes place even in the absence of centrosome or 
chromatin when the activity of Ran-GTP is present in xenopus egg extracts. 
The high concentration of Ran-GTP around the chromosomes promotes 
release of spindle assembly proteins from Importins at the nuclear envelope. 
The released factors form a complex called EXTAH, which contains Eg5, 
XMAP215, Tpx2, Aurora A, and HURP as well as γ-TURC. Aurora A coated 
beads in the xenopus egg extracts could form EXTAH complex and promote 
microtubule assembly in the absence of centrosome or chromatin. Aurora A 
recruits and phosphorylates Tpx2, which leads to the autophosphorylation of 
Aurora A. The active Aurora kinase recruits other components of EXTAH 
complex where,  γ-TURC nucleates; XMAP215 stabilizes; HURP bundles; 
and Eg5 and Tpx2 crosslink microtubules. Thus Aurora A is at the center of 
mitotic microtubule organization. 
 
2.2.2. Mitotic entry 
 
 Aurora A depletion causes delay in mitotic entry. Mitotic entry and exit 
are controlled by the key mitotic kinase Cdk1, and Aurora A is known to 
regulate it in two ways. First, the earliest activation of Cdk1-cyclin B occurs 
at the centrosome and Aurora A is essential for the centrosomal recruitment 
and activation. In human cell lines, Aurora A depletion impaired the 
recruitment and initial activation of Cdk1-cyclin B at the centrosome. As 
Cdk1 inhibition impairs Aurora A activation, there seems to be a positive 
feedback loop between Aurora A and Cdk1. When Aurora A is depleted, 
delay in mitotic entry was also observed in C. elegans. In the first mitotic 
division of C. elegans embryos, male pronuclei-associated centrosomes are 
Targeting mitotic kinases for anti-cancer treatment   163 
crucial for the timely mitotic entry and Aurora A is the major player in this 
process. Secondly, Aurora A regulates mitotic entry via regulating CPEB 
(Cytoplasmic Polyadenylation Element Binding Protein). The polyadenylation-
induced translation of cyclin B was initially shown to be critical to the meiotic 
progression in xenopus oocytes. Similar translational control was found in 
xenopus embryos for mitotic progression where phosphorylation of CPEB by 
Aurora A regulates polyadenylation and cell cycle [10]. Embryonic CPEB is 
localized at the centrosome with other factors involved in the polyadenylation, 
indicating that CPEB phosphorylation by Aurora A is associated with 
centrosome. As oocytes do not have centrosome and centrosome disruption 
does not cause as significant mitotic delay as Aurora A depletion, the role of 
Aurora A in mitotic entry is exerted in both centrosome dependent and 
independent ways. 
 
2.2.3. Aurora A and cancer  
 
 In 1997, human Aurora A was identified as a ‘breast tumor activated 
kinase (BTAK)’ mapped to the locus 20q11-13 that is frequently amplified in 
breast cancer [11]. The gene amplification as well as over expression of 
Aurora A is found in many other epithelial cancers [12]. The over-expression 
of Aurora A kinase transformed Rat1a cells and NIH3T3 cells to form 
colonies in vitro and tumor mass in nude mice [13,14]. These studies 
assigned Aurora A as an oncogene. However, Aurora A failed to transform 
primary mouse embryonic fibroblasts [15] and failed to induce tumorigenesis 
when expressed as a transgene in mice [16]. These results indicate that 
Aurora A is not a bona fide oncogene, and other genetic alterations are 
necessary for the transformation.  
 Nevertheless, Aurora A surely contributes to the tumorigenesis. First, 
over-expression of Aurora A kinase induces polyploidy and abnormal 
centrosome number. This is likely to cause genetic instability and may 
contribute to tumorigenesis, although not sufficient for transformation. 
Secondly, Aurora A phosphorylates p53 and inhibits its transactivation and 
also induces its degradation. The inactivation of p53 would abrogate the G1 
checkpoint, and abnormal cells may enter cell cycle. Thirdly, reports suggest 
that Aurora A might regulate Ras signal and influence cell growth and 
enhance Ras-mediated transformation [17,18].  
 The association between Aurora A and cancer prompted the development 
of Aurora A targeted small molecules, which showed promising drug 
response in cancer cells and animal models. When aurora A is depleted or 
inhibited, abnormal spindle formation takes place. The cells -both normal and 
transformed- undergo abnormal cell division after delay in mitotic entry and 
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anaphase onset. The resulting cells end up with polyploidy. The long mitotic 
delay and the abnormal chromosome trigger apoptosis in most cells. 
Recently, it was found that the abnormal chromosome segregation leads to 
cell death depending on the time spent in mitosis trying to fix the problems. If 
cells have normal checkpoint function, apoptotic pathway is the preferred 
pathway after Aurora A inhibition because the absence of aurora A does not 
override checkpoints. This is why the aurora A specific inhibitor is a 
promising but potentially dangerous cancer therapeutic target. Primary 
mechanism how Aurora A inhibition induces cell death is through generation 
of abnormal cell division. If cells escape the death pathway, Aurora A 
inhibition could generate more genetically unstable, potentially cancer-prone 
cells in the treatment. Development of anti-cancer drugs targeting Aurora A 
specifically will be discussed later. 
 
2.3. Function of Aurora B 
 
 Aurora B forms the chromosomal passenger complex (CPC) and 
regulates chromosome cohesion, chromosome-microtubule attachment, and 
cytokinesis. To coordinate these processes, the CPC moves dynamically from 
chromosomes to midbody during mitosis.  
 
2.3.1. Chromosome passenger complex 
 
 Aurora B is the enzymatic subunit of CPC; whose nonenzymatic subunits 
INCENP, Survivin, and Borealin are conserved from yeast to mammals. The 
nonenzymatic components are phosphorylated by Aurora B and regulate the 
localization and kinase activity of Aurora B. INCENP binds Aurora B 
through the C terminal IN box, which is required for the full activation of the 
Aurora B kinase. INCENP also functions as a scaffold to accommodate 
Survivin and Borealin at the N-terminus. Survivin is primarily responsible for 
the CPC targeting to centromeres and central spindles. Borealin is also required 
for targeting of CPC by bringing INCENP and Survivin together. In fact, 
Survivin-INCENP fusion proteins can target functional CPC to centromeres 
and central spindle in the absence of Borealin. Depletion of any CPC component 
disturbs proper localization and function of the complex and manifests similar 
mitotic defects, indicating that the CPC functions as a single structural unit. 
 
2.3.2. Chromosome condensation 
 
 Aurora B is localized at chromosome arms during prophase and 
concentrated on the centromere at prometaphase. The chromosome 
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association continues to the onset of anaphase, then Aurora B moves to the 
central spindle. While associated with chromosome, Aurora B is known to 
regulate the mitotic chromosome structure. First, Aurora B phosphorylates 
Histone H3 at Ser10, which is a hallmark of mitosis and linked to the 
chromosome condensation. In tetrahymena, nonphosphorylated S10A H3 
causes elongation of mitotic micronuclei. Histone H3 phosphorylation is 
thought to cause dissociation of HP1 from heterochromatin, which allows 
chromosome to access to the condensin complexes for chromosome 
condensation and cohesion during mitosis. Second, Aurora B phosphorylates 
condensin I subunits to allow its chromosome association. Condensin I is 
required for the chromosome compaction and also for the displacement of 
cohesins from chromosome arms for chromatid separation. Third, the 
maximal chromosome compaction is achieved during anaphase and Aurora B 
inhibition causes decompaction in an unknown mechanism. Therefore Aurora 
B regulates the chromosome structure throughout mitosis.  
 
2.3.3. Microtubule-kinetochore attachment 
 
 Accurate chromosome segregation is the climax of mitosis. The 
segregation is mediated by bi-oriented microtubule spindles attaching to the 
sister kinetochores and pulling them to the opposite ends. This amphitellic 
microtubule-kinetochore (MT-KT) attachment is critical to ensure accurate 
chromosome segregation. Molecular machineries in monitoring the false 
attachments have been evolved to sense unattached kinetochores or the lack 
of tension. How these physical states are biochemically translated has been a 
major issue in cell biology. Now Aurora B is thought to be the key translator, 
which destabilizes the MT-KT attachment by phosphorylating kinetochore 
substrates in the absence of proper tension. Microtubule attachment is a 
dynamic process that many weak interactions, both enforcing and 
destabilizing, determine stable attachment. A protein called Ndc80 
destabilizes the MT-KT interaction, which requires phosphorylation by 
Aurora B. Thus phosphorylation by Aurora B could re-enforce MT-KT 
dynamics to destabilization and generate unattached kinetochores, which will 
resume microtubule attachment until proper tension is generated. The 
phosphorylation by Aurora B could be limited by regulation of kinase activity 
and/or spatial separation between Aurora B at the inner centromeres and its 
substrates at the outer kinetochores.  Liu had shown that the spatial 
segregation indeed regulated Aurora B mediated phosphorylation [19], and 
proper tension led to dephosphorylation of kinetochore substrates.  
 Alternatively, and not exclusively, regulation of kinase activity per se 
plays a role. Aurora B kinase activity is known to require microtubules and 
Hae-ock Lee  et al. 166
microtubule-associated factor TD-60 [20]. Microtubule attached to the inner 
centromere in the absence of tension activates Aurora B kinase activity. 
Nucleosomal structure also affects Aurora B kinase activity by allowing close 
association of CPCs and activation of Aurora B kinase activity by other CPC 
components in trans [21]. Contribution from the different pathway is not yet 
clear, but clearly Aurora B is required for the bipolar MT-KT attachment. 
 Aurora B, the crucial kinase for amphitellic MT-KT attachment, also 
plays a role for spindle assembly checkpoint (SAC) that prevents the 
activation of APC/Cdc20 until all the chromosomes are properly aligned at 
the metaphase plate and bipolar spindle attachment is established. After the 
inhibition of Aurora B with small molecule inhibitors, ZM447439 or 
Hesperadin, abnormal cell division takes place indicative of SAC inactivation 
and premature anaphase onset [22,23]. Consistent with these findings, 
microtubule stabilizing agent Taxol or Eg5 inhibitor Monastrol do not arrest 
cells when Aurora B is inhibited or other CPC component is depleted [24,25]. 
Interestingly, however, in the presence of ZM447439 or Hesperadin, cells 
arrest after microtubule destruction with Nocodazole, suggesting that SAC 
activation could take place regardless of Aurora B. In this case, concomitant 
depletion of Bub1 overrides SAC and cells do not arrest with Nocodazole 
[26]. Thus Morrow and Taylor suggested that SAC activation occur via Bub1 
monitoring unattached kinetochores and Aurora B monitoring bipolar 
attachment. Although how SAC activation is achieved by Aurora B is not 
fully defined, involvement of Ndc80 [27] has been suggested.  
 
2.3.4. Cytokinesis 
 
 When Aurora B function is disrupted, multinucleated cells are formed, 
suggesting for cytokinesis failure [28,29]. Cytokinesis is the last stage of cell 
division where actin, myosin, and other cytoskeletal components are 
redistributed to the contractile ring to create cleavage furrow and induce 
division of plasma membrane in animal cells. At the anaphase onset, Aurora 
B is relocated from chromosomes to central spindles and regulates cleavage 
furrow formation. The signals for cleavage furrow formation come from both 
microtubule asters and central spindles at the midzone [30,31] and Aurora B 
is implicated in both [31]. The stabilization of midzone requires microtubule 
bundling activity of microtubule associated proteins (MAPs) and 
centralspindlin complex composed of Mklp1 and RacGAP. The localization 
of centralspindlin is dependent on Aurora B and either the depletion of 
Aurora B or Mklp1 show similar cytokinesis defects ranging from the 
complete lack of furrow formation [32] to asymmetric furrow formation 
depending on cell types. As RacGAP/CYK-4 is a putative GTPase activating 
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protein for RhoA GTPase that directs contractile ring assembly, Aurora B 
might indirectly affect the contractile ring formation as well.   
 While Aurora B plays a role in the initiation of furrow formation, Aurora B 
also delays completion of cytokinesis until all the chromosome segregation is 
complete [33-35]. This “NoCut” checkpoint was dissected in the budding yeast 
that midspindle defects or chromosome bridges delay abscission, which is 
dependent on Ipl1. Similar “Abscission checkpoint” was also identified in 
mammalian cells, as chromosome bridges located at the cleavage furrow delayed 
abscission in Aurora B dependent manner. The kinase activity of Aurora B is 
required for the delay, and Aurora B-mediated phosphorylation of Mklp1 is 
implicated. Thus Aurora B regulates the initiation and completion of cytokinesis. 
 
2.4. Inhibitors of Aurora kinases in clinical trials for anti-cancer 
treatment  
 
 The Aurora kinase inhibitors such as ZM447439, MK-0457 (VX-680), 
and PHA-739358 are pan-Aurora inhibitors, which inhibit Aurora A, B, and 
sometimes C activities in vitro [22]. Although ZM447439 is still on the 
preclinical development, MK-0457 (VX-680) and PHA-739358 are actively 
being evaluated in the clinical fields.  
 MK-0457 (VX-680) is a pyrimidine derivative with affinity for aurora A, 
B, and C at a value of nanomolar concentrations. It inhibits the growth of 
tumor xenograft, and is effective in chronic myeloid leukemia cells and other 
solid cancer cells.[36,37]. In the phase I clinical trial, MK-0457 was observed 
to stabilize the refractory solid tumors in 3 patients [38]. Three patients with 
T315I phenotype-refractory CML or Philadelphia-positive ALL have shown 
clinical responses to doses of MK-04547 that are not related with adverse 
events [39]. Phase II clinical trials are currently underway in the patients with 
advanced NSCLC (NCT00290550, www.clinicaltrial.gov), and in the patients 
with CML and Philadelphia-positive ALL (NCT00405054).  
 PHA-739358 is a pan-Aurora kinase inhibitor with anti-cancer activity 
on variable tumor xenograft models [40,41]. The results of phase I trial were 
presented in 2006, and PHA-739358 is currently being investigated in a 
phase II clinical trial in CML patients relapsed after imatinib mesylate or c-
ABL therapy, including patients with T315I mutation (NCT00335868). Other 
phase II trials are currently being investigated in adult patients with Multiple 
Myeloma who have a history of at least two previous lines of treatment for 
the disease (NCT00872300), and in patients with metastatic hormone 
refractory prostate cancer (NCT00766324). 
 AT9283 is another multi-targeted kinase inhibitor recently developed 
with potent activity against Aurora A and B kinases in the clinical 
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development [42,43]. Side effects and maximum tolerated dose of AT9283 
are being examined in phase I trials when treating patients with advanced or 
metastatic solid tumors or non-Hodgkin's lymphoma (NCT00443976), ALL, 
AML, CML, high-risk myelodysplastic syndromes, or myelofibrosis with 
myeloid metaplasia (NCT00522990). 
 MLN8054 is the first orally administered Aurora kinase inhibitor, and the 
first one to inhibit Aurora A specifically, and much less so to Aurora B. 
Treatment of MLN8054 leads to spindle defects, resulting in the activation of 
spindle assembly checkpoint and inhibition of proliferation in various human 
cancer cells [44]. Growth of human tumor xenografts in nude mice was 
inhibited after oral administration at well-tolerated doses, and the tumor 
growth inhibition was sustained even after the discontinuation of the 
treatment. In xenografts, MLN8054 induced mitotic arrest and apoptosis. The 
preliminary results of a phase I study showed that MLN8054 was absorbed 
rapidly with a reasonably long half-life. It inhibits Aurora B at higher doses. 
However, dose-limiting toxicities limited dose escalation before mechanism-
based toxicity was seen [45].  
 MLN8237 is a second-generation, selective Aurora A kinase inhibitor 
designed for greater potency and fewer benzodiazepine-like effects observed 
in first-generation agent, MLN8054. In the phase I trial, MLN8237 was 
tolerable with adequate doses and exhibited favorable clinical antitumor 
activity when treated for the advanced solid tumors [46]. The results 
supported the continuation for phase II development, and MLN8237 is 
currently in phase II clinical trials. MLN8237 is administered for the 
treatment of patients with platinum-refractory or platinum-resistant epithelial 
ovarian, fallopian tube, or primary peritoneal carcinomas (NCT00853307). 
MLN8237 is also effective on hematological malignancies, as well as on 
solid tumors. The phase I study in patients with advanced hematological 
malignancies who have limited standard treatment options is active 
(NCT00697346). In addition, phase I/II trial is currently recruiting subjects 
for treating pediatric patients with relapsed, refractory solid tumors or acute 
lymphoblastic leukemia (NCT00739427). Phase II studies for patients with 
relapsed or refractory non-Hodgkin’s lymphoma (NCT00807495), AML or 
myelodysplastic syndrome (MDS) (NCT00830518) are underway.  
 AZD1152 is a dihydrogen phosphate pro-drug of a pyrazoloquinazoline 
Aurora kinase inhibitor. It showed a potent and selective inhibition of Aurora 
B in tumor xenografts [47,48]. AZD1152 was reported to be effective in 
inhibiting growth of acute leukemia cells when used in combination with 
vincristine and daunorubicin both in vitro and in vivo [49]. Phase I trial on 
patients with colon cancer, melanoma, or various other solid tumors revealed 
that AZD1152 made significant disease stabilization with tolerable toxicity 
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[50]. Phase I studies to assess the effect of AZD1152 on the rate of complete 
remission in patients with relapsed AML (NCT00530699) and in patients 
with advanced solid tumors (NCT00338182, NCT00497679, NCT00497731) 
are currently on going.  
 Various Aurora kinase inhibitors, apart from the inhibitors described 
above, are currently being evaluated in clinical setting. Phase I trial is 
studying escalated dose and the side effects of CYC116, a pan-Aurora kinase 
inhibitor, in treating patients with advanced solid tumors (NCT00530465, 
NCT00560716). PF-03814735, a pan-Aurora kinase inhibitor, which is 
administered orally as single agent in patients with advanced solid tumors 
with preliminary results (NCT00424632) [51] and SNS-314, a selective 
Aurora A kinase inhibitor, in advanced solid tumors with preliminary results 
(NCT00519662) [52] are on phase I clinical trials. Moreover, there are many 
more Aurora inhibitors in preclinical development: CHR-3520, CTK-110, 
ENMD-981693, JNJ-7706621, PHA-680632, MP-529, MP-235, 
GSK1070916 and so on [53,54].  
 
3. Polo-like kinase  
 
3.1. Entry and exit from mitosis with Plk1 
 
 The master regulator of mitosis is Cdk1, bound and activated by cyclin 
B. Mitotic entry and exit is controlled by Cdk1. Following Cdk1, Polo-like 
kinases (Plks) play critical roles in the progression of mitosis; mitotic entry, 
centrosome maturation, spindle assembly, chromosome alignment, APC/C 
regulation, and cytokinesis. Four Plk family members, Plk1-4 are found in 
vertebrates. Of the four Plks, Plk1 is believed to carry out most of the 
functions attributed to Cdc5, Plo1, and Polo of budding yeast, fission yeast, 
and Drosophila, respectively. Plk1 exerts its multifaceted functions in mitosis 
through localizing to all of the important places like chromosomes, 
centrosomes, central spindle at the right time. As Erich Nigg describes, Cdk1 
is the conductor in mitosis and Plk1 is the first violin [55].  
 Plks have serine/threonine kinase domain at the N-terminus, D-box 
degradation signals for APC/C in the middle, and the unique PBD (Polo box 
domain) in the C-terminus. Two polo box domains, PB1 and PB2, are 
thought to confer substrate selectivity and regulate subcellular localization of 
the kinase. The PBD domain serves as an inhibitor of the kinase when 
substrate binding is absent. When the docking proteins are phosphorylated by 
priming kinases, often Cdk1, they bind to the PBD domain in Plk1, relieving 
the PBD’s autoinhibition of the kinase, and being further phosphorylated by 
Plk1. This way, substrate specificity is elegantly coordinated in a cell division 
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cycle-dependent manner, following CDK1-cyclin B [55,56]. It is also shown 
that Plk1 can activate Cdk1 at G2/M transition indirectly [55], and also can 
phosphorylate cyclin B and promote accumulation of this mitotic cyclin B in 
the nucleus [57,58]. Conceivably, this synergistic and sequential interplay 
between Cdk1 and Plk1 is thought to regulate timely mitotic entry.    
 Without Plk1, mitosis cannot be continued; depletion of Plk1 from 
Xenopus oocyte extracts impaired mitotic entry, whereas depletion of Plk1 
resulted in delay in anaphase progression in human cells, flies [59], and in 
zebrafish embryogenesis (our unpublished data). The mitotic arrest by Plk1 
abrogation is thought to result from defective spindle assembly, impaired 
centrosome maturation, and impaired MT-KT attachments. All of these 
defects provoke the spindle assembly checkpoint (SAC) activation, since 
SAC ensures the bipolar spindle attachments and tension at kinetochores. The 
outcome is the delay in mitosis followed by frequent apoptosis, through the 
mechanism not yet understood satisfactorily. These results indicate that Plk1 
is essential for progression in mitosis, and the primary role of Plk1 may be in 
microtubule organization, microtubule spindle formation, and MT-KT 
attachments.   
 It was believed that Plk1 on its own is not involved in SAC, evidenced by 
the fact that abrogating Plk1 resulted in the activation of SAC. Nonetheless, 
Plk1 can regulate SAC through phosphorylating BubR1 in a tension-sensitive 
manner [60]. With these notions, the interaction and interplay between SAC, 
Plk1, microtubule spindles are not as simple as it first seemed. A good reason 
why revealing the mechanism orchestrating mitosis is crucial, even for the sake 
of developing anti-cancer drugs targeting mitosis.  
 Multifaceted roles of Plk1 in mitotic entry and progression have hampered 
the finding of its role in cytokinesis; when Plk1 function is compromised, the 
cells first arrest in mitosis. With the development of chemicals inhibiting Plk1 
function, it became clear that Plk1 localizes to central spindle in telophase and 
even in the place where abscission takes place and plays essential roles in 
cytokinesis [59,61,62]. The advantage of the chemical biology is that treating 
the cells with the drugs can be controlled in a timely- controlled manner. Cells 
were treated with specific inhibitors to Plks after they committed chromosome 
segregation. With chemical biology, unveiling the function of Plk1 in the last 
step of cell division, cytokinesis, has just begun.  
     
3.2. Is Plk1 an oncogene?  
 
 Like Aurora A, Plk1 over expression is observed in many tumors of 
diverse origin, including breast, ovary, colon, stomach, pancreas, lung, head 
and neck, skin, esophagus, and brain [63-66]. Its over expression correlates 
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with poor outcome [64,67,68]. In immortalized rodent cells, over expression 
of Plk1 induced transformation, growth in soft agar assays, and formed tumor 
in nude mice, suggesting for an oncogenic potential [69]. However, depletion 
of Plk1 with siRNA or small molecular inhibitors caused genomic instability 
accompanied by sudden death as well [70-74], suggesting that both depletion 
and over expression of Plk1 can attack genome integrity. Live-imaging in 
zebrafish embryogenesis revealed that both depletion of Plk1 and over 
expression of it cause spindle defects and centrosome abnormality in mitosis, 
resulting in arrest in mitosis (our unpublished results). These results 
altogether point to the hypothesis that the adequate level of Plk1 is essential 
for progression in mitosis and genome integrity. In this regard, Plk1 is not an 
oncogene. Rather, it behaves as a balance for regulated mitosis and abnormal 
tumorigenesis.  Taken together, it is conceivable to think that targeting Plk1 
with chemically designed inhibitors can be cancer cell-selective. Indeed, 
varieties of small molecular compounds have been developed so far.  
 
3.3. Plk1 inhibitors for anti-cancer treatment 
 
 First generation Plk1 inhibitors such as LY294002 and other related 
compounds are in clinical trials. Most recently, BI 2536 has been developed, 
which showed increased sensitivity towards Plks. In vitro, BI 2536 inhibits 
Plk1 and induces mitotic arrest with low concentration; IC50 value below 1 
nM, and inhibits the growth of cancer cell lines in the IC50 value ranged 
between 2 to 30 nM [61,62]. BI 2536 binds to the catalytic domain of Plk1 
with high potency. Results of phase I trials have reported that BI 2536 was 
well tolerated and showed a favorable pharmacokinetic profile in advanced 
solid tumors [75]. Phase II trial has been conducted to evaluate the efficacy, 
safety and pharmacokinetics of BI 2536 in the treatment of unresectable 
advanced pancreatic cancer as first line or second line therapy 
(NCT00710710), in the treatment of advanced or metastatic NSCLC of stage 
IIIB or IV in patients who relapsed after or failed first-line therapy 
(NCT00376623), in the treatment of prostate cancer (NCT00706498), in 
second line treatment in sensitive-relapse SCLC patients (NCT00412880).  
 ON01910Na is a small-molecule Plk1 inhibitor that is not an ATP-
mimetic but competes for the substrate-binding site of Plk1 [76]. Recent 
phase I study with an accelerated titration dose-escalation design of 
ON01910Na showed objective response with moderate toxicities, especially 
in refractory ovarian cancer patients [77]. Another phase I trial was opened 
for evaluation of ON01910Na when given together with gemcitabine for 
treating patients with advanced or metastatic solid tumors (NCT00822939).  
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 Plk1 inhibitors in preclinical or clinical development include 
GSK461364, BI 6727, and HMN-214. GSK461364 is a benzimidazolyl-
thiophene which inhibits Plk1 in an ATP-competitive way [78]. GSK461364 
leads to G2 phase arrest at high concentrations and M phase arrest at low 
concentrations. BI 6727, the second generation dihydropteridinone 
derivative, shows highly potent and selective anti-tumor activity in cancer 
models including taxane-resistant colorectal cancer [79]. Both GSK461364 
and BI 6727 are in early clinical trials. Phase I clinical trial is being 
conducted to determine the maximum dose and adverse effects of 
GSK461364 in adult patients with solid tumors and Non-Hodgkins 
lymphoma (NCT00536835). Preliminary results for escalating dose in the 
subjects with solid tumors are reported [80]. The preliminary results of phase 
I trial with BI 6727 also showed anti-cancer effects with tolerable dose [81]. 
Phase II study is underway to evaluate whether BI 6727 monotherapy or in 
combination with pemetrexed is effective in the treatment of advanced or 
metastatic NSCLC in patients with recurrent or refractory first-line platinum 
based therapy (NCT00824408). Phase I/IIa is also on the way to investigate 
for monotherapy and in combination with low dose cytarabine in patients 
with relapsed or refractory AML that are not eligible for intensive treatment. 
In the phase IIa part, the combination of BI 6727 at MTD with cytarabine and 
cytarabine monotherapy is under investigation to explore the efficacy of the 
combination schedule in previously untreated AML patients who are not 
eligible for intensive treatment (NCT00804856). HMN-214, an oral stilbene 
derivative, affects indirect disruption of Plk1 and leads to G2/M phase arrest 
causing anti-tumor activity in vitro and in vivo mouse model [82]. The phase 
I trial demonstrated the tolerable dose for the patients with advanced solid 
tumors [83].  
 Besides these Plk1 inhibitors in clinical development, Plk1 inhibitors, 
such as ZK-thiazolidinone and DAP-81, are under the preclinical 
development [84,85].  
 
4. BubR1 kinase 
 
4.1. The key spindle assembly checkpoint component, BubR1 
 
 The climax of mitosis is at the metaphase to anaphase transition where 
the chromosome segregates in a pole-ward direction. This event is critical in 
ensuring the genetic instability. At every kinetochores of chromosomes, 
amphitellic attachments of microtubule spindles are checked by the spindle 
assembly checkpoint (SAC). SAC inhibits APC/C E3 ligase, the multisubunit 
E3 ligase that is responsible for the destruction of Securin and cyclin B. 
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Securin is the inhibitor for Separase that cleaves Cohesins. Cyclin B is the 
mitotic cyclin that binds to Cdk1 and conducts mitosis. Therefore, 
chromosome segregation and anaphase onset, are governed by APC/C, and 
SAC inhibits the APC/C until the chromosomes are ready to segregate [86].  
 Until now, the modifications and control on the 13 subunits of APC/C, 
the key feature in understanding the regulation of APC/C, have not been fully 
elucidated yet. However, the fact that APC/C activation requires WD40 
domain-containing coactivators Cdc20 in mitosis or Cdh1 in mitotic exit is 
firmly established [87]. Therefore, the inhibition or the control of APC/C 
activity in mitosis can be controlled in this layer; titrating out the coactivator 
Cdc20 away from APC/C. Indeed, Mad2 (first identified from the mad2 
mitotic arrest deficient mutant in yeast) binds to Cdc20 in vitro and in vivo, 
sequestrating it from APC/C thereby inhibiting Securin and cyclin B 
destruction [87].     
 Identified later, but not less important inhibitor of APC/C is the kinase 
BubR1. Unlike Mad2, BubR1 is a kinase not found in yeast. The N-terminus 
of BubR1 resembles Mad3 of yeast, but it has the kinase domain like Bub1 at 
the C-terminus. Therefore, it would be fair to say that the vertebrates have 
evolved another kinase BubR1 to modulate the crucial APC/C activity in 
mitosis. In vitro experiments suggest that BubR1 is a more potent inhibitor 
for APC/C-Cdc20 than Mad2 [88]. At first, it seemed that the way BubR1 
inhibits APC/C is similar to Mad2 by sequestrating Cdc20 away from 
APC/C. However, accumulating evidences indicate otherwise.  
 Studies revealed that the way SAC functions is through forming a 
complex of composed of Mad2, Bub3, BubR1 and Cdc20, named MCC 
(Mitotic Checkpoint Complex), to inhibit APC/C [89]. This way, the 
coactivator Cdc20 is sequestered away from APC/C and the anaphase is 
delayed (Figure 2a). However, this model harbors some problems. BubR1 is 
capable of binding to both Cdc20 and APC/C. Furthermore, BubR1 was 
bound to APC/C before and after anaphase onset [90]. More detailed 
biochemical studies showed that Mad2 only loads Cdc20 to BubR1 to 
kinetohcores then leaves the complex. Cdc20 is ubiquitinated and degraded 
until SAC is satisfied. From this model, the MCC model in SAC activation 
has been refined; BubR1 is bound to APC/C at kinetochores, Mad2 loads 
Cdc20 to BubR1 and APC/C then leaves the complex. Until bipolar spindle 
attachment is achieved, Cdc20 is degraded. When the kinetochores are all 
attached with bipolar spindles, BubR1-APC/C-Cdc20 complex changes their 
conformation and APC/C gets activated with Cdc20 now bound [91]. In this 
model, as well as the MCC model, BubR1 is the key player in the inhibition 
of APC/C until SAC is satisfied (Figure 2b). 
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Figure 2. Proposed models of spindle assembly checkpoint.  (a) In the MCC model, 
BubR1, Mad2, Bub3 and Cdc20 form a complex and this complex sequesters Cdc20 
coactivator from APC/C, therefore APC/C E3 ligase activity is inhibited. (b) 
Alternatively, recent biochemical and cell biological studies suggested that Mad2 only 
loads Cdc20 onto BubR1, which is complexed with APC/C, and leaves the complex. 
Cdc20 is ubiquitinated and degraded when SAC is active and in SAC off condition, 
Cdc20 ubiquitination is prohibited and it serves as a coactivator for APC/C. Activated 
APC/C E3 ligase activity results in the anaphase onset. In addition, BubR1 
acetylation/deacetylation provides another layer of modulating APC/C activity. 
 
 Then how is bipolar spindle attachments and tension sensed to SAC? The 
key molecule to this question seems to be BubR1. BubR1 kinase activity is 
dispensable for inhibiting APC/C E3 ligase activity in vitro [88]. However, a 
microtubule motor protein CENP-E is a binding partner of BubR1 and 
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functions like cyclins for Cdks. This way, microtubule spindle binding to 
kinetochores controls the activity of BubR1 kinase [92-96]. In this delicate 
signaling of bipolar spindle attachments to kinetochores, activation of 
BubR1, and inhibition of APC/C, and Plk1 [60,97] play essential roles by 
phosphrylating BubR1 kinase. It is noteworthy that BubR1 in prometaphase 
or upon spindle disruption shows a characteristic slower migrating form of 
phosphorylation in SDS-PAGE.  
 
4.2. Signals that activate BubR1 
 
 All of APC/C substrates have short stretches of destruction motifs called 
D box or KEN boxes that are recognized by APC/C and coactivators [90]. 
APC/C inhibitor BubR1 also has D box and two KEN boxes. However, how 
BubR1 makes use of these motifs to bind to APC/C and Cdc20 and not being 
degraded by APC/C has not been understood. Recently, it was found that 
BubR1 is acetylated by PCAF in prometaphase when it is active. Acetylated 
BubR1 is prohibited from being a substrate of APC/C. When the SAC is 
satisfied, BubR1 is deacetylated and becomes a substrate of APC/C. 
Degradation of BubR1 further activates APC/C, initiating the anaphase onset, 
thus BubR1 acetylation/deacetylation is a molecular switch for BubR1 from 
being a inhibitor to a substrate of APC/C. [98] (Figure 2b). This study 
revealed that in addition to BubR1 phosphorylation, acetylation provides 
another layer of signaling in SAC control.  
 
4.3. Potentials of BubR1 as a molecular target for cancer therapy 
 
 Notably, BubR1 function is crucial for cells in mitosis. In interphase, 
BubR1 is mainly at cytoplasm. As cells enter mitosis, Bub3 brings BubR1 to 
the kinetochores [99]. Localization of BubR1 at outer kinetochores is crucial 
for SAC function for it bound with CENP-E monitors the bipolar spindle 
attachment at kinetochores. Only in proliferating cells, the localization and 
signaling of BubR1 becomes crucial.  
 Conventional anti-cancer therapy has been the DNA damaging drugs or 
alkylating drugs to kill proliferating cancer cells. It had been noticed that 
upon the treatment of DNA damaging drugs, cancer cells suddenly die in 
mitosis. This so called mitotic catastrophe is specific to cancer cells because 
normal cells with intact G2 checkpoint would arrest the cells in G2 after 
genotoxic insult. Thus, cancer cells with abrogated interphase checkpoints, 
e.g. by mutation of p53, would be the ones targeted for mitotic catastrophe 
after treatment with DNA damaging drugs. Then what is the key molecule 
receiving and sending the death signals after DNA damage in mitosis? 
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Studies suggest that BubR1 is phosphorylated and activated in response to 
adriamycin [100]. Indeed, BubR1 has been suggested to induce mitotic 
catastrophe in HeLa cells [101]. With these notions, it is conceivable that 
BubR1 can be an efficient target for cancer therapy. That acetylation of 
BubR1 regulates SAC activity and modulation of APC/C renders another 
possibility that specific inhibition of BubR1 deacetylation can be adopted for 
targeting cancer, since HDAC inhibitors are actively being investigated for 
anti-cancer therapy in clinical trials [102].  So far, our understanding of 
BubR1 kinase substrates are poor, and targeting the kinase activity of this 
important protein in mitosis is yet to be explored.  
 
5.  What’s next? 
 
 We are now living in the interesting times to face the most rapid 
development of bench to bedside research on mitotic kinase inhibitors for anti-
cancer strategy. Hundreds of preclinical results indicate that mitotic kinases are 
effective targets for the treatment of variety of tumors. However, as we have 
seen from the cases of Aurora A and Plk1 where both depletion and over 
expression of them can be dangerous for genomic integrity, inhibition of these 
kinases do not straightforwardly kill cancer. In fact, we learn more on the 
mechanisms of how these kinases work in cell division using the specific 
inhibitors. Thus, clinical trials to validate the efficacy and safety of the mitotic 
kinase inhibitors should be accompanied with the basic side of science. Right 
now, we are still waiting for the further phase III clinical trials.  
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Abstract. Atypical Dual Specificity Phosphatases (A-DUSPs) are 
a group of 19 phosphatases poorly characterized. They are included 
among the Class I Cys-based PTPs and contain the active site motif 
HCXXGXXR conserved in the Class I PTPs. These enzymes present 
a phosphatase domain similar to MKPs, but lack any substrate 
targeting domain similar to the CH2 present in this group. Although 
most of these phosphatases have no more than 250 amino acids, their 
size ranges from the 150 residues of the smallest A-DUSP, 
VHZ/DUSP23, to the 1158 residues of the putative PTP DUSP27. 
The substrates of this family include MAPK, but, in general terms, it 
does not look that MAPK are the general substrates for the whole 
group. In fact, other substrates have been described for some of these 
phosphatases, like the 5’CAP structure of mRNA, glycogen, or 
STATs and still the substrates of many A-DUSPs have not been 
identified. In addition to the PTP domain, most of these enzymes 
present no additional recognizable domains in their sequence, with 
the exception of CBM-20 in laforin, GTase in HCE1 and a Zn 
binding domain in DUSP12. Although some of these enzymes have 
been now studied for years there is a great lack of data about the true 
physiological role of this group of phosphatases.  
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Introduction 
 
      Protein tyrosine phosphorylation is a post-translational modification that, 
in a reversible manner, regulates many cellular functions such as 
proliferation, differentiation or citokinesis to cite a few. This process is 
controlled by two groups of enzymes, protein tyrosine kinases (PTKs) and 
protein tyrosine phosphatases (PTPs). PTKs constitute a family of proteins 
with the same evolutionary origin [1], whereas PTPs share a similar 
enzymatic activity but show a diverse evolutionary origin [2]. Thus, PTPs 
have been classified, according to the key aminoacid involved in the 
catalysis, on Cys-based PTPs or Asp-based PTPs [2]. The Cys-based PTPs 
share a canonical motif (P-loop) in the phosphatase domain, CX5R, that 
contains the Cys required to form the thiol-phosphate intermediate and can be 
further subdivided based on the characteristics of the catalytic domain in 3 
classes. Class I is the more populated with 99 proteins and contains 2 groups, 
the well-known classical PTPs with 38 sequences [3] and the VH1-like PTPs 
with 61 members, a quite diverse group with an ample range of substrates, 
from the 5’CAP structure of mRNA to inositol phospholipids, including 
phospho-Ser, phospho-Thr and phospho-Tyr. Class-I consensus sequence for 
the P-loop can be extended to HCX2GX2R(S/T). In addition, these 
phosphatases present an Asp, approximately 30 amino acids upstream of the 
catalytic Cys, which acts in the catalysis as a general acid, protonating the 
leaving group. The phosphatase domain of Class I PTPs presents a 
characteristic structure, different from the topology that shows the 
phosphatase domain of the other two classes of Cys-PTPs. LMW-PTP, the 
only member of Class II, presents a distinctive fold and CDC25 
phosphatases, which constitute the class III, contain a phosphatase domain 
that displays a rhodanese fold. The Asp, N-terminal to the catalytic Cys in 
Class I PTPs, is located in the C-terminus of LMW-PTP and is absent in 
Class II CDC25 enzymes. Although CDC25 phosphatases have been 
included frequently in a group of dual-specificity phosphatases along with 
VH1 phophatases, they belong to a different group that shows an exquisite 
specificity for their substrates, cyclin-dependent kinases. In addition to the 
different phosphatase domain topology, CDC25 proteins lack any sequence 
similarity to other DSPs, apart from the CX5R motif common to all Cys-
based hydrolases.  
 There is a fourth class of PTPs that belong to the family of Haloacid 
Dehalogenases (HAD) and use Asp as the nucleophile in the catalysis. The 
activity of these phosphatases depends on the presence of divalent cations. 
The first proteins of this group characterized as phosphatases were the 
transcription factors Eyes absent (EYA) [4]. While EYA proteins seem to 
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dephosphorylate phosphor-Tyr [5], other members of this group 
dephosphorylate substrates in Ser/Thr: Chronophin, which regulates the 
cytoskeleton by targeting Ser-3 in cofilin [6]; FCP1, which dephosphorylates 
the C-terminal domain of RNA polymerase II, regulating transcription [7]; 
and dullard, which is implicated in nuclear membrane biogenesis through 
dephosphorylation of the phosphatidic acid phosphatase lipin, functioning in 
a phosphatase cascade [8]. 
 
Table 1. A-DUSPs present in the human genome. The table includes their names and 
their synomins as well as the uniprot accession numbers to identify these 
phosphatases. Under the column of substrates, proteins that have been shown to be 
dephosphorylated have been included, along with those that have been tested but are 
not targets of these phosphatases. 
 
PROTEIN SYNONIMS AA UNIPROT SUBSTRATES 
VHR DUSP3 185 P51452 ERK, JNK, p38, STAT5 
MDSP BEDP, DUSP13a 188 Q6B8I1 Unknown 
TMDP SKRP4, TS-DSP6, 
DUSP13b 
198 Q9UII6 Unknown and Negative on ERK, JNK, 
p38 and DYRkβ 
DUSP14 MKP-6, MKP-L 198 O95147 ERK, JNK 
DUSP15 VHY 295 Q9H1R2 Unknown 
DUSP18 LMW-DSP20 188 Q8NEJ0 JNK 
DUSP19 DUSP17, SKRP1, TS-
DSP1, LMW-DSP3, 
LDP-2 
217 Q8WTR2 JNK 
DUSP21 LMW-DUSP21 190 Q9H596 Unknown and negative on ERK, JNK, 
p38 
DUSP22 JSP-1, MKP-X, JKAP, 
LMW-DSP2, VHX 
184 Q9NRW4 ERK, JNK (upstream protein), p38, 
ERα, STAT3  
  
DUSP23 LDP3, VHZ 150 Q9BVJ7 ERK, JNK (upstream protein), p38 
DUSP26 DUSP24, LDP4, 
MKP8, NATA1, 
SKRP3, NEAP 
211 Q9BV47 ERK, JNK, p38, Akt, Kap3 
DUPD1 DUSP27; FMDSP 220 Q68J44 Unknown 
STYX  223 Q8WUJ0 Inactive 
PTPM1 MOSP, PLIP, PNAS-
129 
201 Q8WUK0 PI(5)P 
Laforin  331 O95278 Glycogen, GSK3β  
DUSP11 PIR1 330 O75319 5’CAP 
HCE1 CAP1A, HCAP1A 597 O60942 5’CAP  
DUSP12 HYVH1, T-DSP4, 
GKAP 
340 Q9UNI6 GKAP 
Negative on ERK, JNK, p38 
DUSP27 STYXL2 1158 Q5VZP5 Inactive 
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 In this chapter, we will discuss the group of VH1-like phosphatases 
known as A-DUSPs. These enzymes are included in the VH1-like group of 
Class I PTPs and contain 19 proteins (see table 1) that will be discussed in 
detail, focused on the physiological role played by these phosphatases. The 
viral protein VH1 (Vaccinia virus H1 open reading frame) was the first 
DUSP identified by Dixon and colleges in 1991 [9]. The next year, VHR 
(VH1-related PTP) was isolated and cloned [10]. Efforts to identify the PTPs 
present in the human genome and other genomes have advanced in parallel to 
the sequencing of the human genome. Thus, some sequences were isolated at 
the end of the 90s, but most the A-DUSPs sequences were identified in the 
new milleniun. DUPD1 is the most recently characterized phosphatase [11] 
and it still remains in the databases, DUSP27, an inactive A-DUSP whose 
mRNA has been detected but no study has been published yet on this protein. 
 Substrates of these enzymes are diverse, as they target not only proteins 
phosphorylated on Ser, Thr, and Tyr but also the mRNA capping structure or 
glycogen. A great effort has been dedicated to show that these enzymes 
dephosphorylate MAPKs (mitogen activated protein kinases) with negative 
results in some cases and controversial data in others. In general terms, data 
available on many of these phosphatases is still limited, given the recent 
identification of many of them. 
 
VHR /DUSP3 
 
 VHR is a phosphatase of 185 amino acids that was cloned in 1992 with 
an expression cloning strategy [10]. In all these years, VHR has been widely 
used as a model to research general aspects of Class I PTPs, as the kinetic 
mechanism of PTPs [12-14] or to design inhibitors for these enzymes [15]. 
However, research about the physiological role has not been very productive, 
although VHR has started to reveal its role in cell cycle regulation [16] and in 
the activation of several signalling pathways related with the immune 
response [17, 18]. VHR was the first A-DUSP to be crystallized [19] and its 
three dimensional structure showed that VHR presents a catalytic cleft 6 Å 
deep, able to accommodate phospho-Ser and phospho-Tyr, in contrast to the 
deeper pocket (9 Å) of classic PTPs, like PTP1B [20]. This difference would 
explain the substrate preference of classic PTPs toward phospho-Tyr. VHR 
can be found in the cytosol as well as in the nucleus, and the localization 
might have important implications for its pathological function associated 
with proliferation [16]. Expression of VHR is ubiquitous [21] and is 
regulated during the cell cycle [16]. 
 Similarity between VHR and MKPs catalytic domain suggested that 
VHR could dephosphorylate MAPKs in a similar way to MKPs. However, it 
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took a few years to demonstrate this point. In fact, it was not until 1999 when 
VHR was shown to dephosphorylate ERK (extracellular regulated kinase) 
[22], and a few years later when VHR was proven to dephoshorylate JNK (c-
jun N-terminal kinase) [21, 23]. In addition, some studies have claimed 
dephosphorylation of p38 by VHR [24, 25]. In experiments in vitro using 
synthetic diphosphorylated peptides, corresponding to the activation loop of 
ERK and JNK, it was determined that VHR preferencially hydrolyze the 
phospho-Tyr residue in that sequence, thereby VHR would dephosphorylate 
phospho-Tyr followed by slow dephosphorylation of phospho-Thr [26]. 
However, a later study using phosphorylated recombinant ERK as substrate 
demonstrated that, in vitro, ERK is a poor substrate for VHR [27], indicating 
that, in vivo, it must exist some mechanism that allows the dephosphorylation 
of ERK and JNK by VHR. One possibility is the existence of a scaffold that 
would bring together this phosphatase and its substrate, function that could be 
developed by VRK3 [28] (see below). Reduction in VHR expression using 
siRNA interference has also shown an increase in the phosphorylation of 
ERK and JNK [16]. Although the capacity of A-DUSPs, including VHR, to 
dephosphorylate MAPK remains controversial, at least in this case, the 
available data suggest that VHR is a true MAPK phosphatase. 
 Regulation of VHR function is accomplished by Tyr phosphorylation. In 
T cells, VHR is phosphorylated by the tyrosine kinase Zap70 [17], which is 
critical for antigen signalling through the TCR (T cell receptor), in Tyr-138, 
phosphorylation that is required for VHR to inhibit ERK2; conversely, the 
mutation of Tyr-138 by Phe in VHR increases TCR-induced ERK2 kinase 
activity as well as activation of interleukin 2 (IL-2) promoter [17]. In a 
different situation, it has been described that VHR dephosphorylates STAT5 
in cells stimulated by IFN-α and IFN-β [18]. Again, phosphorylation of VHR 
at Tyr-138 was required for its phosphatase activity toward STAT5. The 
tyrosine kinase Tyk2, which phosphorylates STAT5, is also responsible for 
the phosphorylation of VHR at Tyr-138. Thereby, these two reports suggest 
that phosphorylation of VHR in Tyr-138 links kinases that participate in the 
activation of signalling pathways to its ulterior down-regulation of the 
pathway by returning the components to the basal state. 
 The biological function of VHR has started to be uncovered in recent 
years. In this sense, it has been shown, using siRNA interference that cells 
with a reduced expression of VHR arrest at the G1-S and G2-M transitions of 
the cell cycle and exhibit senescence [16]. In agreement with this notion, 
cells lacking VHR were found to upregulate the cyclin dependent kinase 
inhibitor p21 (Cip-Waf1), and to reduce the expression of genes for cell-cycle 
regulators, DNA replication, transcription and mRNA processing. Loss of 
VHR also caused, after serum-induced activation, a several-fold increase of 
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its substrates, the MAPKs ERK and JNK. VHR-induced cell-cycle arrest was 
dependent on this hyperactivation of JNK and ERK, and was reversed by 
ERK and JNK inhibition or knockdown by RNA interference. These data 
supports the involvement of VHR in cell-cycle progression, role that is linked 
to its regulation of MAPK activation in the cell-cycle. 
 A few reports have implicated VHR in different types of cancer [29-31]. 
This role of VHR seems to be related to its role as a MAPK phosphatase. In 
the prostate cancer cell line LNCaP androgens protect from TPA (12-O-
tetradecanoylphorbol-13-acetate) or thapsigargin-induced apoptosis via 
down-regulation of JNK activation. This effect could be explained by an 
increased in VHR expression induced by androgens [29]. Transfection of 
wild-type VHR, but not a catalytically inactive mutant, interfered with TPA 
and TG-induced apoptosis. Consistently, siRNA-mediated knockdown of 
endogenous VHR increased apoptosis in response to TPA or TG in the 
presence of androgens. In this work, it is also found that VHR expression is 
augmented in prostate cancer cells compared with normal prostate cells. 
Overexpression of BRCA1-IRIS, a product of the BRCA1 gene, in breast 
cancer, augments Cyclin D1 expression and increases cell proliferation. 
Increase in Cyclin D1 is explained by a reduction in VHR expression 
regulated by BRCA1-IRIS by an unknown mechanism [30]. Furthermore, 
overexpression of Cyclin D1 could be blocked by transfection of VHR in 
those cells. An additional study in cervix cancer has reported an increase in 
the expression of VHR and a change in its location [31]. Thus, in invasive 
cervix cancer, in addition to be highly expressed, VHR changes its 
localization to the nucleus, while in normal tissue VHR is always in the 
cytoplasm. In addition, cervix cancer cell lines such as HeLa, SiHa, CaSki, 
C33 and HT3 also present a higher expression of VHR, compared to primary 
keratinocytes. Altogether, the role that plays VHR in cell cycle progression 
along with VHR implications in several cancer types, suggest that this 
phosphatase could be a therapeutical target in this disease.  
 
DUSP26 
 
 Several independent groups initiated the characterization of this 
phosphatase and published their studies between 2005 and 2007. The results 
obtained by these researches were as diverse as to show one effect, for 
example inhibition of p38 [32, 33] and JNK [33, 34], and the opposite, 
stimulation of p38 and JNK [35]. It has also been reported inhibition of ERK 
[34], in this case mediated by the interaction of DUSP26 with the protein 
Hsf4 (heat shock transcription factors 4), a substrate of MAPKs. 
Furthermore,  an independent study in PC12 cells found no effect in any of  
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Figure 1. Domains present in the A-DUSPs. Apart of the characteristic PTP domain 
(150 aminoacids) presented by these proteins, only three of these phosphatases present 
an additional domain: CBM-20 (carbohydrate binding module-family 20) in Laforin, a 
GTase (guanylyltransferase) domain in HCE1, the mRNA capping enzyme and a Zn 
binding domain (Zn) in DUSP12. All the phosphatases have drawn to scale except 
DUSP27 that is the longest (1158 aminoacids). 
 
the main MAPKs, ERK, JNK or p38 [36]. Apart of MAPKs, an additional 
substrate has been described for DUSP26 in PC12 cells, Akt, since 
overexpression of DUSP26 reduced Akt phosphorylation on Ser-473 [37]. 
 DUSP26 is localized mainly in the nucleus [32, 35], although in PC12 
cells is found in the cytosol [36]; and its expression is enriched in the brain 
[34, 35], particularly in neurons [34]. In addition, this phosphatase has been 
detected in several cancer cell lines, retinoblastoma, neuroepithelioma, and 
neuroblastoma [38]. In this sense, 8p12, the chromosomal region where 
DUSP26 gene is present, has been found to be amplified in anaplastic thyroid 
cancer (ATC) and, consequently, DUSP26 expression was increased in 
primary ATC tumors and ATC cell lines. In three ATC cell lines, cell growth 
was inhibited and apoptosis was increased by DUSP26 siRNA. In this study, 
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DUSP26 was detected in a complex with p38, which was dephosphorylated 
by this phosphatase. Therefore, in that report the authors propose that this 
phosphatase acts as an oncogen by promoting cell survival of ATC cells 
through inhibition of p38 induced apoptosis. 
 In PC12 cells, DUSP26 expression is up-regulated by nerve growth 
factor (NGF) and suppression of DUSP26 expression by siRNA enhanced 
NGF-induced neurite outgrowth and Akt activation. Moreover, DUSP26 
impaired cell growth in response to EGF (epidermal growth factor) by 
reducing EGFR (EGF receptor) mRNA and protein, through down-regulation 
of the Akt pathway and Wilms' tumor gene product (WT1). Taken together, 
these studies suggest that DUSP26 could be involved in PC12 differenciation 
in response to NGF and EGF via regulation of the PI3K/Akt signalling 
pathway. 
 Recently, DUSP26 has also been involved in intracellular transport and 
cell adhesion [38], since it was found that DUSP26 binds KIF3, a 
microtubule-directed protein motor involved in transport of β-catenin/N-
Cadherin to the plasma membrane. DUSP26 would be recruited to the KIF3 
complex through interaction with one subunit of this complex, Kif3a, to 
dephosphorylate Kap3, which should be critical for transport of β-catenin/N-
Cadherin. In this sense, over-expression of DUSP26 increases cell-cell 
contacts and adhesion. These authors also described a down-regulation of 
DUSP26 in gliomas, suggesting a tumor-suppressive role of this phosphatase.  
 
DUSP12 
 
 DUSP12 was identified based on similarity with the yeast VH1 (YVH1) 
phosphatase, and then it was named human orthologue of YVH1 (hYVH1) 
phosphatase [39]. Several studies support a role for this phosphatase in cell 
growth [40], and meiosis and sporulation [41] in yeast. Independently, the rat 
orthologue was cloned from a liver cDNA library in a yeast-two hybrid 
screen with glucokinase and, thus, named glucokinase-associated 
phosphatase (GKAP) [42]. This protein contains an N-terminal DUSP 
domain and a cysteine-rich C-terminal domain capable of binding 2 mol of 
zinc/mol of protein, defining it as a novel zinc finger domain, which is 
essential for in vivo function [39]. DUSP12 in human cells is expressed in all 
tissues analyzed [39] and similar results have been obtained for GKAP. 
Expression of GKAP was also verified by RT-PCR in β-pancreatic cells [42]. 
 DUSP12, in vitro, dephosphorylated phospho-Tyr, but not the artificial 
substrate phosphoseryl kemptide, although it could hydrolyze phosphate from 
Ser phosphorylated glucokinase [42]. GKAP fused with GFP (green 
fluorescent protein) was found in the cytosol, where glucokinase 
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phosphorylates glucose. Furthermore, addition of DUSP12 enhanced 
glucokinase activity in vitro in a dose-dependent manner, suggesting that this 
association is of functional significance. 
 Implications of DUSP12 in glucose metabolism have received further 
support from genetic studies that have shown that the chromosomal region 
1q21-23, where the DUSP12 gene resides, is linked to type 2 diabetes (T2D) 
[43]. Furthermore, it has been found that several polymorphisms in DUSP12 
are associated with T2D [44]. In addition, this chromosomal region is 
amplified in human liposarcomas and DUSP12 gene showed the highest level 
of amplification within that region [45]. 
 A recent work has reported the interaction of Hsp70 (heat-shock protein 
70) with DUSP12 [46]. The Zn-binding domain is required for this 
interaction, along with the ATPase domain of Hsp70. DUSP12 phosphatase 
activity towards an exogenous substrate under non-reducing conditions was 
increased by Hsp70. This study also supports a role of this phosphatase in 
cell survival, since overexpression of DUSP12 reduced the number of 
apoptotic cells in response to various apoptotic inducers, such as heat shock, 
H2O2 and Fas receptor activation. Activity of DUSP12 on ERK, JNK or p38 
was tested under the stress conditions analysed, finding that this phosphatase 
does not dephosphorylate any of these kinases [46]. Furthermore, purified 
DUSP12 was unable to dephosphorylate purified activated MAPKs in vitro in 
the absence or presence of Hsp70. Therefore, substrates for DUSP12 remained 
to be identified. The role of this phosphatase on cell survival is further 
supported by data from a large-scale siRNA screening conducted by Blenis 
and co-workers that showed that knockdown of DUSP12 with siRNA caused 
significant apoptosis [47]. However, overexpression of DUSP12 could not 
rescue the cells exposed to cisplatin, which initiates apoptosis via the DNA 
damage response pathway, and suggest that hYVH1’s effects are selective to 
specific cytotoxic stimuli, just mentioned above, which involve redox-
sensitive signalling pathways. Both phosphatase and Zn-binding domains are 
required for the anti-apoptotic effects caused by this phosphatase. In an independent 
study, looking for genes that increase resistance to Fas-induced apoptosis, the 
expression of DUSP12 was found to be down regulated [48], confirming the 
role of this phosphatase in resistance to apoptosis and cell survival. 
 
LAFORIN 
 
 Mutations in this DUSP cause the Lafora disease (LD) (OMIM254780) 
[49, 50], an autosomal recessive neurodegenerative disorder that results in 
progressive myoclonus epilepsy with onset in adolescence and death within 
10 years of appearance. This disease was described at the beginning of last 
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century, in 1911, by the neurologist Gonzalo Rodríguez Lafora [51], a 
disciple of Santiago Ramón y Cajal. The hallmark of the disease is the 
formation of Lafora bodies, which contain insoluble, poorly branched 
glycogen-like polysaccharide or “polyglucosan”. These bodies develop in 
different tissues: liver, muscle, heart, skin, and neurons that normally 
accumulate little glycogen. Approximately 60% of the cases of LD result 
from mutations in the gene that encodes laforin, EPM2A. This phosphatase 
contains a glycogen binding domain in the N-terminus (GBM-20), followed 
by the phosphatase domain. Another gene has been identified, EPM2B 
(NHLRC1), whose mutation causes 20–30% of the cases of Lafora disease 
[52, 53]. EPM2B codes for a protein called malin that is an E3 ubiquitin 
ligase, which promotes ubiquitination and proteasomal degradation of laforin 
[54, 55], among other proteins related to glycogen metabolism. 
 The first protein identified to interact with laforin was PTG (protein 
targeting to glycogen) or R5 [56], a protein that targets the Ser/Thr 
phosphatase PP1 to glycogen [57]. PP1 regulates glycogen synthesis by 
dephosphorylating key enzymes involved in glycogen metabolism. Thus, PP1 
activates glycogen synthetase (GS) and inactivates the glycogen degradation 
enzymes phosphorylase (Ph) and phosphorylase kinase (PhK). 
Overexpression of PTG/R5 markedly increases glycogen accumulation, and 
reduction of PTG expression diminishes glycogen stores. In contrast to PP1 
phosphatase, several kinases such as AMPK (AMP-activated protein kinase), 
PKA, CKI and GSK3 could inhibit glycogen synthesis by acting on the same 
proteins than PP1. Later, it was shown that laforin and malin form a complex 
that promotes the ubiquitination and proteasome dependent degradation of 
PTG/R5, and, accordingly, inhibit glycogen accumulation in neurons [58]. In 
these cells, which do not express the enzymes involved in glycogen 
hydrolysis Ph and PhK, it was demonstrated that the malin-laforin complex 
caused proteasome-dependent degradation of MGS (muscle glycogen 
synthase) [58], thus mutant laforin and malin proteins would impair the 
capacity to degrade MGS with the consequence of increasing the amount of 
glycogen in neurons. Furthermore, Solaz-Fuster et al. [59] demonstrated, in 
FTO2B hepatoma cells, that malin, in concert with laforin, decreases PTG/R5 
levels and glycogen stores without affecting glycogen synthase. Degradation 
of PTG/R5 by this complex could explain how the mutations that impair the 
physiological function of laforin or malin increase PTG levels and glycogen 
synthesis in the cells. In laforin-malin complex, laforin seems to behave as a 
substrate adaptor, recruiting proteins present in glycogen particles for 
ubiquitination by malin and subsequent degradation by the proteasome. 
Additional glycogen metabolism-related proteins have been reported to be 
degraded by this complex, as the glycogen debranching enzyme 
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(GDE)/amylo-1, 6-glucosidase,4-alpha-glucanotransferase (AGL)[60]. It has 
been also shown that malin promotes ubiquitination of laforin, which would 
mean that the same E3 ubiquitin ligase complex regulates its own quantity 
by controlling the amount of one of its components, the substrate adaptor 
laforin. 
 Interaction between laforin and malin is regulated by phosphorylation of 
laforin by AMPK, which binds directly to laforin [59]. Moreover, AMPK 
also phosphorylates PTG/R5 on Ser-8 and Ser-268, which accelerates its 
ubiquitination by the laforin-malin complex [61], following the classical 
mechanism of tagging proteins for ubiquitination by phosphorylation. 
 Interaction of laforin with other proteins has been described, although the 
functional significance of these interactions is unknown. Among these 
proteins are: EPM2AIP1 [62], a protein of unknown function; HIRIP5, a 
cytosolic protein that contains a NifU-like domain that could be involved in 
iron homeostasis [63]; GSK3β, which was shown to be dephosphorylated by 
laforin [55, 64], although this remains controversial. In addition, it has been 
described that laforin forms homodimers [56, 64], which are critical for its 
phosphatase activity.  
 The complex malin-laforin could develop additional functions related to 
the clearing of misfolded proteins through the ubiquitin–proteasome system 
[65]. In this sense, it has been observed that malin and laforin co-localize in 
the endoplasmic reticulum (ER) and form aggregates when neurons are 
treated with proteasomal inhibitors [66]. In the same direction, knockdown of 
laforin by siRNA treatment in HEK293 and SH-SY5Y cells increased the 
sensitivity to agents that triggers ER-stress, impairing the ubiquitin-proteasomal 
pathway and augmenting apoptosis [67]. Therefore, the regulation of glycogen 
synthesis by proteasomal degradation of key proteins required for this process 
could be a particular case in the general function that laforin and malin develop 
in the cell, which could be the control of the accumulation of misfolded 
proteins under stress conditions. It is well known that protein aggregates in 
neurons lead to several fatal neurodegenerative disorders.  
 In addition to its function in protein degradation it has been proposed that 
laforin presents phosphatase activity against glycogen, dephosphorylation 
that is required for the maintenance of normal cellular glycogen [68]. 
Glycogen, a branched polymer of glucose, contains a small amount of 
covalently linked phosphate that can be release by Laforin in vitro. Moreover, 
glycogen from laforin-deficient mice is increased in several tissues, and this 
glycogen presents an increase in the covalent phosphate content [69]. These 
authors proposed that an increase in glycogen phophorylation leads to 
aberrant branching and Lafora body formation. Thus, the fisiological role of 
laforin would be to prevent excessive glycogen phosphorylation. 
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DUSP14 
 
 DUSP14 was initially identified as a CD28 interacting protein, called 
MKP6, in a yeast two-hybrid assay [70]. The potential substrates of DUSP14 
can be ERK, JNK and p38, as GST-DUSP14 dephosphorylates them in vitro. 
Nevertheless, the expression of a catalytically inactive DUSP14 mutant, Cys-
111 to Ser, in T-cells produces only an increase in ERK and JNK 
phosphorylation, whereas p38 phosphorylation remains invariable. This 
augmented phosphorylation in ERK and JNK is accompanied by an enhanced 
interleukin-2 production. DUSP14 seems to negatively regulate co-
stimulatory signalling in T-cells, possibly by interacting directly with CD28. 
This would localize DUSP14 close to the cell membrane where the 
phosphatase could interact with the MAPKs activated early after stimulation. 
In fact, DUSP14 may function as an early response gene, since DUSP14 
mRNA and protein expression are rapidly induced after co-stimulation of 
peripheral blood T lymphocytes through the TCR and CD28 receptors [48].  
 Apart of T cells, DUSP14 has been associated with different functions in 
other cell types. A recent study has suggested that DUSP14 could be the non-
specific suppressor factor that regulates some types of hypersensitivity, such 
as delayed-type hypersensitivity or contact hypersensitivity [71]. There is 
also recent evidence that involves DUSP14 in the proliferation of pancreatic 
β-cells, possibly acting through modulation of ERK activity [72]. In this cell 
type, DUSP14 expression is augmented in response to Glucagon-like peptide-
1 (GLP-1), which is a growth and differentiation factor for β-cells. However, 
GLP-1 has very limited proliferative skills. Thus, finding mechanisms that 
increase this proliferative ability could be of great interest in the treatment of 
diabetes. In this sense, blocking DUSP14 expression increases the 
proliferative effect of GLP-1 on β-cells. Another study, in a different context, 
has shown that DUSP14 expression is induced by the transcription factor 
Klf4 and by corticosteroids in the development of the epidermis in mice [73], 
suggesting a possible role of this phosphatase in the development of this 
tissue. This gene is also up-regulated in mice dorsal striatum by acute 
administration of MDMA (3-4-methylenedioxymethamphetamine), active 
compound of the widely abused drug ecstasy [74], along with two other 
DUSPs, DUSP1 and DUSP5. Induction of DUSP14 is partially due to 
activation of dopamine D1 receptors and independent of dopamine D2 
receptors. Overall, it appears that DUSP14 is highly regulated at the 
transcriptional level in the cells studied. 
 An interesting fact reported by Nakano [71] is the possible existence of 
DUSP14 as a dimer in non-reducing conditions, suggesting that this 
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phosphatase might be functional in cells as a dimer. This is in agreement with 
a recent work that reports the crystal structure of VH1, which adopts a 
dimeric quaternary structure mediated by an N-terminal α-helix that 
protrudes from the PTP domain [75]. 
 
STYX: An inactive A-DUSP 
 
 STYX (phospho-Ser or Thr or Tyr interaction protein) is an inactive 
phosphatase that presents a Gly instead of the catalytic Cys in the P-loop of 
its phosphatase domain. The rest of the features of A-DUSPs are conserved in 
this protein. In fact, mutation of Gly to Cys recovers the phosphatase activity 
of this protein to dephosphorylate p-NPP and phospho-Tyr and phospho-Thr 
residues from peptide sequences of MAPK [76]. The PTP domain of this 
protein has been crystallized showing the same overall topology of the PTP 
fold [77]. Expression of STYX is found in all tissues studied with higher 
abundance in skeletal muscle, testis, and heart [76]. 
 The generation of a knockout mouse that does not express this protein 
has shown that STYX is essential for normal spermiogenesis [78]. These 
mice present a great reduction in spermatozoa production with the result of 
male infertility. In addition, this study has described the interaction of STYX 
with an RNA-binding protein, CRHSP-24 (Ca2+-regulated heat-stable protein 
of 24 kDa), which is phosphorylated in Ser and also targeted by the Ser/Thr 
phosphatase calcineurin (PP2B). It has been speculated that inactive 
phosphatases like STYX used the inactive domain to bind phosphorylated 
proteins in a similar way to SH2 domains and this way may regulate their 
function, for example, by protecting them from dephosphorylation by active 
phosphatases. In any case, as judging from the results obtain with the STYX 
knockout mouse, this inactive phosphatase does develop a key function in the 
cell that is required for spermiogenesis, although the mechanism is unknown. 
 
PIR1 and HCE (RNGTT): RNA phosphatases 
 
 Two RNA phosphatases have been found in the human genome, PIR1 
(Phosphatase that interacts with RNA/RNP complex 1)/DUSP11 [79, 80] and 
HCE1 [81]. Both possess an N-terminus phosphatase domain that contains 
the P-loop consensus motif for Cys-PTPs HCX2GX2R(S/T), although they 
lack the Asp required for the catalysis and present in most of the Cys-based 
PTPs. These two RNA phosphatases belong to different subgroups: HCE1 is 
included among the bifunctional metazoan mRNA capping enzymes, where 
the triphosphatase domain exclusively hydrolyzes the γ-phosphate of RNA; 
and PIR1 is included in monofunctional enzymes that hydrolize RNA 5’ 
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triphosphate to 5’-diphosphate and 5’-monophosphate [82]. In this last group, 
it is also included the baculovirus phosphatase BVP, the first enzyme shown 
to have RNA phosphatase activity, isolated from the Autographa californica 
nuclear polyhedrosis virus [83, 84]. Bifuctional metazoan capping enzymes 
as HCE possess two domains, the previously mentioned N-terminal RNA 5'-
triphosphatase domain and a C-terminal guanylyltransferase domain [82]. It 
is this second domain that is absent in monofuctional enzymes such as PIR1 
and BVP. HCE1 RNA triphosphatase domain removes the γ-phosphate from 
the 5' end of nascent mRNA to leave a diphosphate terminus and the 
guanylyltransferase domain catalyzes the subsequent transfer of a guanylyl 
group from GTP to produce the unmethylated 5' cap structure [82]. This 
modification facilitates transcript translation and later processing of the mRNA. 
Then, PIR1/DUSP11 lacks the guanilyltransferase domain, and although shows 
greater activity for RNA than for proteins, its function is unclear. 
 To our knowledge a function for PIR1 has not been established in 
eukaryotic cells and since PIR1 dephosphorylates RNA 5’ triphosphate to 5’-
monophosphate, its function as a capping enzyme seems unlikely because it 
needs a 5’diphosphate in order to form the CAP structure [80]. Consistent 
with this, BVP, the other monofunctional domain RNA phosphatase, is not 
required for the formation of a 5’CAP structure on late viral mRNAs [85] and 
is not essential for viral replication [86]. Although its function is not fully 
understood, a recent report has shown that could be related to a change in the 
insect host behaviour that favours dispersion of the viruses by increasing the 
locomotory pattern during the larval stage [87]. In addition, A. californica 
nuclear polyhedrosis virus contains a proper bifunctional capping enzyme 
with RNA triphosphatase and guanylyltransferase activities, LEF-4. 
 BVP and the mouse orthologue of HCE1 phosphatase (PDB 2C46) 
domains have been crystallized and both show the typical fold of the PTP 
domain of Class I phosphatases [88]. 
 
DUSP13: One gene, two phosphatases 
 
 The gene DUSP13 is located in human chromosome 10q22.2, 50kb 
downstream of the gene of another A-DUSP, DUPD1, which suggests that 
the two genes might have originated by gene duplication. DUSP13 and 
DUPD1 have been also found in mammals and in chicken, then the gene 
duplication that gave rise to the DUPD1/DUSP13 pair occurred prior to the 
divergence of mammals from birds [11]. The mRNA transcribed from 
DUSP13 gene is translated in two different phosphatases using alternative 
open reading frames [89]. These two proteins are encoded from different 
exons, but their transcripts share the same polyadenylation signal in exon 9. 
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These phosphatases are TMDP (testis and skeletal muscle-specific dual 
specificity phosphatase) also called DUSP13b, and MDSP (muscle-restricted 
dual specificity phosphatase) or DUSP13a. The finding that a gene is 
transcribed into an mRNA that produces two proteins from alternative open 
reading frames that belong to the same family is unique among eukaryotes. 
Expression of these two proteins is quite restricted; while TMDP is mainly 
expressed in testis, MDSP is found in skeletal muscle. Expression of both 
proteins is increased with tissue maturation [89]. TMDP has been found by in 
situ hybridization in spermatocytes and round spermatids [90]; and this has 
been taken as an indication of the role of this phosphatase in spermatogenesis. 
 TMDP dephosphorylates phospho-Tyr and phospho-Ser in artificial 
substrates as MBP (myelin basic protein) [90], but no physiological 
substrates have been identified yet. MDSP has been tested in co-transfection 
experiments for its ability to dephosphorylate several MAPkinases (ERK2, 
JNK1, p38α and β) producing a negative result [89]. Given the restricted 
expression of this phosphatase to the skeletal muscle, other kinases were 
tested, in particular dual specificity tyrosine-regulated kinases (DYRKs) 
because of the similarity of the activation loop with MAPK, in addition to the 
role of DYRK1B in skeletal muscle development [89]. However, MDSP was 
also unable to dephosphorylate this kinase in cotransfection experiments. 
 The structure of the complete TMDP has been solved at a resolution of 
2.4 Å [91]. Although the crystal showed an asymmetric unit with four 
molecules in two potential dimers, however, the dimeric contacts were not 
significant enough to hold the two molecules in solution. Furthermore, 
additional experiments such as gel filtration chromatography and dynamic 
light scattering showed that TMDP exists as a monomer in solution. TMDP 
structure is most similar to VHR. The main differences between the 
structures of these PTPs are found in the loop α1–β1, involved in substrate 
recognition, and in the loop β3–α4, part of so-called variable insert, which is 
shorter in TMDP. Unlike VHR, TMDP contains a wide and shallow pocket 
that seems to be adequate for accommodation of both phospho-Tyr and 
phospho-Thr and could explain its preference for dually phosphorylated 
substrates. 
 
DUSP19 and DUSP23: Putative scaffold A-DUSPs 
 
DUSP19 
 
 DUSP19 was initially described as SAPK (stress activated protein 
kinase) pathway-regulating phosphatase 1 (SKRP1) [92], LDP-2 (low-
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molecular-mass DSP-2) [25] and LMW-DSP3 (low molecular weight dual 
specificity phosphatase 3) [93]. The mRNA of this phosphatase has been 
found in all tissues examined [25, 92]. DUSP19 sequence presents an Ala 
instead of a Ser after the Arg155 in the P-loop, HCXXGXXRS, which is 
conserved in most of the DUSPs. Endogenous DUSP19 is mainly detected in 
the cytoplasm, where it co-localizes with JNK. Recombinant DUSP19 protein 
showed extremely low phosphatase activity towards p-nitrophenyl phosphate 
(pNPP) and mutation of Ala-156 to a Ser increased this activity. However, 
DUSP19 and the Ala-156 Ser mutant exhibited similar activity to both 
phospho-Ser/Thr and phospho-Tyr residues of myelin basic protein. 
 DUSP19 was found to be specific for JNK [25, 92]. This phosphatase 
showed a greater inhibition when JNK was activated by TNF-α (tumor 
necrosis factor alpha) or thapsigargin, in contrast to UV light or anisomycin 
[92]. DUSP19 formed a complex with the JNK upstream activating kinase 
MKK7, but not with MKK4, and did not bind directly to JNK. Thereby, 
DUSP19 targeted its substrate, JNK, through MKK7 interaction. In addition, 
it has been reported that DUSP19 co-precipitated MKK7-activating MAPKK 
kinase (MAPKKKs) ASK1 (apoptosis signal-regulating kinase 1), but not 
MEKK1 (MAP kinase kinase kinase 1) [94]. In agreement with this, DUSP19 
overexpression increased ASK1-MKK7 complexes and enhanced the 
activation of MKK7 by ASK1. The authors of this work proposed that this 
phosphatase acts as a scaffold in the JNK activation pathway, although the 
mechanism remains unknown and deserves further study. 
 
DUSP23: The smallest A-DUSP 
 
 At the end of 2004 several studies reported the initial characterization of 
this phosphatase as VHZ [95], LDP-3 (low-molecular-mass dual-specificity 
phosphatase-3) [24] and DUSP23 [96]. This A-DUSP is the smallest active 
phosphatase with 150 aminoacids (16 kDa), whereas the catalytic domain of 
classical PTPs presents 280 aa [3]. Expression of this phosphatase has been 
detected as mRNA in every tissue tested, in mouse [24] and human [95]. As a 
protein, DUSP23 has been detected in peripheral blood lymphocytes (PBL), 
and in different cell lines of hematopoietic origin: Jurkat T cells, RAMOS B 
cells, HL-60 myeloid cells as well as the tumor cell lines M45 and HT29 
[95]. Endogenous DUSP23 is detected in the cytosol [95] and overexpression 
of this protein produced the same results [24, 95, 96], although in one study 
some cells presented nuclear staining, in some cases in the nucleolus [95]. 
The structure of VHZ/DUSP23 reported recently [97] is particularly 
interesting since two aminoacids from another molecule in the crystal, Thr-
135–Tyr-136, bind in the catalytic pocket with a malate ion, mimicking the 
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TXY motif found in the activation loop of MAPK, in a similar way to an 
enzyme-substrate complex. The fold of VHZ/DUSP23 is closer to VHR, but 
binding of the substrate peptide to the active site resembles more closely to 
PTP1B due to the presence of similar residues surrounding the active pocket, 
which provide a similar orientation to the substrate. 
 DUSP23 is an active phoshatase against pNPP and also dephosphorylates 
Tyr and Ser/Thr phosphorylated peptides [24, 96]. Its ability to 
dephosphorylate MAPK has been tested by different laboratories obtaining 
different results. In one study, recombinant GST-DUSP23 dephosphorylated 
ERK2 in vitro without affecting JNK or p38 [96]. In a different report, 
overexpression of DUSP23 produced an increase in JNK and p38 activity by 
sorbitol [24]. However, DUSP23 did not affect ERK activation by EGF. 
Osmotic stress stimuli other than sorbitol, such as mannitol, glucose or 
glycine, also increased the activation of the stress kinases JNK and p38, but 
other kinds of stresses, oxidative stress, heat shock, or UV irradiation, did not 
induce that effect. Interestingly, it was also observed a sorbitol-induced 
activation of upstream kinases of JNK and p38, MKK4 and MKK6. 
Surprisingly, the effect observed on JNK and p38 is independent of its 
phosphatase activity since Cys to Ser or Asp to Ala inactive mutants 
produced the same increase in sorbitol-induced activation of these kinases 
[24]. One explanation for these results would be that DUSP23 works as a 
scaffold in these pathways, although no interaction with proteins in this 
pathway has been reported. An alternative hypothesis would be that this PTP 
dephosphorylates a negative regulatory site on a protein acting on the initial 
steps of this signalling pathways.  
 
PTPMT1, DUSP18 and DUSP21: Mitochondrial atypical-
DSPs 
 
PTPMT1 
 
 PTPMT1 (Protein-tyrosine phosphatase mitochondrial 1) is the first A-
DUSP that has been demonstrated to be localized in the mitochondria [98]. 
Afterwards, another two DUSPs were also found in the mitochondria, 
DUSP18 and DUSP21 [99]. PTPMT1 was referred previously as PLIP 
(PTEN-like phosphatase) [100] and MOSP [2]. Initially this PTP was cloned 
from Dictiostelium after a database search for phophatases similar to PTEN 
[101]. In fact, it presents two basic aminoacids in the P-loop, Arg-133 and 
Lys-136, in equivalent positions to PTEN Lys-125 and Lys-128, aminoacids 
that give PTEN specificity for PI(3,4,5)P3. Initial characterization of the 
substrate specificity of this phosphatase using several phosphoinositides 
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showed as the preferred substrate PI(5)P [100]. PTPMT1 is targeted to the 
mitochondria by an N-terminal signal sequence and it is found anchored to 
the matrix face of the inner membrane (IM) in this organelle, where it 
colocalizes with members of the respiratory chain. Expression of this 
phosphatase, although is highly enriched in testis tissue, has been shown in 
every tissue tested by PCR. This PTP presents orthologues in all phylogenetic 
kingdoms, including eubacteria. 
 Disruption of PTPMT1 expression by siRNA in the pancreatic β cell line 
INS-1 832/13 caused an increase in ATP production and markedly enhanced 
insulin secretion under both basal- and glucose-stimulated conditions [98]. At 
the same time, knockdown of this phosphatase produced an increase in Ser 
and Thr phosphorylation of some proteins, whereas no change was observed 
in protein tyrosine phosphorylation. However, a reduced expression of 
PTPMT1 did not affect the PI(5)P levels in the mitochondria , despite the in 
vitro observed activity of PTPMT1 [100]. These data support the idea of 
PTPMT1 playing a critical role in mitochondrial function by regulating the 
status of phosphorylation in Ser or Thr of mitochondrial proteins. 
 
DUSP18 
 
 This PTP was characterized by two different groups as LMW-DSP20 
[102] and DUSP18 [103]. This phosphatase is conserved in the different 
groups of vertebrates, is expressed in all tissues studied, and is localized in 
the mitochondria [99]. Unlike, PTPMT1 that presents an N-terminal 
mitochondrial localization signal, DUSP18 contains an internal mitochondrial 
localization signal that allows its internalization in the mitochondria. Inside 
the mitochondria, DUSP18 is localized in the IM, looking to the IMS 
(intermembrane space) compartment. Although it has been shown to be 
present in the cytosol and the nucleus, these results could be likely due to 
overexpression of these PTPs, in addition to the masking effect of N-terminal 
tags over the mitochondrial localization signals [102]. Kinetic analysis of 
DUSP18 with pNPP as a substrate showed that DUSP18 was an active PTP 
and was more efficient using pNPP than the other mitochondrial DUSPs, 
PTPMT1 and DUSP21, but not as efficiently as VHR [99]. DUSP18 
dephosphorylates in vitro diphosphorylated synthetic MAPK peptides, with 
preference for the phospho-Tyr and diphosphorylated forms over phospho-
Thr. However, in vivo, overexpression of DUSP18 was unable to 
dephosphorylate MAPKs in this study [99]. In contrast, there is other report 
showing that DUSP18 targets JNK in vivo [104]. However, in a different 
report has not been possible to detect the presence of JNK in mitochondria 
[99], suggesting that JNK is not a substrate for DUSP18. 
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 Induction of apoptosis, a process in which mitochondria plays a critical 
role, resulted in release of DUSP18 from the mitochondria to the cytosol, in a 
similar way to cytochrome c, a key mediator of apoptosis. Treatment of cells 
with known inducers of apoptosis, such as starurosporine, an inespecific 
kinase inhibitor, or etoposide, a topoisomerase II inhibitor, showed cytosolic 
localization of DUSP18 after the mitochondrial outer membrane 
permeabilization produced during the apoptotic process [99]. 
 
DUSP21 
 
 Expression of DUSP21 mRNA has been detected exclusively in testes 
[102]. DUSP21 presents 69% sequence identity with DUSP18, and, as 
DUSP18, it also contains an internal mitochondrial signal sequence that, in 
this case, localizes the phosphatase to the matrix compartment of this 
organelle. Interestingly, despite this great similarity, these two DUSPs 
localize to different sides of the inner mitochondrial membrane. DUSP21 
dephosphorylates synthetic MAPK peptides in vitro with preference for 
phospho-Tyr or dual-phosphorylated peptides over phospho-Thr. Co-
transfection of this PTP with MAPK resulted in no activity against this 
family of kinases [102]. 
 
DUSP15 and DUSP22: Myristoilated A-DUSPs 
 
DUSP15 
 
 DUSP15 was first described as VHY (VH1-like member Y) because its 
closest relative was VHX (VH1-like member X), currently known as 
DUSP22 [105]. DUSP15 has a very narrow tissue expression pattern. Thus, 
its mRNA was detected only in testes and very weakly in brain, spinal cord 
and thyroid. Protein was also detected in testes by Western Blot and 
histochemistry showed the presence of this phosphatase in spermatocytes 
[105]. The N-terminus of DUSP15 presents high similarity to the consensus 
myristoylation sequence of SFK (Src family kinases) and, as well as them, 
DUSP15 is post-transcriptionally modified by the addition of myristic acid to 
Gly in position 2, as well as DUSP22 [105]. This myristoylation is essential 
for DUSP15 recruitment to the plasma membrane. DUSP15 is an active 
phosphatase as it can dephosphorylate pNPP, but there is no information 
about its physiological substrates. The crystal structure of DUSP15 has been 
reported and shows several particular surface properties, which indicate that 
DUSP15 may have a unique substrate specificity [106]. 
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DUSP22 
 
 DUSP22 presents a broad expression and was characterized under four 
names by different groups: LMW-DSP2, VHX, JSP-1 (JNK Stimulatory 
Phosphatase-1) and JKAP (JNK pathway-associated phosphatase). Results 
obtained in these initial reports were also diverse in relation with MAPK 
activation. Two reports showed that DUSP22 activated JNK [107, 108], other 
showed inhibition of ERK2 and NF-AT by this phosphatase [109]; and the 
fourth showed that DUSP22 bound to and inhibited p38 [110]. Chen et al. 
showed that targeted gene disruption of DUSP22 in embryonic stem cells 
abolished JNK activation by TNF-α and TGF-β, but not by ultraviolet-C 
irradiation [107]. DUSP22, in this report, was also shown to interact in vivo 
with JNK and MKK7, but not with SEK1. However, in vitro, JNK did no 
bind to DUSP22, suggesting that targeting of JNK is mediated by binding to 
other protein. Other group showed that DUSP22 acts as a positive regulator 
of JNK pathway, and its overexpression led to the activation of MKK4 [108], 
another upstream MAPKK. Altogether, the data presented by these two 
papers suggests that DUSP22 would exert its effect on JNK in an indirect 
manner, acting on a protein upstream of this kinase. The fact that DUSP22 is 
myristilated in the N-terminus to target it to the plasma membrane [105] 
should be taken into consideration when interpreting the previous data, which 
has been obtained mainly with overexpressed N-terminal tagged phosphatase. 
 In addition to its role in MAPK signalling pathways, DUSP22 has also 
been implicated in the regulation of the ERα (estrogen receptor-alpha) and 
STAT3. DUSP22 regulates ERα-mediated transcriptional activation by 
dephosphorylation of this receptor on Ser-118 [111]. The function of 
DUSP22 on STAT3 dephosphorylation has been investigated in the context 
of IL-6 stimulation [112]. Interaction between these two proteins has been 
observed in vivo. Despite what this data might suggest, disruption of DUSP22 
in mice to generate knockout animals does not produce any observable 
phenotype in these animals. 
 The structure of this phosphatase has been solved for the peptide that 
contains the phosphatase domain, aminoacids 1-163 [113]. The topology 
resembles that of other DUSPs, but with a shallower catalytic pocket, 4.5 Å 
of depth, smaller than that of VHR, 6 Å, and half the pocket of PTP1b, 10 Å. 
 
DUPD1 and DUSP27: A little of confusion 
 
 DUPD1 (DUSP and pro-isomerase domain-containing 1) was initially 
called DUSP27 [2], but in the HUGO (Human Genome Organisation) 
database appears as DUPD1 with DUSP27 as alias. The name DUSP27 is 
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used to refer to another open reading frame that codes a phosphatase with 
1158 amino acids that corresponds to Swiss-Prot accession number Q5VZP5, 
which is an inactive phosphatase that has been detected as mRNA but no 
report has been published yet about this PTP. First attempts to characterized 
DUPD1 (Swiss-Prot accession number Q68J44) predicted an open reading 
frame that contained a dual specific phosphatase and a pro-isomerase 
domains [2]. Subsequent studies showed that the pro-isomerase domain was 
not included in the sequence [11]. DUPD1 is able to dephosphorylate 
synthetic phopho-Ser and phopho-Thr peptides but it acts more efficiently on 
phospho-Tyr peptides. The catalytic groove of DUSP27 can accommodate a 
dual-phosphorylated substrate where the two phosphorylated residues are 
separated by two amino acids instead of one as in the case of MAPKs. This 
finding indicates that DUPD1 substrates are not MAPKs. Although further 
studies are needed to identify DUPD1 substrates, its specific tissue 
distribution, restricted to adult fat, skeletal muscle and liver [11], suggest that 
DUSP27 may participate in the regulation of energy metabolism.  
 
Conclusions and futures perspectives 
 
 A-DUSPs are a heterogeneous group of enzymes according to the range 
of substrates targeted. The controversial results obtained regarding substrates 
and the rich synonimia used to name these proteins have produced some 
confusion over this group of proteins. Nomenclature has been fixed, adopting 
the name DUSP followed by a number, and new substrates identified lately 
for these phosphatases have widen the repertoire of this family outside the 
MAPK world. The search for substrates has been done under the influence of 
sequence similarity between these proteins and MKPs. Therefore, most of the 
studies tried to show the effect of these phosphatases on MAPK. As we have 
shown along this review, results were negative in many cases and 
controversial in most of the rest. Nevertheless, some A-DUSPs have been 
shown to be true MKPs, for example VHR. Even in these cases, the absence 
of a targeting domain similar to the rhodanese in MKPs raises the question 
about the mechanism by which these phosphatases target MAPKs. In this 
sense, in at least two cases, VHR and DUSP26, two proteins have been found 
that may work as adaptors that facilitate phosphatase access to their 
substrates, VRK3 [28] and Hsf4 [34], respectively. At the same time, it has 
become evident that other substrates could exist for these phosphatases, as, 
for example, STAT transcription factors. 
 Although the information about these phosphatases is still scarce and the 
physiological role for most of them is unknown, some studies have suggested 
the implication of these phosphatases in some cellular functions, such as 
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apoptosis, DUSP12, or cell-cycle regulation, VHR; and in some pathologies, 
such as cancer, VHR and DUSP26, or diabetes, DUSP12. In this sense, the 
lack of knockout mice for A-DUSPs has been an obstacle in the 
determination of the physiological role of these phsophatases. So far, out of 
19 A-DUSPs, only 3 have been disrupted in mice, STYX [78], DUSP22 
[107] and laforin [114]. STYX deficient mice showed that this phosphatase is 
involved in spermatogenesis. 
 It seems likely that the next few years will see a critical advance in our 
understanding of A-DSPs. This will be thanks to approaches that manipulate 
gene expression, such as siRNA interference or generation of knockout mice, 
as well as proteomics and mass spectrometry technologies that will provide 
new data to dissect the substrate repertoire of A-DUSPs and the physiological 
function of these phosphatases. 
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